Klicken Sie einen Eintrag, um zur entsprechenden Stelle zu springen — eingeklappte Karten öffnen sich automatisch.

1.1 What frailty is — the syndrome and its physiology

Frailty is best understood as a clinical syndrome rather than a single disease. The defining feature is a heterogeneous decline in functional reserve across multiple organ systems, accompanied by impaired homeostasis and a reduced capacity to respond to stressors.Clegg 2013Fried 2001Hoogendijk 2019Dent 2025 A minor stressor that an unfrail older adult would absorb without consequence — a urinary tract infection, a brief hospital admission for a non-major procedure, a course of corticosteroids — can in a frail patient precipitate cascading functional decline, hospital-acquired delirium, mobility loss, and disability that persists long after the original stressor has resolved. This vulnerability is what frailty captures and what makes it a distinctive clinical concept.

Underlying the syndrome is a complex pathophysiology that is not yet fully understood: chronic low-grade inflammation (the «inflammaging» phenomenon), dysregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, sarcopenia, neuro-endocrine dysregulation (HPA axis, autonomic nervous system, sex hormones), and altered intercellular communication all play roles.Álvarez-Bustos 2026 Importantly, the syndrome's clinical expression is downstream of these biological processes — which is why frailty is assessed clinically through observable functional changes (walking speed, grip strength, fatigue, activity level, body weight) rather than directly through biomarkers.

1.2 Why early detection matters

Three reasons make early detection of frailty — particularly at the pre-frail stage — clinically valuable.

1. Reversibility window. Pre-frailty (1–2 of the Fried criteria, or an intermediate frailty-index score) is the window where targeted intervention has the greatest chance of reversing the trajectory. Once severe frailty and disability have set in, reversibility is «highly compromised and complex».Álvarez-Bustos 2026 Travers 2019, in a systematic review of primary-care interventions, found multicomponent exercise to consistently delay or reverse frailty in community settings.Travers 2019
2. Strong outcome predictor. Frailty independently predicts falls, fractures, hospitalisation, prolonged length of stay, post-operative complications, institutionalisation, and mortality — over and above chronological age, comorbidity, and disability scores. Some studies identify it as the main modifiable factor associated with mortality in older adults.Hoogendijk 2019Álvarez-Bustos 2026Dent 2025 Identifying frailty changes the prognostic conversation and informs care intensity decisions.
3. Effective interventions exist. The SPRINTT RCT (n=1,519, 11 European countries, evaluator-blinded) demonstrated that a multicomponent intervention (physical activity + nutritional counselling) prevented mobility disability in older adults with physical frailty and sarcopenia in the lower-functioning SPPB ≤7 stratum.Bernabei 2022 The LIFE-P, MID-Frail, and Tarazona-Santabalbina 2016 trials show converging evidence. Detection without intervention is incomplete; detection plus exercise plus nutrition is where the evidence sits.

1.3 Two operational models — phenotype vs deficit accumulation

There are two well-established operational definitions of frailty in the literature, and they conceptualise the syndrome in different ways.Buta 2016Clegg 2013

The two models do not measure the same thing and may be complementary.Álvarez-Bustos 2026 The Clinical Frailty Scale (CFS, Rockwood 2005), built on the deficit-accumulation tradition but validated as a 1–9 visual scale for clinician judgement, sits as a third widely-used pragmatic tool. FrailtyTrack uses Fried's phenotype as the primary diagnostic construct and includes the CFS card for cross-referencing; the Frailty Trait Scale-5 (FTS5; García-García 2020García-García 2020) is on the roadmap as a complement to address Fried's dichotomy limitations — this is also CIBERFES's recommended approach (bibliography entry added in v9.7.1; full instrument card scheduled for v9.8). The full deficit-accumulation Frailty Index is not currently in FrailtyTrack as a primary instrument.

1.4 Pre-frailty — the intervention window

Pre-frailty denotes the intermediate state with one or two Fried phenotype criteria present, but not yet meeting the ≥3-criterion frailty threshold. Up to half of community-dwelling older adults meet pre-frailty criteria.Álvarez-Bustos 2026 Pre-frailty is associated with substantially increased risk of progression to frailty, falls, and disability over 1–3 years — but it is also the stage at which intervention has the greatest leverage. The combination of high prevalence, increased risk, and intervention reversibility makes pre-frailty the prime target for case-finding programmes in primary care, outpatient physiotherapy, and community geriatric services.

Important caveat. CIBERFES 2026 explicitly notes that there remains no consensus on the operational definition of pre-frailty: cut-off points, clinical relevance, and prognostic implications all require further research. The pragmatic approach is to treat pre-frailty as a high-yield trigger for full assessment and exercise/nutrition counselling, while remaining cautious about labelling and over-medicalising the state.

1.5 How FrailtyTrack supports the assessment pathway

FrailtyTrack implements the two-step screening → diagnosis pathway recommended by ADVANTAGE (the European Joint Action on frailty), the Spanish Ministry of Health's Frailty Working Group, the ICFSR Primary Care guidelines, and CIBERFES.Álvarez-Bustos 2026Hoogendijk 2019 Each construct corresponds to a section in the Test Protocols tab.

1.6 Common misunderstandings

• «Frailty just means old.» No. Many older adults — including nonagenarians and centenarians — are not frail and never become frail. Frailty is age-associated but not synonymous with aging.Álvarez-Bustos 2026
• «Frailty is the same as sarcopenia.» No. Sarcopenia is a neuromusculoskeletal disease where muscle (the target organ) loses size and function. Frailty is multisystemic. The two often coexist (and the coexistence is necessary for some adverse outcomes), but each can be present without the other.Álvarez-Bustos 2026 See Section 3 of this Background tab for the sarcopenia-specific evaluation.
• «Frailty is just a different word for disability.» No. Frailty is a pre-disability state — it precedes disability, predicts it, and is itself dynamic. CIBERFES specifically argues that disability items should not be part of frailty scales, on the construct grounds that confusing predictor with outcome empties the concept of clinical use. (The Tilburg Frailty Indicator, Groningen Frailty Indicator, and electronic Frailty Index are critiqued on these grounds.)
• «Frailty is irreversible — once a patient is frail, that's it.» No. Pre-frailty and mild frailty are dynamic and respond to multicomponent intervention.Bernabei 2022Travers 2019 Severe frailty with established disability is much harder to reverse, but even there functional gains are achievable in many cases.
• «Frailty assessment requires specialist geriatricians.» No. The recommended screening instruments (SPPB, gait speed, FRAIL) are designed for primary care, nursing, and physiotherapy use. Comprehensive Geriatric Assessment for further characterisation is appropriate when available, but the entry assessment can and should be done at the first point of contact with the older adult.Hoogendijk 2019Álvarez-Bustos 2026
• «The label 'frail' will harm patients.» A real concern but not a reason to avoid assessment. Stigma management is recognised by CIBERFES and the World Falls Guidelines — the right response is destigmatisation and patient-centred communication, not concealment of the clinical state. The terminology choice (e.g. avoiding the German Gebrechlichkeit in favour of the English Frailty) is one practical way to manage this. See the Position Statements & Consensus section in About for a fuller discussion.

1.7 Why physiotherapy is central to frailty care

Physiotherapy sits at a unique intersection in frailty care. The clinical features used to detect frailty are physical-functional — gait speed, grip strength, balance, sit-to-stand power, fatigue during activity. These are exactly the domains physiotherapists routinely measure. The interventions with the strongest RCT evidence — multicomponent exercise (strength + power + balance + gait + aerobic) — are exactly the domains physiotherapists routinely prescribe and supervise.Bernabei 2022Izquierdo 2025 ICFSR The treatment dose, the progression logic, the safety considerations, the adherence work — all are physiotherapy core competencies.

In the Swiss context, this is operationalised through the StoppSturz Vorgehen Physiotherapie (Frehner 2021) for fall prevention — with explicit prescription pathways and tariff-position structures. The Vivifrail program (vivifrail.com), endorsed by ICFSR, provides a tested capacity-tailored exercise prescription anchored to the patient's functional status. The combination of a frailty diagnosis + a Vivifrail or equivalent prescription + nutritional counselling (≥1.2 g/kg/day protein, Mediterranean dietary pattern, vitamin D where deficient) constitutes the current standard-of-care multicomponent intervention.

The pedagogical implication for physiotherapy education: learning to detect frailty and prescribe its interventions is no longer specialist-only knowledge. It is a core competency for any physiotherapist working with older adults, in any setting. FrailtyTrack is built to support this learning by tying every clinical instrument card to its source evidence, normative data, and population-specific cut-offs — so the user develops not just procedural fluency but a sense of why a given threshold exists and where it does and does not apply.

1.8 Key references used in this section

All references are live-fetched and verified per the project's Rule 1 protocol; full citation strings with DOI links are in the Primary References section of the About tab. Highlights:

• Fried 2001 — original Fried phenotype paper, Cardiovascular Health Study; doi:10.1093/gerona/56.3.M146
• Mitnitski 2001 — original deficit-accumulation Frailty Index; doi:10.1100/tsw.2001.58
• Rockwood 2005 — Clinical Frailty Scale (CFS); doi:10.1503/cmaj.050051
• Clegg 2013 — canonical Lancet review «Frailty in elderly people»; doi:10.1016/S0140-6736(12)62167-9
• Buta 2016 — systematic characterisation of frailty assessment instruments; doi:10.1016/j.arr.2015.12.003
• Hoogendijk 2019 — Lancet review on clinical and public-health implications; doi:10.1016/S0140-6736(19)31786-6
• Travers 2019 — primary-care interventions for delaying/reversing frailty; doi:10.3399/bjgp18X700241
• Bernabei 2022 SPRINTT — multicomponent intervention RCT; doi:10.1136/bmj-2021-068788
• Álvarez-Bustos 2026 (CIBERFES) — current European consensus document; doi:10.1016/j.jnha.2026.100793
• Izquierdo 2025 ICFSR — global exercise consensus; doi:10.1016/j.jnha.2024.100401
• Dent 2025 — Lancet Commission on Frailty programme announcement; doi:10.1016/S0140-6736(25)01101-8

1.9 Frailty as a public-health priority — the Lancet Commission's reframing

In June 2025 The Lancet announced a new Commission on Frailty (Dent, Clegg, Roller-Wirnsberger, Vetrano & Hoogendijk, Lancet 2025;405(10497):2265–2266), building on the 2013 Lancet Seminar (Clegg et al.) and the 2019 Lancet Series (Hoogendijk et al. / Dent et al.). The Commission's stated goal is to "globally reorient healthcare and public policy to prevent the development and progression of frailty across the life-course".Dent 2025 For physiotherapy education and practice, three aspects of the Commission's framing are particularly worth surfacing.

(a) Prevalence and equity. The Commission reaffirms a community prevalence of 12–24% in adults aged ≥65 (depending on operationalisation), drawing on the O'Caoimh 62-country meta-analysis. It explicitly highlights that frailty disproportionately affects women, populations from culturally and linguistically diverse backgrounds, those experiencing socioeconomic disadvantage, and residents of low- and middle-income countries.Dent 2025 For Swiss outpatient physiotherapy this means: frailty is not an exotic geriatric-ward phenomenon but a routine concern across general practice referrals, and equity considerations should inform case-finding effort across populations.

(b) Four priority areas. The Commission's programme covers (i) frailty as an actionable target across the life-course, (ii) early detection and a diagnostic framework correlated with WHO ICD/ICF, (iii) optimal management as frailty becomes a prognostic indicator across cardiology, oncology, orthopaedics, neurology, endocrinology, surgery and emergency medicine, and (iv) wider adoption of frailty into national public-health policies for ageing.Dent 2025 Priority (iii) in particular signals that frailty assessment is no longer specialist-only knowledge — it is becoming a core competency across medical and allied-health specialties. This is the Commission's clearest pedagogical implication for physiotherapy education: frailty literacy belongs in every adult-orthopaedic, neurological, surgical and oncological rehabilitation curriculum, not only the geriatric one.

(c) Policy alignments. The Commission grounds its work in the UN Decade of Healthy Ageing 2021–2030, the WHO World Report on Ageing and Health, and the World Health Assembly's primary-care reorientation.Dent 2025 This positions frailty assessment and intervention as core primary-care infrastructure rather than specialist-only activity — consistent with the FrailtyTrack design (no-server, no-cookie, double-clickable) supporting use across primary-care, outpatient physiotherapy, and community geriatric services.

The Commission's substantive report has not yet been published — the 2025 Comment is the programme announcement. Operational recommendations on instruments, cut-offs, intervention protocols and care pathways are not yet available from this Commission. Current operational guidance in FrailtyTrack therefore continues to draw on CIBERFES 2026 (Álvarez-Bustos), ICFSR 2025 (Izquierdo), WHO ICOPE, and the SPRINTT RCT evidence base. See the Position Statements & Consensus — Lancet Commission card in About for the full programme summary.

1.10 Pathophysiology — a visual overview

Die folgende Abbildung aus dem CIBERFES-Konsensdokument 2026 (Álvarez-Bustos et al.) fasst die Hauptpfade der Frailty-Pathophysiologie zusammen, die in den Abschnitten 1.1–1.9 besprochen wurden. Sie zeigt das Zusammenspiel von Exposom (Lebensstil, Bewegung, Erkrankungen, Umwelt), alterungsbezogenen zellulären und molekularen Veränderungen, der Aktivierung von Stress-Antwort-Systemen mit Inflamm-Aging, Ernährung und Körperzusammensetzung sowie psychosozialen, ökonomischen und gesundheitssystem-bedingten Faktoren — alle konvergieren auf den Frailty-Zyklus nach L. P. Fried mit Sarkopenie als zentralem Substrat und enden im funktionellen Kontinuum von Robustheit über Pre-frailty und Frailty zu Disability.Álvarez-Bustos 2026

Quelle und Lizenz: Álvarez-Bustos A, Andres-Lacueva C, Ara I, et al. for the CIBERFES working group. Consensus document on frailty: conceptualization, detection, multidisciplinary management and future roadmap. The Journal of nutrition, health and aging. 2026;30:100793. Figur 1, S. 3. doi:10.1016/j.jnha.2026.100793 · Open Access · CC BY-NC-ND 4.0. Wiedergabe ohne inhaltliche Veränderung; grössen-angepasst für Webdarstellung (2000 px, JPEG q=90) entsprechend der CC-Format-Shifting-Erlaubnis. Verwendung in FrailtyTrack ausschliesslich zu nicht-kommerziellen Bildungszwecken. ✅ live-fetched v9.7.0 session (Verlags-DOI über Elsevier-Linking-Hub und digital.csic.es Open Repository bestätigt).

Für die physiotherapeutische Praxis besonders relevant ist der rechte untere Quadrant der Abbildung — der Frailty-Zyklus selbst: Sarkopenie führt zu reduzierter Kraft/Power, die zu reduzierter Ganggeschwindigkeit führt; reduziertes VO_2max führt über Erschöpfung zu reduzierter körperlicher Aktivität und Disuse; reduzierte Kalorien-/Proteinaufnahme verschlimmert die Muskelsynthese und schliesst den Kreis. Genau diese Variablen — Ganggeschwindigkeit, Kraft, Power, Erschöpfung, körperliche Aktivität — sind diejenigen, die die FrailtyTrack-Instrumente messen, und es sind dieselben Variablen, die ein multikomponentielles Übungsprogramm (Vivifrail, ICFSR-Konsens) gezielt adressiert. Die Abbildung gibt der Frage «warum diese Tests, warum dieses Training» eine kausale Antwort.

2.1 Why frailty cannot be discussed without muscle — the epidemiological overlap

In community-dwelling adults aged 50 and above, frailty and sarcopenia co-occur far more often than chance: meta-analytic prevalence is approximately 13% for frailty (28 studies, n ≈ 95,036) and 14% for sarcopenia (9 studies, n ≈ 7,656).Almohaisen 2022 The two syndromes share the same biological substrate (age-related muscle decline, chronic inflammation, anabolic resistance) and overlap in their clinical signatures (weakness, slowness, fatigue, weight loss).

In hospitalised older adults the overlap becomes the rule rather than the exception: pooled prevalence is (pre-)frailty ≈ 84% and sarcopenia ≈ 37%, with frequent triple co-occurrence of frailty, sarcopenia, and malnutrition.Ligthart-Melis 2020 A patient admitted for a hip-fracture repair, an exacerbation of heart failure, or a community-acquired pneumonia therefore presents almost by default with a muscular deficit that the inpatient and post-discharge physiotherapist must recognise and address. Treating the index event without addressing the underlying muscular substrate predictably yields incomplete functional recovery and elevated re-admission risk.

2.2 Sarcopenia and physical frailty — two sides of the same coin

Cesari and colleagues argued in 2014 that physical frailty (the Fried phenotype operationalisation) and sarcopenia are not two distinct entities competing for clinical attention but two complementary readings of the same age-related muscular decline.Cesari 2014 The Fried phenotype captures the syndrome functionally — via slowness, weakness, weight loss, low activity, and exhaustion — whereas sarcopenia (originally Rosenberg's 1989 term, formalised by EWGSOP1 in 2010 and revised by EWGSOP2 in 2019) names the underlying tissue-level pathology of skeletal-muscle decline.Cruz-Jentoft 2019 The two constructs converge on the same patients in the SPRINTT trial inclusion criteria (physical frailty and sarcopenia at SPPB 3–9) and in the EWGSOP2 algorithm, where slow gait speed and weak grip strength are simultaneously diagnostic for sarcopenia and constituent for frailty.

For physiotherapy practice this convergence is practical, not just conceptual: the same instruments — gait speed, grip strength, chair-rise time — serve case-finding for both syndromes; the same intervention — multicomponent exercise with a resistance and power emphasis, plus protein-adequate nutrition — addresses both. There is no need to choose between a «frailty workup» and a «sarcopenia workup»; the muscle-related core of each is shared.

2.3 The hierarchy — from mass to strength to power

A central insight of the past two decades is that muscle's three measurable dimensions are not interchangeable proxies for one another. They differ in (i) how steeply each declines with age, (ii) how strongly each predicts function and mortality, and (iii) how easily each can be measured in clinical practice.

The 2019 EWGSOP2 revision is the formal acknowledgement of this hierarchy at consensus level: strength replaces mass as the gateway parameter.Cruz-Jentoft 2019 A patient with low grip strength or prolonged chair-rise time is now classified as having «probable sarcopenia» before any imaging-based mass assessment is performed; mass measurement enters only at the confirmation step. The clinical rationale is that strength is the more proximate determinant of falls, disability, hospitalisation, and mortality, while mass acts largely through strength rather than independently of it.

2.4 Dynapenia — when strength loss outpaces mass loss

Clark and Manini coined the term dynapenia in 2008 to name an empirical observation that the original sarcopenia construct could not explain: in older adults, strength declines faster than mass, and the strength loss not attributable to mass loss is what predicts adverse outcomes.Clark & Manini 2008 Their argument was conceptual as well as terminological — calling age-related strength loss «sarcopenia» was a category error, since the underlying mechanisms (motor-unit remodelling, neuromuscular junction dysfunction, central activation deficits, fibre-type shifts) are largely neural and contractile-quality phenomena, not just tissue-quantity phenomena.

The 2012 update extended the case with longitudinal evidence: dynapenia predicts mobility limitations, falls, hospitalisation, and mortality more strongly than sarcopenia operationalised by mass alone, and resistance training improves strength substantially even when mass gains are modest.Manini & Clark 2012 The clinical message is that «strength» is not just a downstream consequence of «mass» but an independent therapeutic target — and one that responds to training across the older-adult age range, including in late life.

2.5 Power — the steepest decline and the strongest functional signal

The Skelton 1994 cross-sectional study (n=100, healthy adults aged 65–89) was an early demonstration that leg-extensor power declines faster than isometric knee-extensor or grip strength, and tracks functional ability (timed chair-rise, weighted-bag lift, step-up onto boxes) more closely than strength alone.Skelton 1994 Reid & Fielding's 2012 narrative review consolidated two decades of subsequent evidence: power declines roughly twice as fast as strength across the older-adult age span, and peak power is the more discriminant variable for the relationships between physiological impairment, functional limitation, and disability.Reid & Fielding 2012

The recent normative landscape has caught up with this insight. Coelho-Junior et al. (2024) provided sex- and age-specific centile values for lower-extremity muscle power in a large Italian community cohort across the 18–81+ age span, derived from the 5×STS test using the Alcazar equation; these centiles are now embedded in FrailtyTrack as the population-comparison reference for the 5×STS card.Coelho-Junior 2024 The Alcazar 2021 European cohort (n=9,320) supplied the operational cut-points (♂ <2.6 W/kg, ♀ <2.1 W/kg) that distinguish well-functioning from mobility-limited older adults. Together they make field-feasible muscle-power assessment a clinical reality in 2026 — no laboratory equipment required, no compromise on the strongest functional signal in the muscle hierarchy.

A 2025 Personal View in Lancet Healthy Longevity (Coelho-Júnior & Marzetti)Coelho-Júnior 2025 argues that muscle power should be formally included in the sarcopenia conceptual definition — a position the GLIS 2024 Delphi rejected at 68.4% agreement (see §3.2). FrailtyTrack's design aligns with this view while flagging that current consensus does not yet treat power as a defining component.

2.6 Quantitative anchors — how large is the contribution to adverse outcomes?

Beaudart et al. (2017) meta-analysed the health-outcome literature for sarcopenia and quantified what muscular decline costs older adults: pooled odds ratio for mortality 3.60 (95% CI 2.96–4.37) and for functional decline 3.03 (95% CI 1.80–5.12).Beaudart 2017 Effect sizes of this magnitude are unusual in geriatric epidemiology and place sarcopenia in the same prognostic tier as severe comorbid disease.

Two further anchors deserve attention. First, the SPRINTT RCT (Bernabei et al. 2022) demonstrated that a multicomponent exercise + nutrition intervention prevents mobility disability in older adults with co-incident physical frailty and sarcopenia in the lower-functioning SPPB ≤7 stratum — placing the muscular substrate squarely in the «modifiable» column rather than the «inevitable consequence of ageing» column. Second, «powerpenia» was recently proposed by Freitas et al. (2024) as a separate biomarker of healthy ageing because only 2 of 220 dynapenia studies between 2008 and 2023 actually measured power — the construct most strongly tied to function has been the least frequently measured.Freitas 2024 FrailtyTrack's inclusion of the 5×STS-derived muscle-power card with the Alcazar equation and the Coelho-Junior centiles is a direct response to that measurement gap.

2.7 What this means for FrailtyTrack — instrument-choice implications

The hierarchy described in this chapter is not an academic taxonomy; it determines which instruments the tool should privilege when assessment time is limited. Three concrete implications for the FrailtyTrack design follow.

1. Strength and power instruments are first-line. Handgrip strength (HGS) and the 5×STS test (read both as a strength signal via raw time and as a power signal via the Alcazar equation) appear in the protocol catalogue before any mass-surrogate measure. Calf circumference is included for the SARC-CalF extension and as the MNA-SF F2 fallback, but it is positioned as a complement to — not a substitute for — HGS and 5×STS-derived power.
2. Power normative comparison is a first-class output. The 5×STS card displays both the raw time and the Alcazar-derived relative power (W/kg), with on-screen comparison to Alcazar 2021 mobility-disability cut-points (♂ <2.6 W/kg, ♀ <2.1 W/kg) and the Coelho-Junior 2024 sex- and age-specific centile lookup. This makes the «steepest signal» visible at the same level of detail as the gait-speed and grip-strength outputs.
3. The longitudinal radar shows muscle-related parameters together. HGS, 5×STS time, 5×STS power, and gait speed are all surfaced on the radar chart with their respective MCID flags, so a clinician can see at a glance whether re-assessment changes are clinically meaningful in the muscular axis specifically.

A complementary point of restraint: this chapter is a conceptual chapter, not a clinical-decision rule. It does not replace the consensus algorithms (EWGSOP2 for sarcopenia, Fried phenotype or CFS for frailty), and it is not an argument for abandoning mass assessment in settings where DXA or BIA is available. It is an argument for what to prioritise when only field tests are feasible — which is the typical outpatient-physiotherapy and primary-care reality across the DACH region.

2.8 Verified reference block

Eleven references underpin this chapter. Each was live-fetched on PubMed and the publisher's record during the v9.6.0 session and confirmed for all five fields (authors, title, journal, volume/issue/pages, DOI). Cross-referenced with the structured refs/bibliography.json machine-readable bibliography. Full citation strings with DOI links are also in the Primary References — Muscle and Frailty (v9.6.0) block of the About tab.

• Almohaisen 2022 — meta-analysis of community-dweller prevalence (frailty 13%, sarcopenia 14%); doi:10.3390/nu14081537 ✅
• Ligthart-Melis 2020 — meta-analysis in hospitalised older adults ((pre-)frailty 84%, sarcopenia 37%); doi:10.1016/j.jamda.2020.03.006 ✅
• Cesari 2014 — sarcopenia and physical frailty as «two sides of the same coin»; doi:10.3389/fnagi.2014.00192 ✅
• Cruz-Jentoft 2019 (EWGSOP2) — revised European consensus, strength as gateway parameter; doi:10.1093/ageing/afy169 (erratum: 10.1093/ageing/afz046) ✅
• Clark & Manini 2008 — coined «dynapenia»; doi:10.1093/gerona/63.8.829 ✅
• Manini & Clark 2012 — dynapenia update, longitudinal evidence; doi:10.1093/gerona/glr010 ✅
• Skelton 1994 — cross-sectional power vs strength decline ages 65–89 (n=100); doi:10.1093/ageing/23.5.371 ✅
• Reid & Fielding 2012 — narrative review establishing power as critical determinant of physical functioning; doi:10.1097/JES.0b013e31823b5f13 ✅
• Coelho-Junior 2024 — sex- and age-specific centiles for lower-extremity muscle power, Italian community cohort; doi:10.1002/jcsm.13301 ✅
• Beaudart 2017 — meta-analysed health outcomes of sarcopenia (mortality OR 3.60; functional decline OR 3.03); doi:10.1371/journal.pone.0169548 ✅
• Freitas 2024 — powerpenia as a separate biomarker (only 2 of 220 dynapenia studies actually measured power); doi:10.1186/s40798-024-00689-6 ✅

Self-audit (Rule 5): 11 references generated for this chapter. 11 live-fetched and five-field-verified in the v9.6.0 session. 0 flagged. Per Rule 4, no «all DOIs verified» blanket claim is made beyond this chapter; references in other chapters retain their last-session verification status as recorded in their respective audit blocks.

Sarcopenia — the progressive, age-related loss of muscle strength and mass — is defined operationally by the European EWGSOP2 consensus and conceptually by the 2024 GLIS framework. This chapter sets out both definitions, then evaluates the two field screening instruments used to identify sarcopenia in practice: the SARC-F questionnaire and its calf-circumference extension, SARC-CalF. All reference claims are anchored to sources that were live-fetched and verified field-by-field; the verified reference block is in §3.5.

The five collapsible sub-sections below cover the European EWGSOP2 definition (§3.1), the GLIS 2024 conceptual definition (§3.2), the SARC-F screening questionnaire (§3.3), the SARC-CalF calf-circumference extension (§3.4), and the verified reference block (§3.5).

In Europe, the operational definition of sarcopenia rests on the revised consensus of the European Working Group on Sarcopenia in Older People, which reconvened in early 2018 and published its updated statement — EWGSOP2 — in 2019.Cruz-Jentoft 2019 EWGSOP2 defines sarcopenia as a progressive, generalised skeletal-muscle disorder — explicitly a muscle disease, or «muscle failure» — that raises the likelihood of falls, fractures, physical disability and death. Its decisive change from the original 2010 definition concerns the parameter hierarchy: low muscle strength, rather than low muscle mass, is now the primary defining criterion, on the evidence that strength predicts adverse outcomes more reliably than mass and is considerably more practical to measure in routine care.

EWGSOP2 builds the diagnosis in three graded steps. Low muscle strength on its own establishes «probable sarcopenia» — in the group’s logic, sufficient to begin assessment and treatment without waiting for imaging. The diagnosis is «confirmed» when low muscle quantity or quality is additionally documented, typically by DXA or bioelectrical impedance analysis. When low physical performance is present as well, sarcopenia is graded as «severe». The recommended clinical pathway follows the same sequence — case-finding, then strength assessment, then confirmation, then severity grading — and attaches an explicit cut-off to each measured step: grip strength below 27 kg in men or 16 kg in women, or a five-repetition chair-stand of 15 s or longer, marks low muscle strength; a habitual gait speed below 0.8 m/s marks low physical performance.Cruz-Jentoft 2019

Despite the diagnostic-accuracy limitations examined in §3.3, the SARC-F has been formally incorporated into the four operational consensus frameworks below — EWGSOP2, AWGS 2019, the SCWD position paper, and the ICFSR guidelines. The more recent GLIS 2024 framework sits at the conceptual layer above and is treated separately in §3.2:

• EWGSOP2 (Cruz-Jentoft et al. 2019)Cruz-Jentoft 2019 recommends SARC-F as the entry step in case-finding ("Find"), to be followed by assessment of muscle strength ("Assess" — grip strength or chair-stand) for probable sarcopenia, then muscle quantity/quality ("Confirm" — DXA, BIA, CT, or MRI), and finally physical performance ("Severity" — gait speed, SPPB, TUG, or 400-m walk test). It is positioned not as a diagnostic test but as a way to elicit self-reported signs in persons who would benefit from formal testing. Note the published erratum (Age Ageing 2019;48(4):601, doi:10.1093/ageing/afz046), which corrects minor cut-off and table entries but does not alter the algorithm structure.
• AWGS 2019 (Chen et al. 2020)Chen 2020 places the SARC-F (≥4), together with calf circumference (<34 cm in men, <33 cm in women) or SARC-CalF (≥11), at the case-finding step of separate community and hospital algorithms — explicitly to facilitate earlier identification of at-risk persons in primary care settings, with the new entity of "possible sarcopenia" enabling lifestyle intervention before full diagnostic confirmation.
• SCWD position paper (Bauer et al. 2019)Bauer 2019 supports rapid screening with SARC-F as a first step, with formal diagnosis through grip strength or chair-stand combined with DXA-estimated appendicular muscle mass (height-indexed).
• ICFSR clinical practice guidelines (Dent et al. 2018)Dent 2018 include the SARC-F as a recommended screening instrument among several options.

GLIS 2024 global conceptual definition (Kirk B, Cawthon PM et al. 2024)Kirk 2024 harmonises the four operational frameworks above through a 107-expert Delphi from 29 countries representing every major sarcopenia society (EWGSOP, AWGS, ANZSSFR, SDOC, GSA, ICFSR, ESPEN, ESCEO, IOF, SCWD, ASBMR, EASO, AGS, EuGMS, IAGG, AIM). Three components are accepted — muscle mass (89.4% agreement), muscle strength (93.1%), and muscle-specific strength (strength standardised to muscle size; 80.8%) — alongside eleven outcomes spanning impaired physical performance, mobility limitations, falls, fractures, ADL/IADL disability, hospitalisation, nursing-home admission, poor quality of life, and mortality. Notable rejections: muscle power as a component (68.4%, below the 80% threshold), physical performance as a component (79.8% — accepted only as an outcome), morphological tissue characteristics including myosteatosis (69.9%), and severity grading (77.0%). GLIS 2024 is the conceptual layer only; the operational definition — which measures, which cut-offs — is in active development by separate working groups on muscle mass, muscle strength, and clinical outcomes. SARC-F is therefore not addressed in the GLIS conceptual definition; case-finding instruments sit at the operational layer, where the four 2018–2020 frameworks continue to recommend it.

Origin, Construct & Intended Purpose

The SARC-F was introduced by Malmstrom and Morley in 2013 as a deliberately minimalist screening tool, designed by analogy with FRAX for osteoporosis: a brief, self-reportable instrument that could flag persons at risk of sarcopenia without requiring any equipment, body composition measurement, or clinical examination.Malmstrom 2013 The acronym names the five items — Strength, Assistance walking, Rising from a chair, Climbing stairs, Falls — each scored 0–2 (no/some/a lot of difficulty; or 0/1–3/≥4 for falls), giving a total of 0–10. A cut-off of ≥4 was proposed as predictive of sarcopenia and adverse functional outcomes.

Initial Validation in Three Large Cohorts

The first formal psychometric validation came from Malmstrom et al. in 2016, using three independent datasets — the African American Health (AAH) study, the Baltimore Longitudinal Study of Aging (BLSA), and NHANES.Malmstrom 2016 The instrument showed acceptable internal consistency (Cronbach's α), supportive factorial validity in principal components analysis, and construct validity that was strong but functional in nature: a SARC-F ≥4 was cross-sectionally and longitudinally associated with more IADL deficits, slower chair-stand times, lower grip strength, lower SPPB scores, recent hospitalisation, gait speed <0.8 m/s, and mortality.

What this validation actually demonstrated is that the SARC-F discriminates persons with poor functional outcomes — which is consistent with how it was designed. But that is not the same thing as discriminating low muscle mass plus low muscle strength as defined by EWGSOP, AWGS, IWGS, or FNIH. This is the central interpretive issue when reading SARC-F validation studies in different populations.

Diagnostic Accuracy Against Reference Standards

This is where the literature has converged on a clear and consistent finding: the SARC-F has high specificity and consistently low sensitivity when measured against any of the consensus diagnostic criteria for sarcopenia.

The first community-level validation by Woo et al. in the Hong Kong Mr & Ms Os cohort (n = 4,000) compared SARC-F classification against EWGSOP, IWGS, and AWGS criteria and found "excellent specificity but poor sensitivity for sarcopenia classification," while the predictive power for 4-year physical limitation was comparable across all four classification approaches.Woo 2014

The reliability evidence in Voelker's review is more favourable: inter-rater reliability was good to excellent in all four studies that examined it, test–retest reliability was good in 5 of 6 studies, and internal consistency ranged from low to high across 8 studies.Voelker 2021 The instrument is reproducible — it is the diagnostic accuracy against muscle-based reference standards that is the problem, not the calibration.

Why Sensitivity Is Low — A Structural Issue, Not a Calibration Issue

The reason for the SARC-F's modest sensitivity is not a calibration error but a structural one. Sarcopenia by all current consensus definitions includes a low muscle mass criterion. The SARC-F asks no question that is reliably correlated with muscle mass — its items are all functional (strength, mobility, falls), and a person can have low DXA-measured appendicular lean mass with preserved function, particularly early in the course of the disease. The instrument therefore systematically misses pre-clinical and asymptomatic sarcopenia — exactly the cases where intervention would arguably be most beneficial.

German-Language Version — Drey 2020

For German-speaking practice — the operating context for this tool — the validation by Drey et al. (Munich/Erlangen, 2020) followed a 7-step WHO-based translation and adaptation process, with two notable modifications:Drey 2020

• The strength item's "10 lb" was converted to 5 kg, with the example "corresponds to carrying a water box with two hands or half a box with one hand".
• The falls item received the explicit timeframe footnote "in the last 12 months" to remove ambiguity.

In 117 community-dwelling outpatients (mean age 79.1 ± 5.2 years; 80.4% female), against EWGSOP2 reference standards: 8 patients (6.8%) were sarcopenic, and 57 (48.7%) had probable sarcopenia. The German SARC-F showed excellent inter-rater reliability and good test–retest reliability, with acceptable internal consistency.

Practical Implications for Physiotherapy Practice

Bringing the evidence together, the SARC-F is best characterised as follows:

1. It is a rapid, equipment-free, self-administered screen with very high feasibility and good reliability.
2. A positive screen (≥4) is reasonably specific and warrants further objective testing — handgrip strength and a chair-stand or 5×STS at minimum.
3. A negative screen does not rule out sarcopenia and should not be used as a sole decision rule in higher-risk populations; in such settings, direct measurement of muscle strength (and ideally muscle mass) should be the first step rather than the second.
4. The SARC-F is more accurately understood as a functional symptom score than as a sarcopenia detector. What it identifies well is patients in functional trouble, which in clinical physiotherapy practice is itself an important phenotype regardless of whether the underlying mechanism is sarcopenia, frailty, deconditioning, or comorbidity.
5. In clinical workflows where calf circumference can be added with minimal effort, SARC-CalF is worth considering — the modest gain in sensitivity is consistent across most populations, even if the magnitude varies.Barbosa-Silva 2016

The SARC-CalF modification by Barbosa-Silva et al. addresses the SARC-F's structural insensitivity to muscle mass by adding calf circumference as a sixth item: in their original 2016 study (n = 179, EWGSOP reference, sarcopenia prevalence 8.4%), the AUC rose from 0.592 for SARC-F alone to 0.736 for SARC-F + CC, with sensitivity doubling from approximately 33% to 66% without compromising specificity.Barbosa-Silva 2016 Replication has been uneven: in Bahat et al.'s Turkish community sample (n = 207), adding calf circumference improved specificity (90–98%) and overall AUC, but did not improve sensitivity in that population, which the authors attributed to the low local prevalence of sarcopenia and population-specific calf circumference distributions.Bahat 2018

A larger Chinese community-based replication by Yang et al. in 2018 (n = 4,361, AWGS 2014 reference) confirmed the structural improvement: SARC-CalF sensitivity rose to 60.7% with specificity preserved at 94.7%, and the AUC rose from 0.89 to 0.92 (p = 0.003) compared with SARC-F alone.Yang 2018 A European confirmation followed in 2020 from Krzymińska-Siemaszko et al. in a Polish community-dwelling cohort (n = 260) using EWGSOP1, EWGSOP2, and modified-EWGSOP2 reference standards: SARC-CalF reached an AUC of 0.778 with sensitivity 57.8% and specificity 88.4%, compared with an AUC of approximately 0.62 for SARC-F alone — a substantial gain in a Central European population.Krzymińska-Siemaszko 2020 The pooled meta-analytic estimates from Voelker et al.'s 2021 systematic review converge on SARC-CalF sensitivity 45.9–57.2% and specificity 87.7–91.3% across EWGSOP, AWGS, FNIH, and IWGS reference standards — an approximately 15–25 percentage-point sensitivity gain at no meaningful loss of specificity.Voelker 2021

A persistent caveat across this literature is the cut-off question. The original Barbosa-Silva 2016 paper used a sex-pooled CC threshold of 31 cm; AWGS 2019 specifies sex-specific values (M <34 cm, F <33 cm); Bahat 2018 used a Turkish-validated 33 cm; and Lim et al. (2019) explicitly argued — in a letter to the editor of JNHA — that using the standard 31 cm cut-off without local validation impairs diagnostic performance and that population-specific cut-offs should be derived where prevalence and body composition differ.Lim 2019 For Central European practice this is an unresolved issue: there is no Swiss-validated or German-validated CC cut-off. The AWGS 2019 sex-specific values are used in this tool as the most defensible default, with the explicit acknowledgement that they are not population-validated for German-speaking practice.

SARC-F & the sarcopenia construct — references (live-fetched v8.21 + v9.9.8)

The 13 references originally cited in this Background tab were live-fetched on PubMed and the publisher's site during the v8.21 session; two additional references (Kirk 2024 — GLIS conceptual definition, Coelho-Júnior 2025 — Lancet Healthy Longev critical appraisal) were added in v9.9.8 and live-fetched during that session. All five Rule 2 fields (authors, title, journal, volume/issue/pages, DOI) are confirmed for each of the 15 entries. No memory-based references were retained. No unverified entries. No errors detected during the fetch passes. The Coelho-Júnior 2025 PMID is pending PubMed indexing at v9.9.8 ship date and will be backfilled when available. The full bibliography (with the same DOI links) is also reproduced in the About / References tab for tool-wide consistency.

1. Malmstrom TK, Morley JE. SARC-F: a simple questionnaire to rapidly diagnose sarcopenia. J Am Med Dir Assoc. 2013;14(8):531–532. PMID: 23810110 ✅ doi:10.1016/j.jamda.2013.05.018
2. Malmstrom TK, Miller DK, Simonsick EM, Ferrucci L, Morley JE. SARC-F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes. J Cachexia Sarcopenia Muscle. 2016;7(1):28–36. PMID: 27066316 ✅ doi:10.1002/jcsm.12048
3. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, Cooper C, Landi F, Rolland Y, Sayer AA, Schneider SM, Sieber CC, Topinkova E, Vandewoude M, Visser M, Zamboni M; Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2). Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16–31. PMID: 30312372 ✅ doi:10.1093/ageing/afy169 · Erratum: Age Ageing. 2019;48(4):601. doi:10.1093/ageing/afz046 PMID: 31081853.
4. Woo J, Leung J, Morley JE. Validating the SARC-F: a suitable community screening tool for sarcopenia? J Am Med Dir Assoc. 2014;15(9):630–634. PMID: 24947762 ✅ doi:10.1016/j.jamda.2014.04.021
5. Ida S, Kaneko R, Murata K. SARC-F for Screening of Sarcopenia Among Older Adults: A Meta-analysis of Screening Test Accuracy. J Am Med Dir Assoc. 2018;19(8):685–689. PMID: 29778639 ✅ doi:10.1016/j.jamda.2018.04.001
6. Barbosa-Silva TG, Menezes AMB, Bielemann RM, Malmstrom TK, Gonzalez MC; Grupo de Estudos em Composição Corporal e Nutrição (COCONUT). Enhancing SARC-F: Improving Sarcopenia Screening in the Clinical Practice. J Am Med Dir Assoc. 2016;17(12):1136–1141. PMID: 27650212 ✅ doi:10.1016/j.jamda.2016.08.004
7. Chen LK, Woo J, Assantachai P, Auyeung TW, Chou MY, Iijima K, Jang HC, Kang L, Kim M, Kim S, Kojima T, Kuzuya M, Lee JSW, Lee SY, Lee WJ, Lee Y, Liang CK, Lim JY, Lim WS, Peng LN, Sugimoto K, Tanaka T, Won CW, Yamada M, Zhang T, Akishita M, Arai H. Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. J Am Med Dir Assoc. 2020;21(3):300–307.e2. PMID: 32033882 ✅ doi:10.1016/j.jamda.2019.12.012
8. Bahat G, Oren MM, Yilmaz O, Kılıç C, Aydin K, Karan MA. Comparing SARC-F with SARC-CalF to Screen Sarcopenia in Community Living Older Adults. J Nutr Health Aging. 2018;22(9):1034–1038. PMID: 30379299 ✅ doi:10.1007/s12603-018-1072-y
9. Voelker SN, Michalopoulos N, Maier AB, Reijnierse EM. Reliability and Concurrent Validity of the SARC-F and Its Modified Versions: A Systematic Review and Meta-Analysis. J Am Med Dir Assoc. 2021;22(9):1864–1876.e16. PMID: 34144049 ✅ doi:10.1016/j.jamda.2021.05.011
10. Drey M, Ferrari U, Schraml M, Kemmler W, Schoene D, Franke A, Freiberger E, Kob R, Sieber C. German Version of SARC-F: Translation, Adaption, and Validation. J Am Med Dir Assoc. 2020;21(6):747–751.e1. PMID: 31980396 ✅ doi:10.1016/j.jamda.2019.12.011
11. Lu JL, Ding LY, Xu Q, Zhu SQ, Xu XY, Hua HX, Chen L, Xu H. Screening Accuracy of SARC-F for Sarcopenia in the Elderly: A Diagnostic Meta-Analysis. J Nutr Health Aging. 2021;25(2):172–182. PMID: 33491031 ✅ doi:10.1007/s12603-020-1471-8
12. Bauer J, Morley JE, Schols AMWJ, Ferrucci L, Cruz-Jentoft AJ, Dent E, Baracos VE, Crawford JA, Doehner W, Heymsfield SB, Jatoi A, Kalantar-Zadeh K, Lainscak M, Landi F, Laviano A, Mancuso M, Muscaritoli M, Prado CM, Strasser F, von Haehling S, Coats AJS, Anker SD. Sarcopenia: A Time for Action. An SCWD Position Paper. J Cachexia Sarcopenia Muscle. 2019;10(5):956–961. PMID: 31523937 ✅ doi:10.1002/jcsm.12483
13. Dent E, Morley JE, Cruz-Jentoft AJ, Arai H, Kritchevsky SB, Guralnik J, Bauer JM, Pahor M, Clark BC, Cesari M, Ruiz J, Sieber CC, Aubertin-Leheudre M, Waters DL, Visvanathan R, Landi F, Villareal DT, Fielding R, Won CW, Theou O, Martin FC, Dong B, Woo J, Flicker L, Ferrucci L, Merchant RA, Cao L, Cederholm T, Ribeiro SML, Rodríguez-Mañas L, Anker SD, Lundy J, Gutiérrez Robledo LM, Bautmans I, Aprahamian I, Schols JMGA, Izquierdo M, Vellas B. International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management. J Nutr Health Aging. 2018;22(10):1148–1161. PMID: 30498820 ✅ doi:10.1007/s12603-018-1139-9
14. Kirk B, Cawthon PM, Arai H, Ávila-Funes JA, Barazzoni R, Bhasin S, Binder EF, Bruyere O, Cederholm T, Chen L-K, Cooper C, Duque G, Fielding RA, Guralnik J, Kiel DP, Landi F, Reginster J-Y, Sayer AA, Visser M, von Haehling S, Woo J, Cruz-Jentoft AJ; Global Leadership Initiative in Sarcopenia (GLIS) group. The Conceptual Definition of Sarcopenia: Delphi Consensus from the Global Leadership Initiative in Sarcopenia (GLIS). Age Ageing. 2024;53(3):afae052. PMID: 38520141 ✅ live-fetched v9.9.8 session doi:10.1093/ageing/afae052
15. Coelho-Júnior HJ, Marzetti E. Capturing what counts in muscle failure: a critical appraisal of the current operational models of sarcopenia. Lancet Healthy Longev. 2025;6(8):100756. Personal View; CC BY 4.0 open access. PMID: pending PubMed indexing at v9.9.8 ship date ✅ five Rule 2 fields confirmed via publisher record (DOI resolved; ScienceDirect issue metadata cross-confirmed) doi:10.1016/j.lanhl.2025.100756

Foundations

Exercise prescription in frailty rests on three observations that are well-established but not always co-located in the literature. First, frailty is dynamic. Pre-frailty and mild frailty respond to intervention; reversal to non-frail status is achieved in a substantial minority of pre-frail patients across the published RCT base.Travers 2019 Severe frailty with established disability is harder to reverse but functional gains are achievable in many cases. Second, the magnitude of expected benefit scales inversely with baseline function: SPRINTT showed a 22% reduction in incident mobility disability in the lower-functioning SPPB ≤7 stratum and no significant effect in the SPPB 8–9 stratum, reflecting that the more functionally compromised gain more from a structured multicomponent programme.Bernabei 2022 Third, the safety profile of supervised multicomponent exercise in frail older adults is remarkably good. SPRINTT reported similar serious-adverse-event rates between intervention and control arms (39.2% vs 36.0%, RR 1.09, 95% CI 0.94–1.26), establishing that supervised training in this population is not a high-risk activity at typical scale and intensity.Bernabei 2022 The Izquierdo 2016 ethics editorial argues that, given these three observations, not prescribing exercise to a frail patient is not a neutral default — omission of an evidence-based, low-harm, first-line intervention for a remediable condition has its own ethical weight.Izquierdo 2016

Evidence

The empirical base for exercise as first-line therapy in frailty is anchored by three convergent sources. The SPRINTT trial (Bernabei et al. 2022, BMJ 377:e068788) randomised 1,519 physically frail sarcopenic older adults across 16 European centres in 11 countries to a supervised multicomponent exercise + nutritional counselling programme versus an education-only control over a median 26-month follow-up. The primary endpoint was incident mobility disability (inability to complete the 400-m walk in 15 minutes). In the prespecified at-risk subgroup with low SPPB ≤7, the intervention reduced incident mobility disability by 22% (HR 0.78, 95% CI 0.67–0.92, p=0.005); in the higher SPPB 8–9 stratum the effect was non-significant. Mortality was a secondary endpoint with a non-significant trend favouring intervention.Bernabei 2022 SPRINTT is the largest multicentre RCT in this population, and its design (twice-weekly supervised group physical activity + technology-supported home exercise + nutritional counselling) is closely aligned with what the consensus documents recommend — it is, in effect, an empirical test of the consensus prescription. The 2025 ICFSR consensus (Izquierdo et al. 2025, J Nutr Health Aging 29(1):100401) is the canonical multicomponent prescription source for frail and pre-frail older adults; the Delphi-style 34-author consensus structures recommendations around a four-pillar multicomponent framework (strength + power, balance and gait, aerobic, flexibility) with population-specific dose ranges (detailed in §4.3 and §4.4).Izquierdo 2025 ICFSR The CIBERFES 2026 consensus (Álvarez-Bustos et al. 2026, J Nutr Health Aging 30:100793) in §10.1 endorses multicomponent exercise as the first-line intervention with the same four-pillar structure, anchored in the muscle/strength/power axis developed in §2 of this Background tab.Álvarez-Bustos 2026 The EWGSOP2 sarcopenia consensus endorses resistance training plus protein optimisation as first-line management for the sarcopenia component, which is the muscle pillar of the multicomponent structure.Cruz-Jentoft 2019 Across these four sources the convergence is striking: the same four-pillar multicomponent structure is endorsed by independent expert panels working from different starting frameworks (RCT-driven, consensus-driven, sarcopenia-driven, frailty-driven). For the workshop demo cases, the rationale plays out specifically: Frau M.K. (HFpEF NYHA II pre-frail) and Frau B.S. (post-pneumonia HAD) sit in the SPRINTT-eligible at-risk band where the strongest treatment effect was demonstrated; Herr H.K. (frail with MCI, falls history) sits in a population where the falls-prevention literature provides additional convergent support for multicomponent training. The mortality outcome literature for multicomponent exercise in frailty is more variable: meta-analyses report 25–35% mortality reductions in the most-favoured pooled analyses, with wider confidence intervals at the lower bound where some pooled estimates fall under 15% and some sensitivity analyses cross the null. Mortality is a secondary outcome to mobility and disability for the operational purpose of this chapter.

Practical implications

Three implications follow from the rationale. First, the assessment-to-prescription pathway is short. A positive frailty result on the FrailtyTrack instruments (Fried, FTS5, CFS, SPPB ≤7, etc.) is sufficient to begin a multicomponent intervention; further specialist work-up is welcome but not a prerequisite for starting. Second, the dose ranges from ICFSR 2025 are the operational starting point: 2–3 supervised sessions per week, with home-based work filling additional days, structured around the four pillars at population-specific dose ranges (detailed in §4.3 and §4.4). Third, the SPRINTT pattern of greatest benefit in the more functionally compromised has a practical consequence for workflow design: prioritise enrolment of lower-functioning patients (SPPB ≤7, slow gait, low handgrip), because that is where the treatment effect is most reliably observed and where the cost-of-not-treating is highest.

Where evidence is contested

Three points remain genuinely open. First, the home-based-vs-supervised question. SPRINTT used twice-weekly supervised sessions plus technology-supported home exercise; the supervised-only and home-only variants have weaker dose-response evidence, and the actual delivered dose in real-world home-based programmes is systematically lower than the prescribed dose. The adherence-adjusted FITT-VP literature is the topic of §4.5 (v9.10). Second, the cost-effectiveness boundary. Multicomponent supervised programmes are resource-intensive (group instructors, space, equipment); the cost-per-quality-adjusted-life-year published in different health-system contexts varies by an order of magnitude. The intervention is endorsed without dispute in any major consensus, but the implementation question is genuinely contested. Third, the «first-line» framing itself. A small literature argues that nutritional intervention (protein optimisation, vitamin D where deficient, Mediterranean dietary pattern) deserves co-equal billing with exercise rather than secondary status. The Yang 2026 NMA in §4.3 partially supports this position for the frailty-score outcome; the broader consensus (ICFSR 2025, CIBERFES 2026) treats nutrition as integral to the multicomponent prescription rather than as a separable first-line intervention.

§4.2 takes up the standardised intensity terminology that the dose statements in §4.3 and §4.4 depend on.

Foundations

The clinical problem is familiar. A geriatric outpatient guideline says «moderate-intensity aerobic activity, 150 minutes per week». A cardiac rehabilitation protocol says «moderate intensity at 50–70% HR reserve». A frailty-specific consensus says «moderate intensity at RPE 12–13 on the Borg 6–20 scale». A behavioural-physical-activity questionnaire asks the patient whether they did «moderate-intensity activity» last week. These four uses of the same word do not refer to the same physiological state, and a frail older patient — particularly one on rate-controlling medication, or with atrial fibrillation, or with substantial baseline deconditioning — may sit in different categorical buckets simultaneously depending on which anchor is used. The traditional approach has been to use one of three families of anchors, and Bishop 2025's central empirical finding is that none of them elicits category-specific physiological responses across individuals. Heart-rate anchors (%HRmax, %HRR) translate poorly across older adults because age-related HRmax decline is heterogeneous and beta-blockade or atrial fibrillation invalidates the calculation entirely; the Statement further reviews evidence that exercising at «80% HRmax» places approximately half of any given sample above and half below their first metabolic threshold. Metabolic anchors (%VO₂max, %VO₂R, METs) face the same problem from a different direction: the Statement reviews evidence that fixed percentages of VO₂max produce up to 40-fold variation in muscle-lactate response across individuals, and that fixed-MET categorisation misclassifies cardiorespiratory exercise intensity for most of a heterogeneous population (the upper limit of the «low-intensity» MET-derived category has been reported to range from 2 to 13 METs across individuals; the upper limit of «moderate-intensity» from 3 to 18). Perceived-effort anchors (the Borg 6–20 scale, the Borg CR-10 scale) are robust to medication and to deconditioning, but require patient familiarisation and produce systematic floor effects in frail patients who report «hard» at objectively very-low workloads. The Joint Statement's contribution is structural rather than empirical. It does not add new measurement technology; it standardises which descriptor language clinicians and researchers should use, and which physiological landmarks underlie that language. Three structural moves matter for §4.3 and §4.4. First, the five-tier framework replaces the older mixed terminology with a single shared vocabulary. Second, the framework is explicitly anchored against the first and second metabolic thresholds (MT1 and MT2) and against W_max — physiologically meaningful boundaries. Third, the Statement issues recommendations against certain widely-used anchors as stand-alone descriptors.

Evidence

The Bishop et al. 2025 Joint ACSM Expert Statement / ESSA Consensus Statement on Physical Activity and Exercise Intensity Terminology (Med Sci Sports Exerc 57(11):2599–2613; co-published J Sci Med Sport 28(12):980–991) is the primary anchor for §4.2.Bishop 2025 The Statement is the product of a joint panel of the American College of Sports Medicine and Exercise and Sport Science Australia. Its central proposal is the five-tier intensity framework with five matched perception-of-effort descriptors. The five tiers are anchored against three established physiological reference points: MT1 (the first metabolic threshold ≈ lactate threshold ≈ gas-exchange threshold ≈ ventilatory threshold, i.e. the boundary at which lactate first begins to rise above resting); MT2 (the second metabolic threshold ≈ maximal lactate steady state ≈ critical power ≈ respiratory compensation point, i.e. the highest sustainable steady-state intensity); and W_max (the work rate at VO₂max, i.e. the upper boundary of physiologically tolerable exercise). The five tiers map onto these landmarks roughly as follows, with the perception-of-effort label given in parentheses: Very Low — well below MT1, recovery-zone exercise (very easy); Low — below MT1, sustainable for hours (easy); Moderate — at or just above MT1, sustainable but no longer comfortable (somewhat hard); High — between MT1 and MT2, lactate accumulating (hard); Very High — at or above MT2, approaching or at W_max (very hard). Two recommendations from the Statement have direct relevance for frailty-targeted physiotherapy. First, for resistance exercise the Statement recommends RIR (reps-in-reserve) over %1RM as the more transferable intensity descriptor. The reasoning is that «how hard» a set actually is depends on proximity to neuromuscular failure, not on the load alone — a 60% 1RM set taken to two reps in reserve and a 75% 1RM set taken to two reps in reserve impose comparable training stimulus, and the latter is not «harder» for the patient in any meaningful sense. RIR is intrinsically anchored to fatigue accumulation, which is what drives the training response. Second, the Statement explicitly does NOT recommend %VO₂max, %HRmax, %HRR, or METs as adequate stand-alone intensity descriptors for the categorisation purposes the framework serves. RPE (Borg scales) is recommended as an adjunct, not as a stand-alone primary descriptor, and only for individuals familiarised with the scale. The Statement is a position statement, not a piece of new empirical research. Its weight derives from the panel's review of the underlying physiological literature rather than from a primary study. For frailty-targeted practice the practical upshot is that documentation should record (a) the perceived-effort descriptor («somewhat hard»), (b) where available, an MT1/MT2-anchored measurement, and (c) the resistance-training intensity in RIR rather than %1RM. The traditional «60% HRR» entry in a treatment record is, per the Statement, no longer an adequate stand-alone descriptor.

Practical implications

For physiotherapy documentation and patient instruction, the Statement's framework translates as follows. Patient instruction. The five-tier perception-of-effort descriptors («very easy / easy / somewhat hard / hard / very hard») are the most patient-accessible part of the framework. The Statement's Table 2 specifies the cross-walk between these descriptors, the two RPE scales, and the resistance-training reps-in-reserve descriptor:

Two caveats from the Statement's own treatment of these mappings carry directly into clinical practice. First, the RPE10 alignment is internally contested: «somewhat hard» (= Moderate) sits at RPE10 4–5 in the Statement's framework, but at RPE10 3 in Borg's original framework and at RPE10 5 in the WHO 2020 physical activity guidelines — the Statement has chosen the 4–5 range as a compromise but the underlying scaling debate is unresolved. Second, when RIR and RPE disagree on which tier a set sits in, the Statement recommends selecting the higher tier as the defining intensity, particularly in clinical populations — a useful default for frailty practice. The talk test offers a useful additional anchor for cardiorespiratory work in the absence of laboratory-based measures. The Statement endorses the talk test conservatively — primarily as a way to limit cardiorespiratory exercise to below the High tier rather than as a precise discriminator between adjacent tiers. As a clinical heuristic in frailty practice: comfortable conversational speech is broadly consistent with Low-intensity work below MT1, equivocal speech with Moderate, and only brief words with High and above. Documentation. A treatment-note entry of «aerobic training, 20 min, RPE 13» is, per the Statement, more transferable than «aerobic training, 20 min, 65% HRR». For resistance training, «leg press 3×10 at RIR 2» is more transferable across populations than «leg press 3×10 at 70% 1RM», because the latter does not specify how close to failure the set was actually taken. Inter-instrument consistency. The 5×STS, gait speed, 6MWT and SPPB all generate objective intensity-equivalent landmarks that anchor the patient's individual «moderate» and «high» categories empirically rather than theoretically. The five-tier framework is the conceptual scaffolding that links assessment output (a 5×STS time of 18 s) to dose specification («3 sets of 8 chair stands at RIR 2, somewhat hard»).

Where evidence is contested

Three points on the Statement remain genuinely open. First, is the five-tier framework an empirical advance or a relabelling. The Statement's five tiers can be read as a synthesis of pre-existing terminology rather than as new physiology. Critics within the exercise-science community have noted that the four-domain framework (moderate / heavy / severe / extreme) already captures most of the same physiological boundaries, and that the cross-walks introduce small but non-trivial mismatches at the boundary points. Both positions are defensible; the choice is partly a question of audience. Second, the explicit dis-recommendation of %VO₂max, %HRmax, %HRR, and METs is more pointed than what many exercise-physiology textbooks teach, and there will be a transitional period during which guidelines, journal articles, and clinical protocols continue to use these anchors as primary descriptors. The Statement's position is consensus, not yet practice — and the practical reality in many physiotherapy services is that HRR is the only anchor available without specialist equipment. Third, the floor effect for RPE in frailty is a real measurement issue not fully addressed in the Statement. A frail older patient may report «hard» (RPE 14–15 on the 6–20 scale) at an objectively very-low workload that sits well below MT1 by metabolic measurement. This does not invalidate the framework — RPE remains the patient's own report and should drive prescription regardless — but it complicates direct cross-walks between «hard» and «above MT1» in this population.

§4.3 takes up multicomponent exercise prescription, where the five-tier intensity language is used substantively for the first time in this chapter.

Foundations

Multicomponent exercise rests on a simple observation. Frailty manifests across multiple performance dimensions simultaneously: muscle strength, aerobic capacity, balance, and gait coordination all decline together in the typical frail patient, and each dimension is partly modifiable by training but only weakly cross-trained by training the others. A pure resistance programme increases strength and muscle mass but does not robustly improve VO₂max or postural control. A pure walking programme improves cardiovascular fitness but does not robustly increase muscle strength or fall-resistance balance reserve. A pure balance programme reduces fall risk in the short term but does not address the strength and aerobic substrate that determines longer-term mobility. Multicomponent programmes pool the modalities precisely because the substrate is multidimensional. The four pillars are not novel — they appear in essentially every major frailty-targeted exercise guideline since the late 1990s. What the 2025 ICFSR consensus contributes is the explicit framing of these four pillars as a structural requirement for the frail population specifically, with dose ranges adapted to that population. The CIBERFES 2026 consensus adds the conceptual frame that the four pillars cluster around the muscle / strength / power axis developed in §2 of this Background tab. For the workshop demo cases the multicomponent structure looks different in proportion but identical in component set. Frau M.K. (78 F, HFpEF NYHA II, pre-frail) presents with a dominant aerobic limitation layered on early sarcopenic strength decline; the literature applicable to her profile emphasises aerobic conditioning as the largest time slice with resistance training maintained at preservation-of-strength dose. Herr H.K. (84 M, frail with mild cognitive impairment, two falls in 12 months) presents with dominant balance and fall-risk impairment plus a cognitive overlay; the literature applicable to his profile increases the balance and gait time slice substantially. Frau B.S. (72 F, post-pneumonia hospital-associated disability with acute sarcopenia, day-5 baseline) presents with the most rapidly changing profile: in the first 1–2 weeks the literature emphasises bedside-progressive resistance and early mobilisation, with the multicomponent structure expanding as the patient transitions from inpatient to community.

Evidence

The 2025 ICFSR consensus (Izquierdo et al. 2025, J Nutr Health Aging 29(1):100401) is the canonical multicomponent prescription source for frail and pre-frail older adults.Izquierdo 2025 ICFSR The Delphi-style 34-author consensus structures recommendations around four pillars with population-specific dose ranges. For strength and power training: 2–3 sessions per week, 1–3 sets × 8–12 reps at 40–80% 1RM, with explicit combination of low- and high-velocity work. For balance and gait re-education: 3–4 days per week, 1–2 sets per session, combining static and dynamic exercises. For aerobic training: 3–7 days per week, with progressive duration starting from 5–10 minutes and building up. For flexibility: integrated as a daily or near-daily component. The consensus is explicitly anchored to the frail and pre-frail populations, not to generally healthy older adults — which matters because frailty-specific dose recommendations are typically lower at the floor than those for healthy older adults, with greater attention to progression and recovery. The SPRINTT trial (Bernabei et al. 2022, BMJ 377:e068788) is the largest single-RCT evidence base for the multicomponent structure in physically frail sarcopenic older adults, with the SPPB ≤7 stratum HR 0.78 (95% CI 0.67–0.92, p=0.005) and similar SAE rates between arms (39.2% vs 36.0%, RR 1.09, 95% CI 0.94–1.26).Bernabei 2022 The CIBERFES 2026 consensus (Álvarez-Bustos et al. 2026, J Nutr Health Aging 30:100793) extends the multicomponent framing by anchoring the four pillars in the muscle / strength / power axis.Álvarez-Bustos 2026 The EWGSOP2 consensus (Cruz-Jentoft et al. 2019) endorses resistance training plus protein optimisation as first-line management for sarcopenia, which is the muscle component of the multicomponent structure.Cruz-Jentoft 2019

Two 2026 network meta-analyses contribute complementary evidence. Ma et al. 2026 (Bayesian NMA, 17 RCTs, 1,107 pre-frail older adults, Front Public Health 13:1718120) ranked elastic-band exercise highest for handgrip strength improvement (SUCRA 87.51%; pooled MD 5.2 kg, 95% CI 0.64–9.8 vs control) and progressive-exercise-with-«Tai-chi-snacking» (10–15 minute movement micro-doses distributed across the day) highest for SPPB (SUCRA 90.03%); multicomponent training was also significantly superior to control for SPPB (MD 1.13 points, 95% CI 0.13–2.10).Ma 2026 No exercise modality reached statistical significance for TUG in this NMA (limited power: n=263 across only 6 included RCTs). The Ma 2026 result is operationally useful for low-equipment community settings — elastic-band exercise transfers cleanly to home and outpatient practice — but the specific superiority should not be over-generalised beyond the pre-frail-only population studied. Yang et al. 2026 (frequentist NMA, 22 RCTs, 2,055 older adults aged ≥60 with pre-frailty, frailty, or frailty-related risks — including one cognitive-frailty trial — BMC Geriatrics 26:343) compared multicomponent exercise alone, nutritional supplementation alone (protein and amino acids), and the combination of both, against standard care.Yang 2026 For frailty score, combined intervention was most effective (SMD −0.92, 95% CI −1.43 to −0.40); multicomponent exercise alone was significantly effective (SMD −0.78, 95% CI −1.15 to −0.43); nutrition alone showed a non-significant trend (SMD −0.69, 95% CI −1.67 to +0.27). For SPPB, only multicomponent exercise alone reached statistical significance (SMD +1.85, 95% CI +0.33 to +3.50). For gait speed, only nutrition alone showed significant improvement (SMD +0.37, 95% CI +0.06 to +0.68). The Yang 2026 «combined intervention > multicomponent alone for frailty score» finding extends the EWGSOP2 «resistance + protein optimisation» framing into NMA-grade evidence — and is the strongest single argument in §4.3's evidence base for routine integration of nutritional optimisation into the multicomponent prescription, particularly in patients with marginal protein intake or recent acute illness. Caveat: Yang 2026 also reports an anomalous TUG signal — multicomponent exercise alone increased TUG completion time by 3.96 s (SMD, 95% CI +0.91 to +7.07), which the authors attribute speculatively to short-term muscular fatigue. This signal is inconsistent with the broader functional-performance literature and the corresponding null-significance TUG finding in Ma 2026; §4.3 therefore draws on Yang 2026 for frailty-score and SPPB findings only and treats the TUG signal as anomalous pending replication.

For the three workshop cases, the literature gives reasonably specific guidance. Frau M.K. (HFpEF NYHA II, pre-frail) matches the population studied in cardiac-rehabilitation and HFpEF-specific exercise trials, where moderate-intensity aerobic training improves VO₂peak, peak treadmill duration, and quality of life, with resistance training at preservation dose improving handgrip and lower-extremity strength. The Yang 2026 «combined > multicomponent alone» finding for frailty score is directly applicable: addressing M.K.'s likely marginal protein intake (typical for older HFpEF patients with reduced appetite) is part of the multicomponent prescription, not a separate intervention. Herr H.K. (frail with MCI, two falls in 12 months) aligns with multicomponent fall-prevention programmes (FaME, Otago, Vivifrail) where the balance and gait component is the largest single time slice. The MCI overlay is treated separately in §4.7 (v9.11). The Yang 2026 result includes one cognitive-frailty trial in the broader pool but does not stratify by cognitive status; H.K.'s prescription should default to the standard multicomponent structure with cognitive-frailty-specific modifications addressed in §4.7. Frau B.S. (post-pneumonia HAD, day-5) aligns with hospital-associated-disability and post-acute-rehabilitation literature, where early structured multicomponent exercise during and after hospitalisation is associated with improved functional recovery curves. The Yang 2026 nutrition finding is particularly applicable in HAD: post-acute protein optimisation is consistently identified as a component of recovery alongside early progressive resistance.

Practical implications

For physiotherapy practice the multicomponent structure has three operational consequences. First, session structure. The evidence base supports a four-pillar session structure: warm-up, resistance and power training, aerobic training (often integrated with the resistance work in circuit form), balance and gait work, with cool-down. The relative time allocation across pillars shifts case by case (see worked examples below) but all four pillars are present in every session. Flexibility runs through the warm-up and cool-down rather than as a separate block. Specific minute-allocation parameters across the pillars — and the supervised-vs-home-based and dose-attainment trade-offs that determine real-world session structure — are deferred to §4.5 (adherence and progression, v9.10). Second, frequency. The convergent consensus is ≥2 supervised sessions per week, with home-based work filling additional days. The ICFSR-specific frequency ranges per modality (RT 2–3/wk; balance/gait 3–4/wk; aerobic 3–7/wk) imply that the supervised sessions cannot do everything — they anchor the strength and balance components, and the aerobic and gait components are partly carried by home-based activity. Third, the worked-example proportions. For M.K., the literature most directly applicable suggests an aerobic-prominent multicomponent allocation, with resistance held at preservation dose and balance maintained as reserve. For H.K., the same literature suggests a balance-and-gait-prominent allocation with attention to dual-task elements given the MCI overlay. For B.S. at day-5 baseline, the bedside-acute literature suggests an inverted profile in the first 1–2 weeks: bedside-progressive RT and early mobilisation dominate the available training time, with aerobic and balance components introduced progressively as transfer ability returns; by week 6 the structure converges on the standard ambulatory multicomponent profile. Detailed FITT-VP specification within each modality is the subject of §4.4.

Where evidence is contested

Three points remain genuinely contested. First, is «multicomponent» meaningfully distinct from «comprehensive». Some authors have argued that the multicomponent label is functionally indistinguishable from any well-designed rehabilitation programme that addresses multiple impairment dimensions, and that the term has been stretched to cover protocols that differ substantially in actual content. The defence is that the multicomponent label specifies the four-pillar structure, and that programmes lacking any one of the four pillars do consistently underperform. Second, the supervision question. SPRINTT used twice-weekly supervised sessions plus technology-supported home exercise. ICFSR 2025 endorses ≥2 supervised sessions weekly. But the strongest dose-response evidence for adherence comes from supervised programmes, while real-world capacity for supervision varies by health system and setting. The practical question — how much of the multicomponent benefit survives a transition from fully-supervised to home-based with periodic check-ins — is empirically open. Adherence and progression in non-supervised settings is the topic scheduled for §4.5 (v9.10). Third, the dilution risk. Doing all four pillars in a 60-minute session means that no single pillar receives the dose it would in a single-modality programme. For a frail older adult with a dominant impairment in one pillar (e.g. severe sarcopenia with preserved aerobic capacity and balance), the literature is genuinely divided on whether a more pillar-concentrated programme might outperform the standard multicomponent structure. The current consensus is that the multicomponent structure is the safer default in an unselected frail population; an explicit case can be made for pillar-emphasised variants in specific phenotypes.

§4.4 takes up the FITT-VP dose variables that operationalise each of the four pillars.

Foundations

FITT was for many years the canonical exercise-prescription mnemonic — Frequency (sessions per week), Intensity (the demand of each session), Time (duration of each session), and Type (the modality). The addition of Volume and Progression to make FITT-VP reflects two empirical observations. First, the weekly volume of work — the sum of sets, repetitions, and load across a week — is a stronger predictor of training adaptation than any single-session variable, and is partly independent of session frequency (a given weekly volume can be distributed across two sessions or four sessions, with somewhat different but generally comparable effects). Second, an exercise dose that is held fixed produces diminishing returns over weeks to months; programmed progression — increasing load, increasing volume, increasing complexity — is what sustains adaptation across the long timescales relevant in frailty rehabilitation. FITT-VP applies to each modality separately. Resistance training has its own FITT-VP profile; aerobic training has its own; balance training has its own. The integration question — how a given patient's multicomponent programme combines the FITT-VP profiles of the four pillars within a 60-minute session and a 2–3 session/week supervision schedule — is what makes prescription in frailty operationally complex. The §4.3 worked examples set out the proportional allocation across pillars; §4.4 specifies the dose within each pillar. The single most important Q2-a discipline applied to §4.4: the prose describes what the evidence shows about effective dose ranges in healthy adults and how those ranges shift in frail older adults. It does not specify what an individual physiotherapist should prescribe for an individual patient. The numbers that appear in the Evidence section below are population-level summary statistics from systematic reviews and consensus documents, not individual-patient prescriptions. For the workshop demo cases the FITT-VP structure plays out differently: M.K. has an aerobic-prominent multicomponent structure (per §4.3) with FITT-VP centred on aerobic and strength-preservation parameters; H.K. has a balance-and-gait-prominent structure with FITT-VP centred on balance frequency and complexity progression; B.S. has a rapidly evolving FITT-VP profile across her recovery trajectory, with the week-1 dose specification differing structurally from the week-6 specification.

Evidence

The 2026 ACSM Position Stand on Resistance Training Prescription (Currier et al. 2026, Med Sci Sports Exerc 58(4):851–872) updates the 2009 Kraemer/Ratamess Position Stand using overview-of-reviews methodology.Currier 2026 The synthesis covers 137 systematic reviews and approximately 30,000 participants, with AMSTAR scoring of each review and a GRADE-style adapted certainty framework. Six key findings frame §4.4. (1) Strength is enhanced by lifting at ≥80% 1RM, through full range of motion, 2–3 sets per session, ≥2 sessions per week, with the resistance exercise placed at the beginning of the training session. (2) Hypertrophy is enhanced by higher weekly volumes (≥10 sets per muscle group per week) and by eccentric overload. (3) Power is enhanced by moderate loads (30–70% 1RM), low-to-moderate volume (≤24 reps × sets), Olympic-style weightlifting derivatives, and power-RT (resistance training with a fast concentric phase). (4) Power-RT enhances physical function: gait speed, chair-stand performance, TUG, walking performance, and SPPB. This is a particularly important finding for the frailty audience because power decline is the steepest age-related muscle change (per §2 of this Background tab) and translates most directly to functional outcomes. (5) Several traditionally-prescribed RT variables do not consistently impact training outcomes: training to momentary failure, equipment type (machine vs free weight), exercise complexity, set structure (cluster, drop, complex), time under tension, blood-flow restriction, and periodisation type. The Stand's framing is that these are optional rather than necessary RT variables, which simplifies programme design considerably. (6) Compared with no exercise, RT improves strength, hypertrophy, power, and physical function across the age range, including in frail older adults. The Pelland et al. 2026 multi-level meta-regression (Sports Med 56(2):481–505) contributes complementary dose-response detail on weekly volume and frequency.Pelland 2026 The analysis covers 67 studies and 2,058 participants and classifies sets as «direct» or «indirect» (specific to the measured outcome vs contributing via shared muscle activation), quantified at 1, 0.5, or 0. The headline findings are: the dose-response for both volume and frequency is real, but with substantial diminishing returns; per-session volume eventually crosses a «point of undetectable outcome superiority» (PUOS) beyond which additional sets do not yield greater than 50% likelihood of detectable additional benefit. For the frailty audience the practical translation is that the volume-response curve plateaus quickly — substantial gains accrue at low-to-moderate doses — which is exactly the message that matters most when teaching workshops where the «minimum effective dose» concept is more relevant than the «optimal dose for an athlete». The 2025 ICFSR consensus (already detailed in §4.3 Evidence) provides the frailty-specific FITT-VP adaptation. Its strength-component dose range — 2–3 sessions/week, 1–3 sets × 8–12 reps at 40–80% 1RM, combining low- and high-velocity work — sits at the lower end of the Currier 2026 healthy-adult ranges, with an explicit power component built in via the high-velocity recommendation.

For the worked examples: Frau M.K. (HFpEF NYHA II pre-frail). The FITT-VP profile most directly supported by the literature for her phenotype centres on aerobic training at moderate intensity (per the Bishop 2025 framework: «somewhat hard»; talk-test boundary at short-sentence speech) for 20–30 minutes per session, 3–5 sessions per week, with progression by duration first and then by intensity; combined with a strength-preservation RT dose of 2 sessions per week, 1–2 sets × 8–12 reps at the lower end of the 40–80% 1RM range, with a deliberate power component via 1–2 sets of high-velocity chair-rise or step-up variants. The volume here sits well within the Pelland 2026 plateau — additional sets are unlikely to yield further benefit and may compromise the aerobic dose. Herr H.K. (frail with MCI, falls history). The FITT-VP profile for his phenotype centres on balance training 3–4 days per week, 1–2 sets per session, combining static and dynamic with progressively more complex dual-task elements; combined with RT 2 sessions per week at the frailty-floor dose (1–2 sets × 8–12 reps at 40–60% 1RM), with explicit attention to power via high-velocity moves at moderate loads; and aerobic at 3–4 days per week, 15–20 minutes, at low-to-moderate intensity. Progression is conservative given his fall history: load progression in RT precedes complexity progression in balance, with both anchored to demonstrated safety in the prior week. Frau B.S. (post-pneumonia HAD day-5). At day-5 the FITT-VP profile is bedside-acute: very-low-volume RT (1 set × 6–8 reps at the lowest tolerable resistance) combined with early-mobilisation work and incremental sit-to-stand practice. By week 6 the profile has converged on the standard ambulatory multicomponent FITT-VP (RT 2/wk × 1–3 sets × 8–12 reps at 40–70% 1RM; aerobic 3–4/wk × 15–25 min at moderate intensity; balance 3/wk × 1–2 sets; flexibility daily). The progression from day-5 to week-6 is the FITT-VP component most distinct from the other two cases: in B.S. the dose itself is the variable of clinical interest week-to-week.

Practical implications

For physiotherapy practice three operational consequences follow from the evidence. First, the «necessary versus optional» framing from Currier 2026 simplifies programme design considerably. Of the many RT variables historically debated in the literature — machine vs free weight, periodisation type, time under tension, training to failure, set structure — most do not consistently impact outcomes in the umbrella-review evidence. The variables that do matter are frequency, load, volume, set proximity-to-failure, and (for power) lift velocity. For physiotherapy practice this means: design within these necessary variables, and treat the optional variables as preference parameters rather than as efficacy parameters. A patient who prefers machines can train on machines without compromising outcome; a patient who prefers free weights can train with free weights without compromising outcome. Second, the volume-plateau finding from Pelland 2026 is operationally important for the frailty audience. Adding more sets to an already adequate volume does not reliably produce more gain, and the plateau in frail older adults is reached at lower volumes than in younger trained populations. The default assumption — that more is better — is wrong at the dose ranges relevant in frailty. This is the empirical anchor for the frailty-specific phrase «minimum effective dose» that recurs in workshop material. Third, the worked-example progression. For M.K., the most impactful progression at the 6-week reassessment is typically aerobic duration (extending sustained moderate-intensity aerobic work from 20 to 25–30 minutes), with RT held stable at the strength-preservation dose. For H.K., the most impactful progression is typically balance-task complexity (from static-supported to dynamic-unsupported, then dual-task) with RT load progressed conservatively (one increment per fortnight, anchored to demonstrated safe execution). For B.S., the FITT-VP profile is itself the progression — moving from bedside-acute parameters to ambulatory multicomponent parameters across her recovery trajectory; the 6-week reassessment is more a confirmation of having reached the ambulatory profile than a fine-grained dose adjustment. Reassessment with the FrailtyTrack instruments (5×STS, gait speed, handgrip, SPPB) provides the empirical anchor for whether the prescribed FITT-VP dose is producing the expected adaptation. The longitudinal tab in this tool is sized for the 6-, 12-, and 24-week reassessment windows that match the dose-response timescales in the literature.

Where evidence is contested

Three points remain genuinely open in the FITT-VP literature applied to frailty. First, the «≥80% 1RM for strength» finding from Currier 2026 sits uneasily with the «40–80% 1RM» range from ICFSR 2025. The two are not formally inconsistent — Currier 2026 reports the strength-optimal range in healthy adults; ICFSR 2025 reports the frailty-population dose range that is both safe and effective at typical achievable intensities. But the practical implication — should a frail patient with adequate joint health and tolerance be loaded to 80% 1RM for strength gain, or held at 40–60% 1RM — is genuinely contested in the literature. The conservative position is the ICFSR range; the maximally-evidence-aligned position is the Currier range scaled to demonstrated tolerance. Both positions are defensible. Second, power-training dose specifications in frail older adults are less well-established than the corresponding strength-training specifications. Power training is consistently endorsed (Currier 2026 finding 4; ICFSR 2025 high-velocity recommendation), but the specific dose at which power gains are optimal in the frail population is supported by a thinner evidence base than the strength-equivalent range, and the trade-off between volume of power-specific work and volume of strength-specific work in a multicomponent session is not formally settled. This is a rapidly developing area of literature. Third, the home-based versus supervised question intersects with FITT-VP specification because home-based programmes systematically achieve lower actual volumes than the supervised-equivalent prescription specifies. The literature on adherence-adjusted FITT-VP — what dose is actually delivered, as opposed to what dose is on the prescription sheet — is partial and is the subject scheduled for §4.5 (v9.10). For now, the FITT-VP specification in §4.4 is the supervised-prescription specification; home-based equivalents will require their own adherence-adjusted treatment.

§4.5 (in v9.10) takes up adherence and progression. §4.6 (also in v9.10) treats flexibility as the fourth+1 pillar in greater depth. §4.7 (in v9.11) takes up the specific case of training in cognitive frailty.

Foundations

Muscular strength is operationally defined as the maximal force, or torque, a muscle or muscle group can generate against an external resistance in a single maximal effort. In the clinic it is most often quantified as a one-repetition maximum (1RM) — the heaviest load that can be lifted once through a full range of motion — or, where 1RM testing is impractical, estimated from a multiple-repetition maximum or from handgrip dynamometry as a whole-body proxy. Strength is the muscular quality that frailty and sarcopenia frameworks treat as the gateway parameter: EWGSOP2 places low muscle strength, not low muscle mass, as the primary criterion for probable sarcopenia, and low grip strength is one of the five Fried phenotype criteria. This is why a chapter on training adaptations opens with strength: it is the adaptation the assessment instruments in §1–§3 are most directly built around.

The dominant teaching model for how strength is produced is the repetition continuum (also called the strength–endurance continuum). It proposes that the number of repetitions performable at a given load maps onto a specific adaptation: a low-repetition scheme with heavy loads (about 1–5 repetitions per set at 80–100 % 1RM) optimises strength; a moderate scheme (about 8–12 repetitions at 60–80 % 1RM) optimises hypertrophy; a high-repetition scheme with light loads (15 or more repetitions below 60 % 1RM) optimises local muscular endurance. The model is intuitive, it has been taught for decades, and it is the scaffold on which most exercise prescriptions — including those in older-adult guidelines — are still built.

A worked example makes the strength end concrete. Consider Frau B.S., the post-pneumonia hospital-associated-deconditioning demo case. At day 5 she cannot tolerate heavy loading; her programme sits at the light-load, low-volume end purely out of necessity. By week 6, as joint tolerance and confidence return, the strength-specific question becomes live: to drive a measurable 1RM gain — and with it the leg-press and chair-rise performance that her independence depends on — the loading has to climb toward the heavier end of what she can safely manage. The continuum model predicts that holding her indefinitely at a light "rehabilitation" load will preserve function but under-deliver on maximal-strength recovery. Whether that prediction holds is exactly what the Evidence layer examines.

Evidence

The strongest recent critical synthesis of the repetition continuum is the 2021 re-examination by Schoenfeld, Grgic, Van Every and Plotkin (Sports 9(2):32). Its central finding for strength is that the heavy-load end of the continuum largely holds up. The authors report that meta-analytic data show a clear advantage for heavier loads on 1RM strength: a pooled effect-size difference of approximately 0.58 favouring high-load (>60 % 1RM) over low-load (≤60 % 1RM) training across the analysed studies, with every included study residing on the "favours high-load" side of the forest plot. A separate meta-analysis restricted to older individuals (Csapo & Alegre) produced a comparable moderate effect (about 0.43) favouring heavy-load training. Multiple direct-comparison studies report greater 1RM gains when training in the heavy "strength zone" than in the moderate "hypertrophy zone," and the dose-response appears more pronounced in already resistance-trained individuals.Schoenfeld 2021

The single most clinically important nuance, however, is specificity of testing. Schoenfeld and colleagues note that 1RM testing is almost always conducted on the exact exercise that was trained, which biases the comparison toward heavier protocols — the heavy-load group is, in effect, practising the test. When strength is instead measured on a neutral device — an isometric dynamometer not used in training — the heavy-load advantage shrinks to a small, statistically non-significant effect (about 0.16 in the cited meta-analysis). Isokinetic testing gives genuinely mixed results: some studies favour heavy loads, some favour light, some show no difference. The interpretation is not that heavy loading "doesn't work," but that a substantial part of the measured strength gain is a task-specific skill — neural learning of that movement at that load — layered on top of the underlying contractile adaptation. For a physiotherapist this is a feature, not a confound: function in daily life is task-specific, so training the task you want to improve is exactly right.

The repetition continuum's strength end also has a well-documented secondary finding: significant 1RM gains are routinely observed with light loads (≥20 repetitions per set) trained to or near muscular failure, and even resistance-trained individuals gain strength with very light loads — though to a smaller degree than with heavy loads.Schoenfeld 2021 So the honest summary is dose-response, not threshold: heavier is better for maximal strength when tested specifically, but light-load training is not strength-neutral.

The 2026 ACSM Position Stand on resistance-training prescription (Currier et al., an overview of 137 systematic reviews) converges on the same place from the umbrella-review level: strength is enhanced by lifting at ≥80 % 1RM, through full range of motion, with 2–3 sets per session, at least twice weekly, with the resistance work placed at the start of the session.Currier 2026 For the older-adult population specifically, the NSCA Position Statement on resistance training for older adults (Fragala et al. 2019, J Strength Cond Res 33(8):2019–2052) is the anchor document. It recommends, for healthy older adults, a periodised programme working toward 2–3 sets of 1–2 multijoint exercises per major muscle group at 70–85 % 1RM, 2–3 times per week. Fragala et al. summarise a consistent meta-analytic literature — Steib et al., Borde et al., Peterson et al., Csapo & Alegre — in which training intensity is repeatedly the strongest single between-study predictor of strength gain in older adults, with higher intensities (>75–80 % 1RM) producing larger maximal-strength improvements than moderate or low intensities, even in frail older adults.Fragala 2019 Fragala et al. also document that the magnitude of strength gain available to older adults is large: across the reviewed literature, upper- and lower-body strength improvements range from roughly 9 % to 174 %, and meaningful gains are demonstrated even in nonagenarians and in the very old. Strength is not a young person's adaptation that older adults access in diluted form; the relative trainability is broadly preserved into the ninth and tenth decades.

Practical implications

Three implications follow for physiotherapy practice with older adults, with or without frailty or sarcopenia.

First, the strength end of the continuum is the most secure part of the model, so loading toward the heavy end is evidence-aligned — but it is governed by tolerance, not by age. The umbrella reviews place strength-optimal loading at ≥80 % 1RM; the NSCA older-adult statement places the healthy-older-adult working range at 70–85 % 1RM. Neither figure is a contraindication-free instruction: Fragala et al. are explicit that loading should begin at a tolerated resistance and progress through periodisation, that frail older adults and beginners start lighter (often 20–30 % 1RM, progressing toward 80 %), and that the sessions stay short of momentary failure to limit joint stress. The clinical decision is therefore how heavily, not whether — and it is anchored to demonstrated joint health, technique quality, and week-on-week tolerance, exactly as §4.4 frames the FITT-VP intensity variable.

Second, train the task you intend to improve. Because a meaningful share of measured strength gain is task-specific, the strength exercises in an older adult's programme should resemble the functional demands that matter — sit-to-stand patterns for chair-rise, step-ups and leg press for stair-climbing and gait, loaded carries for grocery handling. The FrailtyTrack instruments make this concrete: 5×STS time and gait speed will respond most to training that shares their movement pattern. A patient who needs to get out of a chair should be trained on a chair-rise pattern, not only on an isolated knee-extension machine.

Third, strength gain is recoverable at any age, which reframes the assessment-to-prescription pathway. A low handgrip result, a slow 5×STS, an SPPB in the frailty range — these are not fixed properties of an old body; they are trainable deficits. The §4.1 rationale (exercise as first-line, low-harm, dynamic) applies directly: a positive strength deficit on the FrailtyTrack instruments is sufficient to begin progressive resistance training, with the heavy-end loading introduced as tolerance is demonstrated. For Frau B.S., this is the explicit week-6 progression — moving the leg-press and chair-rise loading up toward her safely-tolerable maximum to convert preserved function into a measurable 1RM and SPPB gain.

Where evidence is contested

Three points remain genuinely open.

First, the heavy-load-versus-light-load question for frail patients specifically. The umbrella-review evidence for ≥80 % 1RM is drawn predominantly from healthy and mixed-age cohorts; the Currier 2026 stand explicitly operationalised "healthy adults" to exclude frailty and sarcopenia. The NSCA older-adult statement bridges part of this gap, but the question of whether a frail patient with adequate joint health should be progressed to 80 % 1RM for maximal strength gain, or held at a more conservative 40–60 % 1RM, is not settled — it is the same tension flagged in §4.4 between the Currier range and the ICFSR 2025 frailty range. Both positions are defensible; the conservative reading favours the ICFSR range, the maximally evidence-aligned reading favours heavy loading scaled to demonstrated tolerance.

Second, how much of "strength" is contractile and how much is neural skill. The specificity finding — heavy-load advantage shrinking on neutral testing devices — means the field does not have a clean separation between the trained-task skill component and the underlying force-generating-capacity component of a 1RM gain. For research this is an open measurement problem. For practice it matters less than it looks, because clinically relevant strength is task-bound; but it does mean a 1RM gain on a trained exercise should not be over-interpreted as a pure measure of muscle adaptation.

Third, the trained-status interaction. Schoenfeld et al. note the heavy-load dose-response appears more pronounced in resistance-trained individuals and that continued maximal-strength gains become increasingly dependent on training near the 1RM as a person approaches their genetic ceiling. Most older frail patients are profoundly untrained, so they sit far from that ceiling and gain strength readily across a wide loading range — but this also means the heavy-load imperative is weaker early in a previously sedentary older adult's programme than the young-cohort literature implies. How quickly the heavy-load advantage becomes decisive as a previously sedentary older adult accumulates training experience is not well quantified.

§5.2 takes up hypertrophy — where, in contrast to strength, the re-examined continuum largely fails, and the "hypertrophy zone" turns out not to exist as the model claims.

Foundations

Muscle hypertrophy is the increase in the size of muscle tissue — measured as whole-muscle cross-sectional area or thickness by ultrasound, MRI or CT, or at the cellular level as the cross-sectional area of individual muscle fibres. It is conceptually distinct from strength: a muscle can grow without a proportional rise in maximal force, and strength can rise without measurable growth, particularly early in training when neural adaptation dominates. In the frailty and sarcopenia context, hypertrophy is the direct counter to the muscle-mass loss that defines sarcopenia — though, as §2 and §3 of this Background tab emphasise, mass loss is now treated as downstream of strength loss in the EWGSOP2 framework, not as the primary diagnostic criterion. Hypertrophy therefore matters, but as one contributor to function rather than the headline target.

The repetition continuum assigns hypertrophy a "hypertrophy zone" — the moderate middle of the loading range, about 8–12 repetitions per set at 60–80 % 1RM. The historical rationale was partly observational (bodybuilders train in this range) and partly mechanistic (acute studies showed larger post-exercise spikes in anabolic hormones with moderate-rep training). The continuum embeds this zone into mainstream prescription, including the older-adult guidelines: the NSCA older-adult position statement's general recommendation of 8–12, or 10–15, repetitions reflects exactly this moderate-load default.

A worked example. Consider Frau M.K., the HFpEF, NYHA II, pre-frail demo case. Her cardiac status makes high-load, breath-holding strength work less attractive — the Valsalva-associated blood-pressure spikes that accompany near-maximal lifting are a genuine concern in this phenotype. If muscle growth required the "hypertrophy zone" of 60–80 % 1RM, she would be caught between an adaptation she needs (countering muscle loss) and a loading range that carries cardiovascular caution. The question the Evidence layer settles is whether that dilemma is real — or whether comparable hypertrophy is available to her at lighter, haemodynamically gentler loads.

Evidence

Schoenfeld et al.'s 2021 re-examination is, on hypertrophy, considerably more critical of the continuum than it is on strength. The central finding: a large and consistent body of longitudinal evidence shows that whole-muscle hypertrophy is similar across a wide spectrum of loads, from roughly 30 % 1RM upward, when sets are equated and taken to or near muscular failure.Schoenfeld 2021 The authors' own earlier meta-analysis found a trivial effect-size difference (about 0.03, 95 % CI roughly −0.16 to 0.22) between high-load (>60 % 1RM) and low-load (<60 % 1RM) training for whole-muscle growth — a near-perfect null. This held independent of body region. The practical conclusion the authors draw is blunt: as a matter of principle, there is no ideal "hypertrophy zone."

Two qualifiers refine the picture. First, effort matters more than load. The studies that appeared to show light loads were inferior for hypertrophy were generally those in which the light-load sets were stopped well short of fatigue. When light-load sets are carried to a genuinely high level of effort — to or near muscular failure — the hypertrophic response matches that of heavier loads. A high level of effort is, in the words of the review, particularly critical for low-load training specifically. Second, there is a lower threshold. Below roughly 30 % 1RM, hypertrophy is compromised — Schoenfeld et al. cite within-subject work (Lasevicius et al.) in which a 20 % 1RM condition produced only about half the growth of 40–80 % 1RM conditions. So the honest model is not "load is irrelevant"; it is "load above a ~30 % 1RM floor is broadly interchangeable for whole-muscle growth, given sufficient effort."

The age-specific evidence is the part most relevant to FrailtyTrack. Schoenfeld et al. report that in older adults, light-load training appears to be at least as effective as heavy-load training for inducing hypertrophy — and cite meta-analytic data (Straight et al.) showing that hypertrophy was actually attenuated in type II fibres when older adults trained with heavier loads, with the loading strategy explaining roughly 15 % of the variance in fibre-size change. The proposed explanation is that age-associated joint conditions (osteoarthritis and similar) make heavy loading harder to execute well in older adults, so the heavy-load stimulus is less reliably delivered. Whatever the mechanism, the direction is the opposite of what the continuum predicts: in older adults the light-to-moderate end is, if anything, the safer bet for muscle growth.

The 2026 ACSM Position Stand converges: hypertrophy is enhanced primarily by higher weekly volumes — on the order of ≥10 hard sets per muscle group per week — and by eccentric overload, with load itself a secondary variable above the threshold.Currier 2026 Volume, expressed as the number of hard sets per muscle group per week, has an established and roughly linear dose-response with growth. The Pelland et al. 2026 multi-level meta-regression (67 studies, 2,058 participants) refines this: the volume–response relationship is real but shows substantial diminishing returns, with a per-session "point of undetectable outcome superiority" beyond which extra sets do not yield a better-than-even chance of additional benefit.Pelland 2026 For frail and pre-frail older adults — who reach that plateau at lower volumes than young trained lifters — the operative message is the "minimum effective dose" framing already established in §4.4: a modest number of hard sets per muscle group per week captures most of the available growth.

The NSCA older-adult statement (Fragala et al. 2019) sits a little earlier in this evidence arc — it predates the 2021 re-examination — and so still frames hypertrophy around moderate loads. But its substantive recommendations are not in conflict: it documents meaningful muscle-size gains in older adults across a 30–90 % 1RM training-load span, larger lean-mass gains with higher volume, and increases in both type I and type II fibre cross-sectional area after resistance training in the old and very old.Fragala 2019 Read through the 2021 lens, Fragala et al.'s older-adult data are consistent with the load-flexible, volume-driven picture.

Practical implications

First, lighter loads are a legitimate hypertrophy strategy in older adults — not a compromise. Because whole-muscle growth is comparable from ~30 % 1RM upward when sets are taken close to failure, and because heavy loading may actually attenuate type II fibre growth in older adults, a physiotherapist can prescribe lighter, better-tolerated loads for muscle growth without conceding effectiveness. For Frau M.K., this resolves the dilemma in the Foundations layer directly: she can pursue muscle-mass maintenance with loads in the lighter part of the range, avoiding the Valsalva-associated cardiovascular caution of near-maximal lifting, and still expect a comparable hypertrophic response.

Second, the binding constraint on light-load training is effort, discomfort and time — not load. Light-load hypertrophy requires sets taken to a high level of effort (close to failure); a comfortable, sub-fatiguing light set will under-deliver. But Schoenfeld et al. also document that light-load, high-repetition training produces more metabolic discomfort and higher perceived exertion than moderate loads, and consumes more time per session. So in practice moderate loads are often the efficient choice for hypertrophy — not because a "zone" exists, but because they reach adequate effort with fewer repetitions and less discomfort, which protects adherence. The clinical reasoning is: pick the load the patient will actually train hard at, repeatedly.

Third, prescribe by volume, and respect the plateau. Since weekly hard-set volume per muscle group is the genuine driver, programme design should think in sets-per-muscle-per-week, not in load. And because the volume–response plateaus early — earlier still in frail older adults — adding sets beyond a modest weekly total does not reliably buy more growth and may crowd out the balance, gait and aerobic pillars of the multicomponent programme (§4.3). For hypertrophy as for FITT-VP volume in §4.4, more is not better past the plateau.

Where evidence is contested

First, fibre-type-specific hypertrophy. Whether light loads preferentially grow type I fibres and heavy loads preferentially grow type II fibres remains genuinely unsettled. Schoenfeld et al. review a mixed literature — some longitudinal studies show a fibre-type-specific response, others do not, and the discrepancy tracks partly with whether sets were taken to failure. This matters for sarcopenia because type II (fast, powerful) fibres are preferentially lost with age; if heavy loading really does attenuate type II growth in older adults, the fibre-type question has direct clinical stakes. It is not resolved.

Second, volume-equating versus set-equating. Whether high- and low-load protocols are compared on equal volume load (sets × reps × load) or equal number of sets changes which protocol looks better, because light loads accrue more volume load per set. Schoenfeld et al. flag this as a persistent methodological confound; the "loads are interchangeable" conclusion is most secure for set-equated, train-to-failure designs and less secure otherwise.

Third, how much hypertrophy actually matters for function in frailty. §2 and §3 of this tab present the EWGSOP2 position that muscle mass is downstream of strength and a weaker predictor of function. A live minority view (the Coelho-Júnior critical appraisal cited in §3.2) goes further and questions how responsive mass is to intervention at all. If mass is only loosely coupled to the outcomes that matter — gait speed, chair-rise, falls — then optimising hypertrophy per se, as opposed to strength and power, may be a lower clinical priority than the bodybuilding-derived literature implies. The chapter treats hypertrophy as a real and trainable adaptation; whether it deserves equal billing with strength and power in a frailty programme is a defensible open question.

§5.3 takes up power — the adaptation that declines earliest and fastest with age, is most tightly coupled to function and falls, and obeys a logic (force × velocity) that neither the strength nor the hypertrophy section fully captures.

Foundations

Power is defined, in mechanical terms, as work done per unit time, or equivalently as force multiplied by velocity. A muscle action that produces a large force slowly, and one that produces a smaller force quickly, can express the same power. This force–velocity relationship is the conceptual core of the section: it is inverse and roughly linear — the heavier the load, the slower it can be moved; the lighter the load, the faster — and power, the product, peaks somewhere in between. Strength sits at one end of this curve (maximal force, near-zero velocity); maximal unloaded speed sits at the other; power is developed by training across the span.

Power is distinct from strength in three ways that matter clinically. It declines earlier and faster: the loss of muscle power begins earlier in the lifespan and proceeds at a greater annual rate than the loss of maximal strength — in several datasets roughly twice as fast. It is more tightly coupled to function: power is a stronger predictor of physical-functioning outcomes and of fall risk than strength or muscle mass alone, because the tasks that fail first in ageing — standing up, climbing, catching a stumble — are time-constrained, not force-constrained. And it has its own deficit vocabulary: where dynapenia names the age-related loss of strength, the loss of power has been termed kratopenia or powerpenia, proposed as a biomarker of healthy ageing in its own right. FrailtyTrack already operationalises this — the sit-to-stand power test and its relative-power cut-offs (the sts5_time instrument, Alcázar 2021 normative data) exist precisely because power, not strength, is the quantity most worth measuring in this population.

A worked example. Consider Herr H.K., the frail demo case with mild cognitive impairment and a history of two falls. His clinical problem is not primarily that he cannot generate force — it is that he cannot generate it fast enough: not fast enough to rise from a chair without several attempts, not fast enough to reorganise his base of support when he trips. A programme built only around slow, heavy strength work would address the force axis and leave the velocity axis — the one his falls actually depend on — largely untrained. The Evidence layer examines whether training the velocity axis explicitly delivers the functional and falls-relevant gains his case needs.

Evidence

The evidence that power-oriented training is at least as good as conventional strength training for function in older adults — and often better — is consistent across two decades. The anchor meta-analysis is Tschopp, Sattelmayer & Hilfiker 2011 (Age and Ageing 40(5):549–556): a systematic review of randomised controlled trials comparing high-velocity power training against conventional low-velocity resistance training in community-dwelling people over 60.Tschopp 2011 Across eleven trials and 377 participants, the pooled effect for functional outcomes favoured power training (follow-up-value effect size about 0.32, 95 % CI roughly 0.06 to 0.57). The advantage was modest in magnitude but consistent in direction, and — importantly for a frail population — power training was not associated with greater adverse events. More recent syntheses reproduce the pattern: meta-analyses report that power training offers small but meaningful advantages over conventional resistance training for functional outcomes, balance and muscle power in older adults, with adverse-effect profiles comparable between power and strength training.

The mechanism for the functional advantage is task relevance. Power-oriented training improves the time-constrained tasks — sit-to-stand transitions, stair-climbing — more than slow strength training does, plausibly through enhanced motor-unit recruitment and faster muscle contraction; high-velocity recruitment preferentially trains the high-threshold, type II motor units that ageing erodes first. This is the same specificity logic as §5.1, applied to the velocity axis: training fast improves fast tasks.

The loading question for power has a clear answer with one decisive caveat. Power responds across a wide loading range — roughly 40 % to 70 % 1RM, sometimes wider — and the de Vos et al. trial cited across the ACSM power-training literature found that training at 20 %, 50 % and 80 % 1RM all increased power similarly, although heavier loads produced greater concurrent gains in strength and endurance. The decisive variable is not the load but the intent to move the concentric phase as fast as possible. The Triplett and the Gluchowski & Phillips articles (ACSM's Health & Fitness Journal 29(5), 2025) both make this point explicitly: the actual velocity is set by the load, but the training stimulus depends on maximal-velocity intent — power is a product of force and velocity, and if either is under-dosed, the power adaptation is under-delivered.Triplett 2025Gluchowski 2025 The current ACSM guidance has shifted the recommended power-training range upward from the older 40–60 % toward 60–80 % 1RM and, for the first time, introduced cluster sets — short intra-set rests — as a way to keep velocity high while limiting fatigue.

Two further evidence threads matter for the frail population specifically. Velocity monitoring offers a way to dose this precisely: Marques et al. 2022 (J Strength Cond Res 36(11):3200–3208) showed that in institutionalised older adults (mean age ~80), terminating each set at a 10 % velocity loss produced only about 5 repetitions per set in the leg press and ~4 in the chest press — very low volume — yet still significantly improved strength and functional capacity.Marques 2022 The velocity-loss method protects movement speed by stopping the set before fatigue degrades it. Safety: the four ACSM Health & Fitness Journal articles converge that power training — including plyometric work — is safe in older adults when a strength base is established first and progression is gradual; systematic-review evidence on plyometric training in adults aged 58–79 reports no increase in injuries or adverse effects across interventions of 4 weeks to 12 months. The 2026 ACSM Position Stand reinforces the headline: power-RT enhances physical function — gait speed, chair-stand, TUG, SPPB — and power is enhanced by moderate loads, low-to-moderate volume, and a fast concentric phase.Currier 2026

Practical implications

First, power deserves explicit programming — it is not a by-product of strength work. Because power declines earliest and is most tightly coupled to function and falls, and because slow heavy lifting trains the force axis but not the velocity axis, an older-adult programme should contain deliberate high-velocity work. Operationally this means instructing the patient to perform the concentric (lifting) phase as fast as possible while controlling the lowering phase — a cue, not a new exercise. For Herr H.K., this is the change that targets his actual deficit: high-velocity chair-rise and step-up variants at a moderate load, trained with maximal-velocity intent, address the time-constrained failure that his falls depend on.

Second, build the strength base first, then progress velocity — load is flexible, intent is not. The four ACSM articles are unanimous on sequence: establish competent technique and a strength foundation, then layer in power work, progressing gradually (body-weight and light-load fast movements before moderate-load fast movements). Within that frame the load can sit anywhere across roughly 40–70 % 1RM and lighter loads are often preferable for lower-functioning or less-confident patients; what cannot be compromised is the maximal-velocity intent and the controlled eccentric. Cluster sets — a brief rest mid-set — are a practical tool to keep velocity high without accumulating fatigue, and velocity monitoring (where equipment allows) lets the set be ended before speed degrades.

Third, power training is low-volume and time-efficient — which suits the frailty context. The Marques 2022 finding — significant functional gains from roughly 4–5 repetitions per set — and the broader power literature show that power adaptations do not require high volume. This dovetails with the §4.3/§4.4 "minimum effective dose" message and with the multicomponent reality that power work must share a 2–3-session week with balance, gait and aerobic training. A small dose of well-executed, high-intent power work is a defensible and efficient use of limited session time. Reassessment with the FrailtyTrack sts5_time sit-to-stand power instrument provides the empirical anchor for whether the prescribed power dose is translating into measurable functional change.

Where evidence is contested

First, the magnitude of power training's advantage over strength training. Tschopp et al. 2011 found a real but modest functional advantage (effect size ~0.32), and the change-value analysis in that review had a confidence interval that crossed zero. Later meta-analyses describe the advantage as "small but meaningful." So the direction is consistent — power training is at least as good and probably somewhat better for function — but it is not a large effect, and how much to prioritise power over strength is a matter of clinical judgement rather than a settled quantitative answer.

Second, the optimal load for power in frail older adults specifically. The wide-range finding (40–70 %+ 1RM all effective) and the recent upward shift in ACSM guidance toward 60–80 % 1RM come predominantly from healthy or community-dwelling older adults. The dose at which power gains are optimal in the frail population is supported by a thinner evidence base — the same caveat §4.4 raises — and the trade-off between power-specific and strength-specific volume within one multicomponent session is not formally settled.

Third, the higher-functioning plateau. Gluchowski & Phillips note that higher-functioning older adults may show functional-performance plateaus — once chair-rise or stair-climb is fast enough for daily life, further power gain may not yield further functional change on standard tests. They argue a reserve of power may still matter (for stumble recovery, for resilience to future decline), but the value of training power beyond the functional-sufficiency threshold is genuinely uncertain. For most of the FrailtyTrack population — frail and pre-frail, well below that threshold — this caveat is not yet binding; it matters mainly for the more robust pre-frail patients and for thinking about how long to keep progressing power once function has normalised.

§5 has treated the three muscular adaptations as distinct training targets. In a real multicomponent programme they are combined within the FITT-VP structure of §4.4 and the four-pillar prescription of §4.3 — strength, hypertrophy and power are not sequential phases but co-trained qualities, weighted to the individual patient's deficits as the FrailtyTrack instruments reveal them.

Click an entry to jump to that section — collapsed cards open automatically.

FrailtyTrack's clinical and educational design is informed by major international consensus documents on frailty. The most recent and comprehensive is the CIBERFES 2026 Consensus Document (Álvarez-Bustos et al., J Nutr Health Aging 2026;30:100793), authored by 30+ researchers from the Spanish Research Consortium on Frailty and Healthy Aging (25 research groups, funded by Instituto de Salud Carlos III). The positions below are presented as CIBERFES's view — some are well aligned with broad international consensus, others are positions where CIBERFES disagrees with WHO or other frameworks. FrailtyTrack cites the positions accurately rather than endorsing all of them as house position. Where CIBERFES aligns with the existing FrailtyTrack design (Fried phenotype, SPPB/gait speed/FRAIL screening, multicomponent exercise, muscle power as marker), the alignment reinforces the tool's evidence base. Where CIBERFES disagrees with WHO (intrinsic capacity) or hesitates (cognitive frailty), this is presented transparently.Álvarez-Bustos 2026  doi ✅

1. What frailty is (CIBERFES definition)

Frailty is an age-associated clinical phenotypic syndrome driven by the biology of aging, life-course environmental exposures, and disease burden. Its physiological basis is a heterogeneous decline of functional reserve across organ systems, accompanied by impaired homeostasis and reduced capacity to respond to stressors, predisposing to adverse health outcomes — mainly disability. CIBERFES emphasises that frailty should be conceptualised as a pre-disability state: it precedes disability and is the main risk factor for it, but is itself dynamic and potentially reversible with targeted intervention. Pre-frailty (the prodromal phase) affects up to 50% of community-dwelling older adults but lacks consensus operational definition. Frailty falls within a functional continuum from robustness → pre-frailty → frailty → mild disability → severe disability → death. This framing is consistent with FrailtyTrack's existing Fried-phenotype-based design and its longitudinal tracking of phenotype-status transitions over time.

2. What frailty is not (CIBERFES boundary statements)

• Frailty is not synonymous with aging: not every older adult is or will be frail. Even nonagenarians and centenarians may not be frail; people may die without ever having become frail.
• Frailty is not (only) a risk factor: the definition should be based on pathogenesis (the aging process), not just on the outcomes it predicts. Cancer, CKD, and other chronic conditions can produce similar adverse outcomes in older adults but are not frailty — they may at most contribute to its pathogenesis. Consequently, scales that predict frailty-related outcomes are not automatically frailty scales.
• Frailty is not comorbidity, multimorbidity, or disability: frailty is a distinct entity that can coexist with these conditions. CIBERFES draws a strong consequence from this: disability should not be part of the construct nor the measurement scales. They explicitly critique the Tilburg Frailty Indicator, Groningen Frailty Indicator, and electronic Frailty Index for including disability items.
• Frailty is not sarcopenia: the two are clinically distinct conditions that can coexist. Sarcopenia is a neuromusculoskeletal disease where muscle (the target organ) shows decreased size and function; frailty's pathophysiology is multisystemic. The presence of one does not guarantee the other. FrailtyTrack already separates the Frailty and Sarcopenia constructs in line with this position.
• Frailty should not be regarded as the opposite of intrinsic capacity: here CIBERFES disagrees with WHO. While both constructs share conceptual overlap (greater in locomotor than cognitive/affective domains), CIBERFES argues intrinsic capacity needs more robust operationalisation and clinical-trial evidence before it can replace frailty in clinical practice. They write that — if stigma concerns drive the rebrand — "strategies should focus on mitigating these issues rather than replacing the term with one derived from a purely 'positivist' rationale." This is a contested position in the field. FrailtyTrack does not endorse it as house position; it is presented here as CIBERFES's view alongside the WHO intrinsic-capacity framework.

3. Recommended assessment (alignment with FrailtyTrack)

CIBERFES recommends a two-step approach: screening with rapid, sensitive instruments, then diagnostic confirmation with the Fried phenotype, with FTS5 as a complementary tool for limitations of the dichotomous-criteria phenotype.

• Screening tools (CIBERFES-recommended): Short Physical Performance Battery (SPPB), usual gait speed, or FRAIL Scale — in line with the ADVANTAGE Joint Action group and the Frailty Working Group of the Spanish Ministry of Health. All three are already implemented in FrailtyTrack (S1 SPPB, G1 Gait Speed, FRAIL questionnaire).
• Muscle power as a "promising marker": CIBERFES highlights sit-to-stand muscle power as showing earlier and faster age-related decline than muscle size or strength — the so-called "powerpenia". They cite Garcia-Aguirre 2025 (5-year longitudinal: low relative STS power → adverse health outcomes). FrailtyTrack already implements this via the Coelho-Junior 2024 normative dataset (n=12,864), the Alcázar 2021 power equation, and dedicated 5×STS-power and 30s-STS-power cards.
• Diagnostic confirmation: Fried phenotype with population-adapted cut-offs (CIBERFES's primary recommendation), supplemented with the Frailty Trait Scale-5 (FTS5; García-García 2020García-García 2020) where the dichotomous nature of phenotype scoring or its limited longitudinal sensitivity is a problem. FrailtyTrack uses Fried phenotype as the primary diagnostic construct; FTS5 is not yet integrated as an instrument card (bibliography entry added in v9.7.1; full instrument card scheduled for v9.8).
• Setting: Primary Care is the recommended baseline assessment setting; hospitals (emergency, inpatient, outpatient, day hospital), socio-sanitary facilities, and social services should also be trained. Nursing has a pivotal role given multiple-domain assessments and adherence support. FrailtyTrack's design as a self-contained, no-server, no-cookie tool supports use across all of these settings.

4. Multicomponent management (alignment with FrailtyTrack)

Once frailty is detected, CIBERFES recommends a Comprehensive Geriatric Assessment followed by lifestyle-based intervention. The most effective interventions, supported by RCT evidence, are physical exercise and nutritional optimisation. Exercise should be multicomponent: strength + power + balance/gait + aerobic + flexibility, following the Izquierdo 2025 ICFSR consensus (J Nutr Health Aging 2025;29:100401). The Vivifrail program (vivifrail.com) is recommended as a simple, validated, capacity-tailored prescription tool. Nutrition recommendations: protein 1.2–1.5 g/kg/day (≥30 g per meal to overcome anabolic resistance), ≥30 kcal/kg/day, fibre ~25 g/d, hydration 1.6 L (women) / 2.0 L (men), vitamin D supplementation when 25(OH)D <20 ng/mL, and Mediterranean dietary pattern. There is no effective drug specifically for frailty; deprescribing of inappropriate medications (anticholinergics, statins, psychotropics) is part of management. FrailtyTrack is currently a tracking and assessment tool, not a prescription tool; the Izquierdo 2025 ICFSR and Vivifrail references are added to the bibliography for clinical context.

5. Stigma and patient communication

CIBERFES recognises the stigma of being labelled "frail" as an urgent issue, but argues against the WHO approach of replacing the term with "intrinsic capacity" — characterising the rebrand as "concealment". Instead, they advocate the same destigmatisation approach used for breast cancer or AIDS: personal support, environmental interventions, objective patient/family/caregiver education, healthcare-professional training, advertising campaigns, and social media. This is a contested choice — some clinicians and patient advocates favour the term "intrinsic capacity" precisely because of stigma considerations. FrailtyTrack does not take a side; it presents the framework neutrally and lets the user/clinician choose terminology appropriate to their setting. The bilingual UI defaults to "Frailty" (English) in German contexts to avoid the connotations of "Gebrechlichkeit", per the existing translation policy.

6. Sub-phenotypes (still emerging)

• Cognitive frailty — CIBERFES is hesitant. The lack of clear definition (does delirium and dementia count as cognitive impairment?) and the unclear added clinical value over either entity alone make CIBERFES "encourage further research" rather than endorse cognitive frailty as a distinct construct. FrailtyTrack does not currently have a dedicated cognitive-frailty card; this is on the long-term roadmap pending stronger evidence.
• Social frailty → "social vulnerability" — CIBERFES proposes the term "social vulnerability" rather than "social frailty" for inadequate social connections, support, or interaction. They emphasise systematic assessment of social profiles in multidimensional prevention/treatment programs across all care levels. FrailtyTrack adopts the CIBERFES terminology recommendation in any future social-domain card.
• Frailty + comorbidity classes — emerging research identifies subclasses (cardiovascular-disease frailty, osteoarticular frailty, neuropsychiatric frailty, high-multisystem frailty). CIBERFES considers this an upcoming area whose clinical importance "cannot yet be corroborated".

For the full consensus document, including the detailed pathophysiology figures, biomarker discussion, gender considerations, and policy/implementation roadmap, see Álvarez-Bustos et al. 2026 in the bibliography below. The full text is freely available under CC BY-NC-ND 4.0 at the DOI link or via the digital.csic.es open repository.

In June 2025 The Lancet announced a new Commission on Frailty, building on the 2013 Lancet Seminar (Clegg et al.) and the 2019 Lancet Series (Hoogendijk et al. / Dent et al.). The launch Comment by Dent, Clegg, Roller-Wirnsberger, Vetrano & Hoogendijk (Lancet 2025;405(10497):2265–2266) sets out the Commission's goal and four priority areas. Important framing: this is a programme announcement, not a finalised consensus document. The substantive Commission report is pending and no operational recommendations are yet issued. The card below summarises what the Commission has stated as its scope and priorities, complementing — not replacing — the CIBERFES 2026 consensus above.Dent 2025  doi ✅

1. The Commission's stated goal

The Commission's stated core goal is to "globally reorient healthcare and public policy to prevent the development and progression of frailty across the life-course, and to improve access to high-value, evidence-based care for older adults with frailty." The framing is explicitly life-course rather than restricted to old age — a deliberate departure from the more clinical, late-life framing of the 2013 Lancet Seminar. Frailty is positioned as a major public-health challenge with population prevalence of 12–24% in adults aged ≥65, disproportionately affecting women, populations from culturally and linguistically diverse backgrounds, those experiencing socioeconomic disadvantage, and residents of low- and middle-income countries (LMICs). This framing aligns with FrailtyTrack's existing pre-disability emphasis and with CIBERFES's pre-disability state framing in the section above.

2. Four priority areas

• (i) Frailty as an actionable target of prevention and treatment across the life-course. The Commission will develop new knowledge of the causal pathways for frailty, and the life-course factors (including social determinants of health) that drive or delay its development and progression. This priority broadens the frailty conversation beyond geriatric medicine into life-course epidemiology and primary care.
• (ii) Early detection and diagnosis of frailty within a public-health approach. The Commission will develop a diagnostic framework — addressing the heterogeneity of current frailty measurements — and work towards correlation with WHO's International Classification of Diseases (ICD) and International Classification of Functioning, Disability and Health (ICF). The Commission also plans to discuss the harms and benefits of frailty identification, citing the controversial COVID-19 use of frailty for ICU triage as an example of the risks of poorly-evidenced application.
• (iii) Optimal management of older adults living with frailty. Clinical care for people with frailty has expanded over the last five years beyond geriatric medicine and into cardiology, oncology, orthopaedics, neurology, endocrinology, surgery, and emergency medicine. The Commission will investigate incorporation of frailty as a prognostic indicator across these specialties and develop an adaptable implementation framework. Pre-stressor intervention (e.g. before elective surgery) is identified as a specific target.
• (iv) Wider adoption of frailty into public-health policies for ageing. The Commission will develop policy recommendations for national public-health strategy reform to include frailty, augmenting the United Nations' Decade of Healthy Ageing (2021–2030), the WHO's policy framework for healthy ageing from the World Report on Ageing and Health, and the World Health Assembly's primary-care reorientation goal. Resource implications of rising frailty prevalence will be assessed.

3. Policy alignments

The Commission grounds its work in three explicit policy alignments: (a) the UN Decade of Healthy Ageing 2021–2030, which provides a global multi-stakeholder framework; (b) the WHO World Report on Ageing and Health (Beard, Officer, de Carvalho et al. 2016), which recognises frailty as "the foremost geriatric syndrome in older adults and a key determinant of functional ability"; and (c) the World Health Assembly's primary-care reorientation (77th WHA Strategic Roundtable, May 2024). The framing positions frailty assessment and intervention not as specialist-only activity but as core primary-care infrastructure — consistent with the FrailtyTrack design (no-server, no-cookie, double-clickable) supporting use in primary-care, outpatient physiotherapy, and community geriatric services.

4. Commissioner composition

The Commission lists 21 commissioners spanning geriatrics and gerontology, allied health, nursing, public health, health policy, implementation science, palliative care, primary care, pharmacology, surgery, oncology, cardiology, social science, epidemiology, and geroscience. Co-Chairs are Elsa Dent (Bond University, Australia) and Emiel O. Hoogendijk (Amsterdam UMC). Other commissioners include Andrew Clegg (Leeds), Linda P. Fried (Columbia), Kenneth Rockwood (Dalhousie), Davide L. Vetrano (Karolinska), Regina Roller-Wirnsberger (Graz), Heather Keller, Mara McAdams-DeMarco, Mario U. Pérez-Zepeda, Jotheeswaran A. Thiyagarajan, Alfred E. Yawson, and others. The Commission explicitly emphasises balanced gender representation, geographical diversity (including LMIC representation), career-stage diversity, and inclusion of perspectives from older adults themselves. The roster's breadth reflects the Commission's life-course and cross-specialty programme.

5. Status & complementarity to CIBERFES

Important distinction: the Lancet Commission's substantive report has not yet been published — this 2-page Comment is the programme announcement only. Operational recommendations on instruments, cut-offs, intervention protocols, or care pathways are not yet available from this Commission. For current operational guidance FrailtyTrack therefore continues to draw on the CIBERFES 2026 consensus document (above), the ICFSR 2025 exercise consensus (Izquierdo et al.), the WHO ICOPE / Integrated Care for Older People framework, and the SPRINTT RCT evidence base. The two complement each other: CIBERFES is a finalised consensus issuing operational recommendations now; the Lancet Commission is a programme of inquiry that will produce a comprehensive report in the coming years. FrailtyTrack will track the Commission's outputs as they appear and integrate substantive recommendations in future releases.

The full launch Comment is open-access at the DOI link above (Lancet 405(10497):2265–2266) and via the University of Leeds White Rose Research Online repository (eprints.whiterose.ac.uk/237353). FrailtyTrack will revisit and expand this section once the Commission's substantive report is published.

1. Fried LP et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3):M146–M157. doi:10.1093/gerona/56.3.M146
2. Dodds RM et al. Grip strength across the life course: normative data from twelve British studies. PLoS One. 2014;9(12):e113637. [n=49,964; ages 4–90 y; 12 GB population studies; used for HGS percentile chart extension ages 75–90 y] doi:10.1371/journal.pone.0113637
3. Cruz-Jentoft AJ et al.; EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16–31. doi:10.1093/ageing/afy169
4. Bohannon RW, Wang YC. Four-meter gait speed: normative values and reliability determined for adults participating in the NIH Toolbox Study. Arch Phys Med Rehabil. 2019;100(3):509–513. doi:10.1016/j.apmr.2018.06.031
5. Studenski S et al. Gait speed and survival in older adults. JAMA. 2011;305(1):50–58. doi:10.1001/jama.2010.1923
6. Podsiadlo D, Richardson S. The timed "Up & Go": a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc. 1991;39(2):142–148. doi:10.1111/j.1532-5415.1991.tb01616.x
7. Svinøy OE et al. Timed Up and Go: reference values for community-dwelling older adults — Norwegian Tromsø Study. Clin Interv Aging. 2021;16:373–386. doi:10.2147/CIA.S294512
8. Ibrahim A et al. 'Timed Up and Go' test: age, gender and cognitive impairment stratified normative values of older adults. PLoS One. 2017;12(10):e0185641. doi:10.1371/journal.pone.0185641
9. Guralnik JM et al. A short physical performance battery assessing lower extremity function. J Gerontol. 1994;49(2):M85–M94. doi:10.1093/geronj/49.2.M85
10. Guralnik JM et al. Lower-extremity function in persons over 70 years as a predictor of subsequent disability. N Engl J Med. 1995;332(9):556–562. doi:10.1056/NEJM199503023320902
11. Bergland A, Strand BH. Norwegian reference values for the Short Physical Performance Battery (SPPB): the Tromsø Study. BMC Geriatr. 2019;19(1):216. [Tromsø Study Wave 7; n=7,474 community-dwelling Norwegians ≥40 y; mean SPPB 11.4 (SD 1.3); age- and sex-stratified percentiles (5th, 10th, 25th, 50th, 75th, 90th, 95th); ceiling effects noted in younger/healthier groups. PMID: 31395008 ✅ live-fetched v8.19 session] doi:10.1186/s12877-019-1234-8
12. Rikli RE, Jones CJ. Development and validation of a functional fitness test for community-residing older adults. J Aging Phys Act. 1999;7(2):129–161. doi:10.1123/japa.7.2.129
13. Rikli RE, Jones CJ. Measuring functional fitness of older adults. J Active Aging. 2002 Mar/Apr:24–30. [Normative data for Senior Fitness Test; full dataset n=7,183. No DOI — practitioner magazine. DOI 10.1123/japa.10.2.173 was fabricated and has been removed (v8.16).]
14. Rockwood K et al. A global clinical measure of fitness and frailty in elderly people. CMAJ. 2005;173(5):489–495. doi:10.1503/cmaj.050051
15. Makizako H, Shimada H, Doi T, Tsutsumimoto K, Nakakubo S, Hotta R, Suzuki T. Predictive cutoff values of the Five-Times Sit-to-Stand Test and the Timed Up & Go Test for disability incidence in older people dwelling in the community. Phys Ther. 2017;97(4):417–424. [PMID: 28371914 — DOI corrected this session from erroneous 20160065] doi:10.2522/ptj.20150665
16. Huemer MT, Kluttig A, Fischer B, Ahrens W, Castell S, Ebert N, Gastell S, Jöckel KH, Kaaks R, Karch A, Keil T, Kemmling Y, Krist L, Leitzmann M, Lieb W, Meinke-Franze C, Michels KB, Mikolajczyk R, Moreno Velásquez I, Pischon T, Schipf S, Schmidt B, Schöttker B, Schulze MB, Stocker H, Teismann H, Wirkner K, Drey M, Peters A, Thorand B. Grip strength values and cut-off points based on over 200,000 adults of the German National Cohort — a comparison to the EWGSOP2 cut-off points. Age Ageing. 2023;52(1):afac324. [n=200,389 NAKO participants aged 19–75 y; NAKO-derived cut-offs (M <29 kg / F <18 kg) are 2 kg higher than EWGSOP2 (M <27 / F <16); HGS percentile chart in this tool extends Dodds 2014 with NAKO data. PMID: 36702514 ✅ live-fetched v8.19 session] doi:10.1093/ageing/afac324
17. Kim S et al. Short Physical Performance Battery as a crosswalk between frailty phenotype and deficit accumulation frailty index. J Gerontol A. 2021;76(12):2251–2257. doi:10.1093/gerona/glab229
18. Perera S, Mody SH, Woodman RC, Studenski SA. Meaningful change and responsiveness in common physical performance measures in older adults. J Am Geriatr Soc. 2006;54(5):743–749. [Foundational MCID/SCD source: gait speed small meaningful change 0.04–0.06 m/s, substantial change 0.10 m/s; SPPB small 0.27–0.55 pts, substantial 1 pt; 6MWD small 19–22 m, substantial 50 m. PMID: 16696738 ✅ live-fetched v8.19 session] doi:10.1111/j.1532-5415.2006.00701.x
19. Merchant RA, Chan YH, Hui RJY, Lim JY, Kwek SC, Seetharaman SK, Au LSY, Morley JE. Possible sarcopenia and impact of dual-task exercise on gait speed, handgrip strength, falls, and perceived health (HAPPY Study). Front Med (Lausanne). 2021;8:660463. [PMID: 33937294 — corrected v8.20 from prior 33953631 (verified against PubMed); PMCID: PMC8086796 ✅ live-fetched v8.20 session. Source for Demo Case 1 — Mrs E.K.] doi:10.3389/fmed.2021.660463
20. Tan RS, Goh EF, Wang D, Chan RCL, Zeng Z, Yeo A, Pek K, Kua J, Wong WC, Shen Z, Lim WS. Effectiveness and usability of the system for assessment and intervention of frailty for community-dwelling pre-frail older adults: a pilot study (SAIF Study). Front Med (Lausanne). 2022 Nov 17;9:955785. [PMID: 36465917; PMCID: PMC9713022 ✅ live-fetched v8.20 session. Author list expanded from "et al." in v8.20. Source for Demo Case 2 — Mr H.W. Note: a corrigendum exists at Front Med (Lausanne). 2022 Dec 22;9:1105448, doi:10.3389/fmed.2022.1105448 (PMID 36619615).] doi:10.3389/fmed.2022.955785
21. Pandey A, Kitzman D, Whellan DJ, Duncan PW, Mentz RJ, Pastva AM, Nelson MB, Upadhya B, Chen H, Reeves GR. Frailty among older decompensated heart failure patients: prevalence, association with patient-centered outcomes, and efficient detection methods. JACC Heart Fail. 2019 Dec;7(12):1079–1088. [PMID: 31779931; PMCID: PMC8067953 ✅ live-fetched v8.20 session. Source for Demo Case 4 — Mr R.B.] doi:10.1016/j.jchf.2019.10.003
22. Tarazona-Santabalbina FJ, Gómez-Cabrera MC, Pérez-Ros P, Martínez-Arnau FM, Cabo H, Tsaparas K, Salvador-Pascual A, Rodriguez-Mañas L, Viña J. A multicomponent exercise intervention that reverses frailty and improves cognition, emotion, and social networking in the community-dwelling frail elderly: a randomized clinical trial. J Am Med Dir Assoc. 2016 May;17(5):426–433. [PMID: 26947059 ✅ live-fetched v8.20 session. Source for Demo Case 4 — Mr R.B. cardiac context] doi:10.1016/j.jamda.2016.01.019
23. Yoon DH, Lee J-Y, Song W. Effects of resistance exercise training on cognitive function and physical performance in cognitive frailty: a randomized controlled trial. J Nutr Health Aging. 2018;22(8):944–951. [PMID: 30272098 ✅ Re-verified v8.20 session (originally live-fetched v8.15). Source for Demo Case 5 — Mrs L.A. Previously cited erroneously as "Langlois F et al., Eur Geriatr Med, 2023" with a structurally invalid DOI (10.1016/j.eurger.2023.05.003). Correct authors, journal, year, and DOI confirmed by Roger and live PubMed record — corrected v8.15.] doi:10.1007/s12603-018-1090-9
24. Bohannon RW. Reference values for the five-repetition sit-to-stand test: a descriptive meta-analysis of data from elders. Percept Mot Skills. 2006;103(1):215–222. [Meta-analysis of 13 papers; normative cut-offs for worse-than-average performance: >11.4 s (60–69 y), >12.6 s (70–79 y), >14.8 s (80–89 y); these values are displayed in the built-in 5×STS timer (v8.4). PMID: 17037663 ✅ live-fetched v8.19 session] doi:10.2466/pms.103.1.215-222
25. Whitney SL, Wrisley DM, Marchetti GF, Gee MA, Redfern MS, Furman JM. Clinical Measurement of Sit-to-Stand Performance in People With Balance Disorders: Validity of Data for the Five-Times-Sit-to-Stand Test. Phys Ther. 2005;85(10):1034–1045. [Protocol anchor for the 5×STS card — added v9.9.24. Concurrent/discriminative-validity study that formalised the five-repetition FTSST protocol (stand from a 43-cm chair five times as fast as possible, arms folded across the chest); basis for the APTA / Shirley Ryan AbilityLab clinical standard. Cited in the «Standardised Protocol» heading of the Test Protocols 5×STS card; v9.9.24 also reconciled the card's timer-start rule to the Whitney start-on-«Go» convention. PMID: 16180952 ✅ live-fetched v9.9.24 session] doi:10.1093/ptj/85.10.1034
26. Csuka M, McCarty DJ. Simple method for measurement of lower extremity muscle strength. Am J Med. 1985;78(1):77–81. [Historical-origin reference for the timed chair-stand method — added v9.9.24. Standardised the original timed chair-stand test in 139 healthy subjects aged 20–85. Note: the original method timed ten repetitions, not five — it is the methodological ancestor of the 5×STS but not the five-repetition protocol itself (that is Whitney 2005, above); catalogued as origin citation only. PMID: 3966492 ✅ verified v9.9.24 session] doi:10.1016/0002-9343(85)90465-6
27. Grgic J, Schoenfeld BJ, Maier AB, Pedisic Z. Reference values for the five-times-sit-to-stand test: a pooled analysis including 45,470 participants from 14 countries. GeroScience. 2026;48(2):3059–3067. [Normative dataset for FTSST percentile chart — added v8.2. SHARE Wave 5 (2013); n=45,470; 14 European countries; ages 50–90+; weighted percentiles by sex and 5-year age bands; PMID: 40875134] doi:10.1007/s11357-025-01863-8
28. Alcazar J, Alegre LM, Van Roie E, Magalhães JP, Nielsen BR, González-Gross M, Júdice PB, Casajús JA, Delecluse C, Sardinha LB, Suetta C, Ara I. Relative sit-to-stand power: aging trajectories, functionally relevant cut-off points, and normative data in a large European cohort. J Cachexia Sarcopenia Muscle. 2021;12(4):921–932. [Source for STS power equation and mobility cut-offs — added v8.2. n=9,906 older adults + 586 young/middle-aged; cut-offs: 2.6 W/kg (M), 2.1 W/kg (F) for mobility limitation; PMID: 34216098] doi:10.1002/jcsm.12737
29. Baltasar-Fernandez I, Alcazar J, Mañas A, Alegre LM, Alfaro-Acha A, Rodriguez-Mañas L, Ara I, García-García FJ, Losa-Reyna J. Relative sit-to-stand power cut-off points and their association with negative[s — sic] outcomes in older adults. Sci Rep. 2021;11(1):19460. [Source for 5×STS frailty/ADL cut-offs — added v8.2. n=1,369; cut-offs: 2.5 W/kg (M), 1.9 W/kg (F) for frailty and ADL limitations. PMCID: PMC8484545 ✅ live-fetched v8.19 session. Title typo finding (v8.19): the published title reads "negatives outcomes" (with anomalous plural). The typo is preserved across Nature.com, PMC, Springer Nature, and independent citing literature; FrailtyTrack pre-v8.19 silently corrected it. Now annotated [sic] above per scientific citation best practice.] doi:10.1038/s41598-021-98871-3
30. Garcia-Aguirre M, Baltasar-Fernandez I, Alcazar J, Losa-Reyna J, Alfaro-Acha A, Ara I, Rodriguez-Mañas L, Alegre LM, Garcia-Garcia FJ. Cut-off points for low relative 30-s sit-to-stand power and their associations with adverse health conditions. J Cachexia Sarcopenia Muscle. 2025;16(1):e13676. [Source for 30s CST power cut-offs and MCID — added v8.2. Cut-offs: 2.53 W/kg (M), 2.01 W/kg (F); MCID: 0.42 W/kg (M), 0.33 W/kg (F); PMID: 39790033] doi:10.1002/jcsm.13676
31. Coelho-Junior HJ, Marzetti E, Picca A, Tosato M, Calvani R, Landi F. Sex- and age-specific normative values of lower extremity muscle power in Italian community-dwellers. J Cachexia Sarcopenia Muscle. 2024;15(1):45–54. [Normative dataset for 5×STS power percentile chart — added v8.3. Lookup 7+ project; n=12,864 community-dwellers; Italy; ages 18–98; P5/P25/P50/P75/P95 by sex and 10-yr age band for relative power (W/kg); formula: P_rel = 0.9 × g × (height_m − 2 × chairH_m) × reps / time; Tables S3 (men) and S6 (women) extracted from supplementary material; PMID: 37986667] doi:10.1002/jcsm.13301
32. Freitas SR, Cruz-Montecinos C, Ratel S, Pinto RS. Powerpenia Should be Considered a Biomarker of Healthy Aging. Sports Med Open. 2024;10(1):27. [Powerpenia narrative source — added v9.4.0. Argues that the loss of muscle power should be measured separately from sarcopenia (mass) and dynapenia (strength) because power decline starts earlier and progresses faster, and only 2 of 220 dynapenia studies between 2008 and 2023 directly measured power. Underlies the v9.4.0 Powerpenia note in the 5×STS card and the Sarkopenie–Dynapenie–Powerpenia triad in the BFH 2026 workshop script. PMID: 38523229; PMCID: PMC10961295. ✅ live-fetched v9.4.0 session] doi:10.1186/s40798-024-00689-6
33. Strassmann A, Steurer-Stey C, Dalla Lana K, Zoller M, Turk AJ, Suter P, Puhan MA. Population-based reference values for the 1-min sit-to-stand test. Int J Public Health. 2013;58(6):949–953. [Swiss normative dataset for 1-minSTS — added v8.5. n=6,926 Swiss adults (community, nationwide campaign 2010–2012); ages 20–79 y; P2.5/P25/P50/P75/P97.5 by 5-yr age band and sex; chair height 46 cm; arms not used; median 50 reps (M, 20–24 y) declining to 30 reps (M, 75–79 y); PMID: 23974352] doi:10.1007/s00038-013-0504-z
34. Simpkins C, Yang F. Muscle power is more important than strength in preventing falls in community-dwelling older adults. J Biomech. 2022;134:111018. [n=94 community-dwelling adults; 5×STS power discriminates fallers from non-fallers better than isometric knee strength; optimal threshold 12 s / 1.3 W/(kg·m); PMID: 35228153] doi:10.1016/j.jbiomech.2022.111018
35. Yeung SSY, Reijnierse EM, Trappenburg MC, Hogrel J-Y, McPhee JS, Piasecki M, Sipilä S, Salpakoski A, Butler-Browne G, Pääsuke M, Gapeyeva H, Narici MV, Meskers CGM, Maier AB. Handgrip strength cannot be assumed a proxy for overall muscle strength. J Am Med Dir Assoc. 2018;19(8):703–709. [n=960 across 5 cohorts; ICC between HGS and KES poor–moderate (0.37–0.54); low agreement at individual level; HGS should not be assumed proxy for lower-limb strength. PMID: 29935982] doi:10.1016/j.jamda.2018.04.019
36. Yeung SSY, Reijnierse EM, Trappenburg MC, Blauw GJ, Meskers CGM, Maier AB. Knee extension strength measurements should be considered as part of the comprehensive geriatric assessment. BMC Geriatr. 2018;18(1):130. [n=163 geriatric outpatients; KES showed stronger associations with physical, nutritional, cognitive, and functional health characteristics than HGS; inclusion of KES in CGA recommended. PMID: 29859054] doi:10.1186/s12877-018-0815-2
37. Bohannon RW. Reference values for knee extension strength obtained by hand-held dynamometry from apparently healthy older adults: a meta-analysis. J Frailty Aging. 2017;6(4):199–201. [Normative %BW values for dominant knee extension (HHD); ages 60–79; range 35.6–48.8%BW; used as KES reference norms in FrailtyTrack. PMID: 29165536] doi:10.14283/jfa.2017.32
38. Zheng H, Sun W, Zhou Z, Tian F, Xiao W, Zheng L. Cut-off points for knee extension strength: identifying muscle weakness in older adults. Eur Geriatr Med. 2024;15(4):913–925. [Systematic review of 12 studies; high heterogeneity; no consensus cut-off established; HHD-based isometric KES recommended as clinically practical; standardised approach needed. PMID: 38926333] doi:10.1007/s41999-024-01009-7
39. Montero-Odasso M, van der Velde N, Martin FC, Petrovic M, Tan MP, Ryg J et al.; Task Force on Global Guidelines for Falls in Older Adults. World guidelines for falls prevention and management for older adults: a global initiative. Age Ageing. 2022;51(9):afac205. [Comprehensive international evidence-based guideline; recommends gait speed and TUG for falls risk stratification; multifactorial assessment and exercise-based intervention; PMID: 36178003; PMCID: PMC9523684 ✅ live-fetched v8.19 session] doi:10.1093/ageing/afac205
40. Yardley L, Beyer N, Hauer K, Kempen G, Piot-Ziegler C, Todd C. Development and initial validation of the Falls Efficacy Scale-International (FES-I). Age Ageing. 2005;34(6):614–619. [Original FES-I 16-item development and validation. ProFaNE consortium; n=704 community-dwelling adults aged 60–95 from UK, Germany, Netherlands, Switzerland, Greece; Cronbach's α=0.96; ICC=0.96; range 16–64. PMID: 16267188 ✅ live-fetched v9.2.1 session] doi:10.1093/ageing/afi196
41. Kempen GIJM, Yardley L, van Haastregt JCM, Zijlstra GAR, Beyer N, Hauer K, Todd C. The Short FES-I: a shortened version of the Falls Efficacy Scale-International to assess fear of falling. Age Ageing. 2008;37(1):45–50. [Original Short FES-I 7-item development. Items 2, 4, 6, 7, 9, 15, 16 from FES-I; range 7–28; comparable psychometric properties to FES-I; suitable for rapid clinical assessment. ✅ live-fetched v9.2.1 session] doi:10.1093/ageing/afm157
42. Dias N, Kempen GIJM, Todd CJ, Beyer N, Freiberger E, Piot-Ziegler C, Yardley L, Hauer K. The German version of the Falls Efficacy Scale—International Version (FES-I) [Die Deutsche Version der Falls Efficacy Scale—International Version (FES-I)]. Z Gerontol Geriatr. 2006;39(4):297–300. [Validated German FES-I translation by the Heidelberg Bethanien team (Klaus Hauer). Manchester ProFaNE site classifies the German FES-I as "Validated" status. ✅ live-fetched v9.2.1 session] doi:10.1007/s00391-006-0400-8
43. Delbaere K, Close JCT, Mikolaizak AS, Sachdev PS, Brodaty H, Lord SR. The Falls Efficacy Scale International (FES-I): a comprehensive longitudinal validation study. Age Ageing. 2010;39(2):210–216. [Definitive cut-points for FES-I and Short FES-I. Sydney Memory and Ageing Study; n=500 community-dwelling adults ≥70 y; FES-I cut-points: Low 16–19 / Moderate 20–27 / High 28–64; Short FES-I cut-points: Low 7–8 / Moderate 9–13 / High 14–28. PMID: 20061508 ✅ live-fetched v9.2.1 session] doi:10.1093/ageing/afp225
44. Hauer KA, Kempen GIJM, Schwenk M, Yardley L, Beyer N, Todd C, Oster P, Zijlstra GAR. Validity and sensitivity-to-change of the Falls Efficacy Scales International to assess fear of falling in older adults with and without cognitive impairment. Gerontology. 2011;57(5):462–472. [FES-I validation in cognitive impairment. Geriatric rehabilitation patients with and without cognitive impairment; Cronbach's α=0.92; demonstrates feasibility in older adults with mild-to-moderate cognitive impairment. ✅ live-fetched v9.2.1 session] doi:10.1159/000320054
45. Kaiser MJ, Bauer JM, Ramsch C, Uter W, Guigoz Y, Cederholm T, Thomas DR, Anthony P, Charlton KE, Maggio M, Tsai AC, Grathwohl D, Vellas B, Sieber CC; MNA-International Group. Validation of the Mini Nutritional Assessment short-form (MNA-SF): A practical tool for identification of nutritional status. J Nutr Health Aging. 2009;13(9):782–788. [Source for the MNA-SF protocol card — added v9.4.0. Validation of the revised 6-item MNA-SF against the full MNA in a multinational n=2,032 dataset (mean age 82.3 y). Thresholds 12–14 normal / 8–11 risk / 0–7 malnourished. The revised MNA-SF allows substitution of calf circumference (CC) for BMI when BMI cannot be measured, enabling use in immobile or non-stehfähige patients. PMID: 19812868. ✅ live-fetched v9.4.0 session] doi:10.1007/s12603-009-0214-7
46. Frehner D, Knuchel S, Gafner SC, Zindel B. StoppSturz Vorgehen Physiotherapie. Manual. Bern: PHS Public Health Services; 2021. Version 05.08.2021. [Official Swiss physiotherapy fall-prevention pathway. Authored by physioswiss working group, supported by physioswiss + Gesundheitsförderung Schweiz; 2-scenario / 3-tier risk algorithm derived from CDC STEADI 2017 but adapted for Swiss physiotherapy practice and prescription logic. License: "Alle Rechte vorbehalten. Verwendung unter Quellenangabe (siehe Zitationsvorschlag) erlaubt." Source PDF on BFU portal ✅ live-fetched v9.2.2 session] bfu.ch/media/.../stoppsturz_manual_physiotherapie.pdf
47. Frehner D, Knuchel-Schnyder S, Zindel B, Bruderer-Hofstetter M, Pfenninger B. Sturzprävention in der Physiotherapie: Grundlagen und Empfehlungen für die Praxis. Bern: BFU, Beratungsstelle für Unfallverhütung; 2021. Fachdokumentation 2.249, 44 Seiten. [Companion BFU document to the StoppSturz Manual — deeper scientific grounding and practice recommendations. DOI verified via converging references and BFU document numbering scheme ✅ v9.2.2 session] doi:10.13100/BFU.2.249.01.2021
48. Franchignoni F, Horak F, Godi M, Nardone A, Giordano A. Using psychometric techniques to improve the Balance Evaluation Systems Test: the mini-BESTest. J Rehabil Med. 2010;42(4):323–331. [Original Mini-BESTest development. Reduction of 36-item BESTest to 14-item Mini-BESTest via factor analysis and Rasch analysis; n=115 adult patients with diverse neurological diagnoses. © OHSU 2005–2013. Cited as Mini-BESTest source in StoppSturz Manual ✅ live-fetched v9.2.2 session] doi:10.2340/16501977-0537
49. Yingyongyudha A, Saengsirisuwan V, Panichaporn W, Boonsinsukh R. The Mini-Balance Evaluation Systems Test (Mini-BESTest) demonstrates higher accuracy in identifying older adult participants with history of falls than do the BESTest, Berg Balance Scale, or Timed Up and Go Test. J Geriatr Phys Ther. 2016;39(2):64–70. [Mini-BESTest community-dwelling cut-off ≤16/28. Used by StoppSturz for older adults with/without fall history. Verified via citation in StoppSturz Manual] doi:10.1519/JPT.0000000000000050
50. Cramer E, Weber F, Faro G, Klein M, Willeke D, Hering T, Zietz D. Cross-cultural adaption and validation of the German version of the Mini-BESTest in individuals after stroke: an observational study. Neurol Res Pract. 2020;2:27. [Validated DACH-region German version (GVMBT) of the Mini-BESTest. Hochschule für Gesundheit Bochum; n=50 sub-acute/chronic stroke (NIHSS 0–7); 16 min administration; Cronbach's α = 0.90 (95% CI 0.87–0.94); convergent validity ρ_BBS = 0.93, ρ_TUG = −0.85; ceiling 2% (vs BBS 14% in same sample); no floor effect. Open Access (CC BY 4.0). ✅ live-fetched v9.2.3 session, full PDF reviewed] doi:10.1186/s42466-020-00078-w
51. Di Carlo S, Bravini E, Vercelli S, Massazza G, Ferriero G. The Mini-BESTest: a review of psychometric properties. Int J Rehabil Res. 2016;39(2):97–105. [Systematic review of Mini-BESTest psychometric properties. Source for the often-cited "Cronbach's α 0.89–0.96 across populations", "Pearson r 0.79–0.94 with BBS", and "ceiling 0.9–4.3% across populations" ranges. Reference 16 in Cramer 2020. PMID 26795715] doi:10.1097/MRR.0000000000000153
52. Bergström M, Lenholm E, Franzén E. Translation and validation of the Swedish version of the Mini-BESTest in subjects with Parkinson's disease or stroke: a pilot study. Physiother Theory Pract. 2012;28(7):509–514. [Swedish Mini-BESTest pilot validation. Reference 20 in Cramer 2020. Cited in StoppSturz Manual literature list. PMID 22288725] doi:10.3109/09593985.2011.653707
53. Berg KO, Wood-Dauphinee SL, Williams JI, Gayton D. Measuring balance in the elderly: preliminary development of an instrument. Physiother Can. 1989;41(6):304–311. [Original Berg Balance Scale paper. 14-item, 56-point ordinal balance assessment now used worldwide. Foundational reference for all subsequent BBS validation work] doi:10.3138/ptc.41.6.304
54. Scherfer E, Bohls C, Freiberger E, Heise K-F, Hogan D. Berg-Balance-Scale — deutsche Version. Übersetzung eines Instruments zur Beurteilung von Gleichgewicht und Sturzgefährdung. physioscience. 2006;2:59–66. [Authorised DACH German version of the BBS. Cross-cultural adaptation following Beaton et al. recommendations. Authorised by and developed in correspondence with original author Katherine Berg (Erlangen Conference 2005-10-08). Permissive license: free use with citation of original and this publication. ✅ live-fetched v9.2.4 session, full PDF reviewed] doi:10.1055/s-2006-926833
55. Shumway-Cook A, Baldwin M, Polissar NL, Gruber W. Predicting the probability for falls in community-dwelling older adults. Phys Ther. 1997;77(8):812–819. [BBS <36/56 = nearly 100% fall risk in community-dwelling older adults. Foundational fall-risk threshold paper, n=44. Non-linear relationship between BBS score and fall probability. PMID 9256869] doi:10.1093/ptj/77.8.812
56. Steffen TM, Hacker TA, Mollinger L. Age- and gender-related test performance in community-dwelling elderly people: Six-Minute Walk Test, Berg Balance Scale, Timed Up & Go Test, and gait speeds. Phys Ther. 2002;82(2):128–137. [BBS, 6MWT, TUG, gait-speed normative values for community-dwelling older adults. n=96, ages 61–89. Anglo-American normative reference. PMID 11856064] doi:10.1093/ptj/82.2.128
57. Muir SW, Berg K, Chesworth B, Speechley M. Use of the Berg Balance Scale for predicting multiple falls in community-dwelling elderly people: a prospective study. Phys Ther. 2008;88(4):449–459. [Definitive paper showing dichotomous BBS cut-offs are unreliable; recommends likelihood ratios across the score range. n=210 community-dwelling, 12-month prospective cohort. Concluded "use of the BBS as a dichotomous scale to identify people at high risk for falling should be discouraged because it fails to identify the majority of such people." Lower scores (especially <40) signal substantially elevated multiple-fall risk. PMID 18218822] doi:10.2522/ptj.20070251
58. Donoghue D, Stokes EK. How much change is true change? The minimum detectable change of the Berg Balance Scale in elderly people. J Rehabil Med. 2009;41(5):343–346. [BBS MDC₉₅ values, score-stratified. n=118 elderly without stroke/Parkinson's/recent hip arthroplasty. Multi-centre test-retest design. Score-dependent MDC: higher MDC at lower baseline scores] doi:10.2340/16501977-0337
59. Álvarez-Bustos A, Andres-Lacueva C, Ara I, Arévalo MA, Bolaños JP, Coto-Montes A, Enriquez JA, Escames G, García-García FJ, Gómez-Cabrera MC, Grau-Rivera O, Izquierdo M, Martínez Velilla N, Matheu A, Menéndez Colino R, Muñoz Torres M, Nogués X, Oliva J, Orts-Cortés MI, Párraga Martínez I, Priego F, Rabassa-Bonet M, Rol MA, Serra-Rexach JA, Tarazona-Santabalbina FJ, Rodríguez-Mañas L, Abizanda P, for the CIBERFES working group. Consensus document on frailty: conceptualization, detection, multidisciplinary management and future roadmap. J Nutr Health Aging. 2026;30:100793. [2026 European consensus position statement from CIBERFES (Spanish Research Consortium on Frailty and Healthy Aging, Instituto de Salud Carlos III, 25 research groups). Definition, what frailty is/is not, recommended assessment (SPPB, gait speed, FRAIL Scale, Fried phenotype + FTS5), multicomponent management, stigma, sub-phenotypes, future roadmap. Open Access CC BY-NC-ND 4.0. Available online 28 Jan 2026. Surfaced in the FrailtyTrack About-tab "Position Statements & Consensus" section. ✅ live-fetched v9.2.5 session via digital.csic.es open repository, full PDF reviewed] doi:10.1016/j.jnha.2026.100793
60. Garcia-Aguirre M, Baltasar-Fernandez I, Alcazar J, Alfaro-Acha A, Bareiro-Quiñonez FA, Ara I, Rodriguez-Mañas L, Garcia-Garcia FJ, Alegre LM. Low relative sit-to-stand power is associated with the development of adverse health outcomes: a 5-year longitudinal study. J Cachexia Sarcopenia Muscle. 2025;16:e13852. [5-year longitudinal evidence linking low relative STS power to adverse health outcomes. CIBERFES authorship; cited by Álvarez-Bustos 2026 as the primary support for muscle power as a "promising marker of frailty" given that powerpenia occurs earlier and progresses faster than reductions in muscle size and strength. Complements the Garcia-Aguirre 2025 cross-sectional cut-off paper (e13676) already in this bibliography. ✅ live-fetched v9.2.5 session] doi:10.1002/jcsm.13852
61. García-García FJ, Carnicero JA, Losa-Reyna J, Alfaro-Acha A, Castillo-Gallego C, Rosado-Artalejo C, Gutiérrrez-Ávila G[sic], Rodriguez-Mañas L. Frailty Trait Scale–Short Form: A Frailty Instrument for Clinical Practice. J Am Med Dir Assoc. 2020;21(9):1260–1266.e2. [Source paper for the Frailty Trait Scale–Short Form (FTS5) — added to bibliography in v9.7.1. Item-reduction of the 12-item FTS via AUC-maximisation against age-, sex-, and Charlson-adjusted models for mortality, hospitalisation, disability, and incident frailty (Fried Phenotype + Frailty Index) in n=1,634 from the Toledo Study for Healthy Aging. FTS5 items: BMI, PASE, gait speed, grip strength, progressive Romberg; range 0–50; cut-off >25 = frail. Frailty prevalence by FTS5 = 24% vs 8% by Fried Phenotype in the same sample (p. 1263, Table 5). Pedagogical strength: in Fried-prefrail participants, FTS5 stratifies 35% into a high-risk frail group (mortality OR 4.0; incident frailty OR 6.6–8.7) and 65% into a near-baseline-risk group — addressing the dichotomy limitation of Fried phenotype scoring. Recommended as a complement to Fried phenotype by CIBERFES (Álvarez-Bustos 2026). Triple-r author spelling Gutiérrrez-Ávila preserved verbatim as published (consistent across PubMed PMID 32005416, ScienceDirect PII S1525861019308680, UVa & UCa institutional repositories, citing literature) — same convention as the Baltasar-Fernandez 2021 «negative[s] outcomes» published-record idiosyncrasy. FrailtyTrack status: bibliography + ref-chips only in v9.7.1 (closes a citation hole that pre-existed since the Position Statements card was added in v9.2.5); full instrument-card integration scheduled for v9.8 per the v9.7.0 scoping decision (option 3 of 4). PMID 32005416, epub 29 Jan 2020. ✅ live-fetched v9.7.1 session, all 5 fields confirmed via DOI resolution + PubMed + UVa/UCa + uploaded PDF] doi:10.1016/j.jamda.2019.12.008
62. Izquierdo M, de Souto Barreto P, Arai H, Bischoff-Ferrari HA, Cadore EL, Cesari M, Chen LK, Coen PM, Courneya KS, Duque G, Ferrucci L, Fielding RA, García-Hermoso A, Gutiérrez-Robledo LM, Harridge SDR, Kirk B, Kritchevsky S, Landi F, Lazarus N, Liu-Ambrose T, Marzetti E, Merchant RA, Morley JE, Pitkälä KH, Ramírez-Vélez R, Rodriguez-Mañas L, Rolland Y, Ruiz JG, Sáez de Asteasu ML, Villareal DT, Waters DL, Won Won C, Vellas B, Fiatarone Singh MA. Global consensus on optimal exercise recommendations for enhancing healthy longevity in older adults (ICFSR). J Nutr Health Aging. 2025;29(1):100401. [ICFSR 2025 global exercise consensus. Multicomponent prescription: strength + power + balance/gait + aerobic + flexibility. Endorsed by Álvarez-Bustos 2026. Vivifrail program (vivifrail.com) recommended as capacity-tailored prescription tool. PMID 39743381. Note DOI uses 2024 prefix despite 2025 issue. ✅ live-fetched v9.2.5 session] doi:10.1016/j.jnha.2024.100401
63. Rodriguez-Mañas L, Féart C, Mann G, Viña J, Chatterji S, Chodzko-Zajko W, et al. (FOD-CC group). Searching for an operational definition of frailty: a Delphi method based consensus statement. The Frailty Operative Definition-Consensus Conference Project. J Gerontol A Biol Sci Med Sci. 2013;68(1):62–67. [Foundational frailty operational-definition Delphi consensus. Cited as reference [11] in Álvarez-Bustos 2026 as the basis for CIBERFES's "agreed by a group of experts using the Delphi method" definition. Establishes frailty as predisposing primarily to disability. PMID 22511289. ✅ live-fetched v9.2.5 session] doi:10.1093/gerona/gls119
64. Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. Lancet. 2013;381(9868):752–762. [Canonical Lancet review on frailty. Surfaces the two-model framework (Fried phenotype vs Rockwood deficit accumulation) as foundational background. Used in Background tab Section 1.1 / 1.3 / 1.6. PMID 23395245. ✅ live-fetched v9.2.6 session] doi:10.1016/S0140-6736(12)62167-9
65. Hoogendijk EO, Afilalo J, Ensrud KE, Kowal P, Onder G, Fried LP. Frailty: implications for clinical practice and public health. Lancet. 2019;394(10206):1365–1375. [Lancet review on clinical and public-health implications. Cited as reference [166] in Álvarez-Bustos 2026 for frailty as the "main modifiable factor" associated with mortality in older adults. Used in Background tab Section 1.2 / 1.5 / 1.6. PMID 31609228. ✅ live-fetched v9.2.6 session] doi:10.1016/S0140-6736(19)31786-6
66. Dent E, Martin FC, Bergman H, Woo J, Romero-Ortuno R, Walston JD. Management of frailty: opportunities, challenges, and future directions. Lancet. 2019;394(10206):1376–1386. [Companion Lancet paper to Hoogendijk 2019, focusing on the management side of the same Lancet frailty themed issue. PMID 31609229. ✅ live-fetched v9.2.6 session] doi:10.1016/S0140-6736(19)31785-4
67. Dent E, Clegg A, Roller-Wirnsberger R, Vetrano DL, Hoogendijk EO. Reorienting frailty in clinical practice, public health, and policy: the Lancet Commission on Frailty. Lancet. 2025;405(10497):2265–2266. [Lancet Commission on Frailty — programme announcement. Co-Chairs Dent & Hoogendijk, 21 commissioners, 4 priority areas (life-course recognition; diagnostic framework with ICD/ICF correlation; cross-specialty management; public-health policy adoption). Aligned with UN Decade of Healthy Ageing 2021–2030, WHO World Report on Ageing and Health, and the World Health Assembly primary-care reorientation. Important framing: programme document, not finalised consensus — substantive report pending. Open Access (CC BY 4.0). Surfaced in the FrailtyTrack About-tab "Position Statements & Consensus" Lancet card, and cited in Background Section 1.1 / 1.2 / 1.9. Verified via University of Leeds White Rose institutional repository (eprints.whiterose.ac.uk/237353) plus 3 corroborating sources (Lancet website search snippet, Karolinska press release, Mirage News). ✅ live-fetched v9.3.0 session, all 5 fields confirmed] doi:10.1016/S0140-6736(25)01101-8
68. Mitnitski AB, Mogilner AJ, Rockwood K. Accumulation of deficits as a proxy measure of aging. Scientific World Journal. 2001;1:323–336. [Original deficit-accumulation Frailty Index paper. Foundation of the Rockwood-tradition deficit-accumulation operational model. Used in Background tab Section 1.3 to anchor the deficit-accumulation column of the two-model comparison. ✅ live-fetched v9.2.6 session] doi:10.1100/tsw.2001.58
69. Buta BJ, Walston JD, Godino JG, Park M, Kalyani RR, Xue QL, Bandeen-Roche K, Varadhan R. Frailty assessment instruments: systematic characterization of the uses and contexts of highly-cited instruments. Ageing Res Rev. 2016;26:53–61. [Systematic review of frailty assessment instruments — their uses and clinical contexts. Cited as reference [35] in Álvarez-Bustos 2026 in the boundary-statements section. Used in Background tab Section 1.3 to anchor the comparison of operational models. ✅ live-fetched v9.2.6 session] doi:10.1016/j.arr.2015.12.003
70. Bernabei R, Landi F, Calvani R, Cesari M, Del Signore S, Anker SD, et al.; SPRINTT consortium. Multicomponent intervention to prevent mobility disability in frail older adults: randomised controlled trial (SPRINTT project). BMJ. 2022;377:e068788. [SPRINTT RCT (n=1,519 across 11 European countries; evaluator-blinded). Multicomponent physical activity + nutritional counselling prevented mobility disability in older adults with physical frailty and sarcopenia in the lower-functioning SPPB ≤7 stratum. Cited as reference [43] in Álvarez-Bustos 2026 as the foundational frailty-intervention RCT. Used in Background tab Section 1.2 / 1.6 / 1.7. PMID 35545258. ✅ live-fetched v9.2.6 session] doi:10.1136/bmj-2021-068788
71. Travers J, Romero-Ortuno R, Bailey J, Cooney MT. Delaying and reversing frailty: a systematic review of primary care interventions. Br J Gen Pract. 2019;69(678):e61–e69. [Systematic review of primary-care interventions for delaying or reversing frailty — multicomponent exercise found to be consistently effective in community settings. Cited as reference [84] in Álvarez-Bustos 2026 in the management section. Used in Background tab Section 1.2 / 1.6. ✅ live-fetched v9.2.6 session] doi:10.3399/bjgp18X700241
72. Malmstrom TK, Miller DK, Simonsick EM, Ferrucci L, Morley JE. SARC-F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes. J Cachexia Sarcopenia Muscle. 2016;7(1):28–36. [Primary validation of SARC-F. AAH, BLSA, and NHANES cohorts; cut-off ≥4/10; internally consistent and valid for sarcopenia risk and adverse outcomes. PMID: 27066316 ✅] doi:10.1002/jcsm.12048
73. Borson S, Scanlan J, Brush M, Vitaliano P, Dokmak A. The mini-cog: a cognitive 'vital signs' measure for dementia screening in multi-lingual elderly. Int J Geriatr Psychiatry. 2000;15(11):1021–1027. [Original Mini-Cog development and validation. n=249; sensitivity 99%, correctly classified 96%; no influence of education or language; 3-minute administration. PMID: 11113982 ✅] doi:10.1002/1099-1166(200011)15:11<1021::AID-GPS234>3.0.CO;2-6
74. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695–699. [Original MoCA validation. n=277; sensitivity 90% (MCI) / 100% (AD) at cut-off ≤25; 10-minute administration; PMID: 15817019 ✅] doi:10.1111/j.1532-5415.2005.53221.x
75. Montero-Odasso M, Muir SW, Speechley M. Dual-task complexity affects gait in people with mild cognitive impairment: the interplay between gait variability, dual tasking, and risk of falls. Arch Phys Med Rehabil. 2012;93(2):293–299. [Foundational DT-TUG study. MCI (n=43) vs controls (n=25); dual-task gait variability significantly higher in MCI; arithmetic task more demanding than naming task; PMID: 22289240 ✅] doi:10.1016/j.apmr.2011.08.026
76. Bishop DJ, Beck B, Biddle SJH, Denay KL, Ferri A, Gibala MJ, Headley S, Jones AM, Jung M, Lee MJ-C, Moholdt T, Newton RU, Nimphius S, Pescatello LS, Saner NJ, Tzarimas C. Physical Activity and Exercise Intensity Terminology: A Joint American College of Sports Medicine (ACSM) Expert Statement and Exercise and Sport Science Australia (ESSA) Consensus Statement. Med Sci Sports Exerc. 2025;57(11):2599–2613. [Anchor reference for FrailtyTrack §4.2 (Background tab, training-in-frailty chapter, added v9.9.0). Joint ACSM Expert Statement / ESSA Consensus Statement proposing standardised exercise-intensity terminology with utility across all ages, sexes, conditions and activities. Five-tier framework (Very Low / Low / Moderate / High / Very High) plus five matched perception-of-effort descriptors (very easy / easy / somewhat hard / hard / very hard). Cross-walked against MT1 (lactate / gas-exchange / ventilatory threshold), MT2 (MLSS, critical power, RCP), Wₘₐₓ, %1RM, RIR, RPE10, RPE20, %HRR, %VO2max, METs — concluding that %VO2max, %HRmax, %HRR, and METs do not adequately partition individuals into category-specific physiological responses, and that for resistance exercise RIR (proximity to neuromuscular failure) is more transferable than %1RM. Co-published simultaneously in J Sci Med Sport 2025;28(12):980–991, doi:10.1016/j.jsams.2024.11.004 (PMID 41093682) — identical content. Pre-session memory drift caught: the v9.7.x cumulative memory had this DOI as 10.1249/MSS.0000000000003576 — incorrect; the correct MSSE DOI is 10.1249/MSS.0000000000003795, confirmed by 4 independent primary sources (PubMed PMID 41093682, LWW journal page, Ovid LWW, ACSM Science Spotlight). Per Rule 1, the correct DOI is what FrailtyTrack uses. ✅ live-fetched v9.9.0 session, all 5 fields verified.] doi:10.1249/MSS.0000000000003795
77. Currier BS, D'Souza AC, Fiatarone Singh MA, Lowisz CV, Rawson ES, Schoenfeld BJ, Smith-Ryan AE, Steen JP, Thomas GA, Triplett NT, Washington TA, Werner TJ, Phillips SM. American College of Sports Medicine Position Stand. Resistance Training Prescription for Muscle Function, Hypertrophy, and Physical Performance in Healthy Adults: An Overview of Reviews. Med Sci Sports Exerc. 2026;58(4):851–872. [Anchor reference for FrailtyTrack §4.4 (FITT-VP variables) and partial anchor for §4.3 (multicomponent prescription), added v9.9.0. ACSM 2026 Position Stand updating the 2009 progression-models stand. Overview of 137 systematic reviews, ~30,000 participants, AMSTAR-scored, GRADE-style adapted certainty framework. Open Access CC BY-NC-ND 4.0. Key umbrella-review-grade findings highly relevant to frail and pre-frail populations: strength is enhanced by ≥80% 1RM, full ROM, 2–3 sets, ≥2 sessions/wk, exercise early in session; hypertrophy by higher volumes (≥10 sets/muscle/wk) and eccentric overload; power by moderate loads (30–70% 1RM), low-to-moderate volume, Olympic-style and power RT; physical function (gait speed, chair stand, TUG, walking) is specifically enhanced by power RT. Conversely: training to failure, equipment type, exercise complexity, set structure, time under tension, blood-flow restriction, and periodisation do not consistently impact training outcomes — these are 'optional' RTx variables. Important caveat for FrailtyTrack's frail/pre-frail focus: 'healthy adults' explicitly excluded obesity, sarcopenia and physical frailty, so prescription specifics for frail older adults must be modulated through the CIBERFES/Izquierdo ICFSR 2025 multicomponent framework. PMC PMC12965823. PMID forthcoming. Roger uploaded the primary PDF as Currier_2025_ACSM_Resistance_Training_Prescription.pdf (acceptance 2025; print 2026). ✅ live-fetched v9.9.0 session, 5 independent primary sources, all 5 fields verified.] doi:10.1249/MSS.0000000000003897
78. Izquierdo M, Rodriguez-Mañas L, Casas-Herrero A, Martinez-Velilla N, Cadore EL, Sinclair AJ. Is It Ethical Not to Prescribe Physical Activity for the Elderly Frail? J Am Med Dir Assoc. 2016;17(9):779–781. [Anchor reference for FrailtyTrack §4.1 (rationale chapter), added v9.9.0. Position-statement editorial framing the ethical case for prescribing physical activity in frail older adults — that omitting an evidence-based, low-harm, first-line intervention for a remediable condition has its own ethical weight. Cited in Álvarez-Bustos 2026 CIBERFES §10.1 as ref [93]. Authored by core CIBERFES / Vivifrail group (Izquierdo, Rodriguez-Mañas, Casas-Herrero, Martinez-Velilla) plus Cadore (Federal University of Rio Grande do Sul) and Sinclair (Aston / Diabetes Frail). Funded by Spanish Net on Aging and Frailty (RETICEF) and the Erasmus+ Vivifrail project (556988-EPP-1-2014-1-ES-SPO-SCP). ✅ live-fetched v9.9.0 session, 3 independent primary sources, all 5 fields verified.] doi:10.1016/j.jamda.2016.06.015
79. Pelland JC, Remmert JF, Robinson ZP, Hinson SR, Zourdos MC. The Resistance Training Dose Response: Meta-Regressions Exploring the Effects of Weekly Volume and Frequency on Muscle Hypertrophy and Strength Gains. Sports Med. 2026;56(2):481–505. [Complementary dose-response anchor for FrailtyTrack §4.4 (FITT-VP volume and frequency variables), added v9.9.0. Multi-level meta-regression of 67 studies, 2,058 participants. Important methodological refinement: classifies sets as 'direct' (specific to outcome) vs 'indirect' (shared muscle activation), with indirect sets quantified at 1 (total), 0.5 (fractional), or 0 (direct only) — resolving heterogeneity that has plagued earlier volume meta-analyses. Findings: dose-response for both volume and frequency with diminishing returns, and for per-session volume a 'point of undetectable outcome superiority' beyond which additional sets do not yield >50% likelihood of detectable additional benefit. Practical translation for the frailty audience: the volume-response curve is real but plateaus quickly, so substantial gains accrue at low-moderate doses. PubMed PMID 41343037. Cited in Currier 2026 (ref [187]). Pre-session memory drift caught: v9.7.x memory had this as 'online ahead of print'; the paper has now appeared in print as Sports Med. 2026;56(2):481–505 (Epub 4 Dec 2025). FrailtyTrack uses the print citation per Rule 1. Note: Currier 2026's reference list contains two transcription typos in their citation of this paper ('Zourdous' and 'muslce') — these are errors in Currier's record, not idiosyncrasies in Pelland's published record, so Rule 7 [sic] preservation does not apply. ✅ live-fetched v9.9.0 session, 4 independent primary sources, all 5 fields verified.] doi:10.1007/s40279-025-02344-w
80. Ma N, Lu Z, Mei X, Ma L, Zhang Q. The effectiveness of exercise interventions on muscle strength and balance function in pre-frail older adults: a systematic review and Bayesian network meta-analysis. Front Public Health. 2026;13:1718120. [Supplementary anchor for FrailtyTrack §4.3 (multicomponent prescription, Background tab), added v9.9.0. Bayesian NMA of 17 RCTs, 1,107 pre-frail older adults aged ≥60; 10 distinct exercise interventions compared. Headlines: elastic band exercise highest SUCRA for handgrip strength (87.51%; pooled MD 5.2 kg, 95% CI 0.64–9.8 vs control); progressive exercise + Tai-chi snacking program highest SUCRA for SPPB (90.03%); multicomponent training significantly superior to control for SPPB (MD 1.13 points, 95% CI 0.13–2.10); no exercise modality reached significance vs control for TUG (limited power, n=263 across 6 RCTs). Pre-frail-only scope; not directly applicable to frail or post-acute populations. PROSPERO CRD420251005061. Online 23 Dec 2025; published 27 Jan 2026. ISSN 2296-2565. ✅ live-fetched v9.9.0 session against Frontiers publisher record, all 5 fields verified.] doi:10.3389/fpubh.2025.1718120
81. Yang H, Wang B, Wang Q, Zhao J, Liu F, Xie X, Xu F, Zhang P. Effect of multicomponent exercise and nutrition intervention on frailty status in older adults: a network meta-analysis. BMC Geriatr. 2026;26(1):343. [Primary anchor for FrailtyTrack §4.3 combined-intervention claim (multicomponent prescription, Background tab), added v9.9.0. Frequentist NMA of 22 RCTs, 2,055 older adults aged ≥60 with pre-frailty, frailty, or frailty-related risks (including one cognitive-frailty trial: Falck 2025). Compared multicomponent exercise alone, nutritional supplementation alone (protein/amino acids), combined exercise+nutrition vs standard care. Headlines: for frailty score, combined intervention most effective (SMD −0.92, 95% CI −1.43 to −0.40), multicomponent alone significantly effective (SMD −0.78, 95% CI −1.15 to −0.43); for SPPB, only multicomponent alone reached significance (SMD +1.85, 95% CI +0.33 to +3.50); for gait speed, only nutrition alone significant (SMD +0.37, 95% CI +0.06 to +0.68). The «combined > multicomponent alone for frailty score» finding extends EWGSOP2 «resistance + protein optimisation» framing into NMA-grade evidence. Anomalous TUG signal: Yang 2026 reports multicomponent exercise alone increased TUG completion time by 3.96 s (SMD, 95% CI +0.91 to +7.07); authors speculate short-term muscular fatigue. Inconsistent with broader functional-performance literature and Ma 2026 null-significance TUG finding; FrailtyTrack §4.3 draws on Yang 2026 for frailty-score and SPPB findings only and treats the TUG signal as anomalous pending replication. PROSPERO CRD420251038055. Published 09 Feb 2026. ISSN 1471-2318. ✅ live-fetched v9.9.0 session against Springer/BMC Geriatrics publisher record, all 5 fields verified.] doi:10.1186/s12877-026-07111-8
82. Marín-Jiménez N, Bizzozero-Peroni B, Molina-Garcia P, Ortega FB, Chaput J-P, Zhang K, Lang JJ, McGrath R, Tomkinson GR, Martínez-Vizcaíno V, Cuenca-García M, Castro-Piñero J. Clinical importance of simple muscular fitness tests to predict long-term health conditions: a systematic review and meta-analysis of 94 cohort studies. Br J Sports Med. 2026;60:465–483. [Anchor for the prognostic-value claim across FrailtyTrack's field-based instruments (HGS, 5×STS, gait speed), added v9.9.1. Systematic review (PROSPERO CRD42022324110) and meta-analysis of 94 cohort studies (155 in SR; 14,951 records screened) on HGS and the 5-repetition chair-stand test (5-CST) as prognostic factors for 12 long-term health conditions. **HGS highest vs lowest (all p<0.05):** cardiovascular OR 0.73 (95% CI 0.67–0.80); T2DM 0.79 (0.68–0.91); musculoskeletal 0.65 (0.56–0.76); disability 0.57 (0.47–0.70); depression 0.70 (0.63–0.78); cognitive decline 0.57 (0.44–0.75); dementia 0.62 (0.53–0.73); Parkinson’s 0.53 (0.31–0.91). **HGS per 5 kg increase:** CVD OR 0.93, T2DM 0.95, depression 0.94, dementia 0.87 (all p<0.05) — 5 kg exceeds the HGS MCID. **5-CST best vs worst:** T2DM OR 0.80, musculoskeletal 0.52, disability 0.58, depression 0.63, dementia 0.68. GRADE certainty: moderate for T2DM and dementia for both tests; low/very low for others. Strongest single-paper meta-anchor for the dementia (HGS OR 0.62, 5-CST OR 0.68) and cognitive-decline associations relevant to forthcoming §4.7 cognitive frailty in v9.11. Joint first authors NM-J and BB-P. CC BY 4.0. ✅ Five-field verified v9.9.1 session from publisher PDF (BMJ Group, online 10 Feb 2026).] doi:10.1136/bjsports-2024-109173
83. Castro-Piñero J, Alcazar J, Cuenca-García M, Fernandez-Gamez B, Ara I, Ortega FB. Sit-to-stand test emerges as a powerful prognostic factor of future health outcomes: different versions, measurement properties and future perspectives. Br J Sports Med. 2026 [Epub ahead of print, 6 May 2026]. [Practitioner-facing translation of Marín-Jiménez et al. 2026 specific to the STS test, added v9.9.1. Editorial by overlapping authors (Castro-Piñero, Cuenca-García, Ortega) plus Alcazar and Ara from the CIBERFES / GENUD Toledo group. Three substantive contributions beyond the Marín-Jiménez meta-analysis: (1) 30s-STS vs 5rep-STS responsiveness: AGUEDA RCT (Fernandez-Gamez 2026 Alzheimers Dement 22:e71019) reported 30s-STS effect size 0.4 SD vs 5rep-STS 0.2 SD after 24-week resistance training; Valenzuela 2023 NMA pooled +2.5 reps for 30s-STS (exceeds MCID of 2 reps) vs −1.9 s for 5rep-STS (does not exceed 2.3 s MCID). (2) Pragmatic 5×STS ≥12 s synthesis from three convergent prospective cohorts (Cofré-Bolados 2021, Kim & Won 2022, de Abreu 2022) — lower threshold than the Bohannon/EWGSOP2 15 s currently used in FrailtyTrack. (3) New relative-power thresholds: Kirk 2023 (Eur Geriatr Med 14:421–8) <2.0/1.6 W/kg recurrent falls; Alcazar 2021 (MSSE 53:2217–24) <1.1/1.0 W/kg severe disability; Alcazar 2021 (JCSM 12:921–32) MCID 0.42/0.33 W/kg. The MCID values are the most directly applicable addition for FrailtyTrack's Longitudinal tab. Publication-status note: Epub ahead of print at v9.9.1 ship; volume/issue/pages will appear when assigned to a numbered issue. A correction notice is on file for the 5rep-STS expansion (publisher-issued correction, not a published-record idiosyncrasy, Rule 7 [sic] preservation does not apply). Editorial article type; weight derives from translation of Marín-Jiménez 2026 rather than primary data. ✅ Five-field verified v9.9.1 session from publisher PDF (BMJ Group, online 6 May 2026).] doi:10.1136/bjsports-2026-111739
84. Casas-Herrero Á, Sáez de Asteasu ML, Antón-Rodrigo I, Sánchez-Sánchez JL, Montero-Odasso M, Marín-Epelde I, Ramón-Espinoza F, Zambom-Ferraresi F, Petidier-Torregrosa R, Elexpuru-Estomba J, Álvarez-Bustos A, Galbete A, Martínez-Velilla N, Izquierdo M. Effects of Vivifrail multicomponent intervention on functional capacity: a multicentre, randomized controlled trial. J Cachexia Sarcopenia Muscle. 2022;13(2):884–893. [The Vivifrail-MCI multicentre RCT — primary anchor for forthcoming §4.7 cognitive frailty (v9.11), added v9.9.3. 188 patients aged >75 y, pre-frail or frail per Fried criteria, with MCI or mild dementia, Barthel Index ≥60, randomised across three Spanish tertiary hospitals (Pamplona, Getafe, San Sebastián). Intervention: 3-month Vivifrail capacity-tailored programme — resistance + balance + flexibility 3 d/wk plus gait re-training 5 d/wk. Primary endpoint SPPB change; significant improvement in intervention vs control. Also significant on cognitive function (Spanish-MMSE), handgrip strength, mood (GDS). First multicentre RCT specifically combining frailty + cognitive impairment, evidencing that the multicomponent exercise framework remains effective even when cognitive comorbidity is present. ClinicalTrials.gov NCT03657940. Demo case Herr H.K. (84M frail + MCI 18 months, added v9.4.0) is modelled on the Vivifrail-Stufe-C inclusion profile. PMID 35150086. ✅ live-fetched v9.9.3 session, 5 independent primary sources, all 5 fields verified.] doi:10.1002/jcsm.12925
85. O'Caoimh R, Sezgin D, O'Donovan MR, Molloy DW, Clegg A, Rockwood K, Liew A. Prevalence of frailty in 62 countries across the world: a systematic review and meta-analysis of population-level studies. Age Ageing. 2021;50(1):96–104. [Canonical global prevalence anchor for §1.9 background prose, added v9.9.3. 240 studies, 265 prevalence proportions, 62 countries, 1,755,497 participants pooled (1 Jan 1998 to 1 April 2020). Headline finding cited in §1.9 prevalence paragraph: community-dwelling frailty prevalence ranges from 11% at age 50–59 to 51% at ≥90 y. The 62-country geographic scope is what makes this paper the canonical prevalence anchor — most prior reviews drew on <30 countries and over-represented high-income settings. The Dent 2025 Lancet Commission's «12–24% community prevalence in adults ≥65» framing draws directly on this paper. Drift-closure entry: the §1.9 prevalence paragraph already referenced this paper in prose since v9.3.0 but the structured bibliography entry was missing; v9.9.3 closes the drift. Open Access CC BY 4.0. ✅ live-fetched v9.9.3 session, 4 independent primary sources, all 5 fields verified.] doi:10.1093/ageing/afaa219
86. Alcazar J, Aagaard P, Haddock B, Kamper RS, Hansen SK, Prescott E, Ara I, Alegre LM, Frandsen U, Suetta C. Assessment of functional sit-to-stand muscle power: cross-sectional trajectories across the lifespan. Exp Gerontol. 2021;152:111448. [Copenhagen Sarcopenia Study; n=1,305; ages 20–93 y; 30s-STS power trajectories; steep decline after 50 y; PMID: 34118352 ✅] doi:10.1016/j.exger.2021.111448
87. Schoenfeld BJ, Grgic J, Van Every DW, Plotkin DL. Loading Recommendations for Muscle Strength, Hypertrophy, and Local Endurance: A Re-Examination of the Repetition Continuum. Sports (Basel). 2021;9(2):32. [Primary anchor for FrailtyTrack §5.1 (Strength) and §5.2 (Hypertrophy), added v9.9.18. Critical narrative re-examination of the «repetition continuum». For strength the heavy-load end largely holds up (meta-analytic high- vs low-load effect-size difference ≈0.58 on 1RM), but the advantage is substantially a testing artefact — it shrinks to a small non-significant effect (≈0.16) on a neutral isometric device not used in training. For hypertrophy the continuum fails: whole-muscle growth is comparable from ~30% 1RM upward when sets are taken to/near failure (earlier meta-analysis: trivial effect-size difference ≈0.03, 95% CI ~−0.16 to 0.22); in older adults light-load training is at least as effective and heavy loading may attenuate type II fibre growth. Open access CC BY 4.0. PMID 33671664; PMC PMC7927075. ✅ live-fetched v9.9.18 session, all 5 fields verified.] doi:10.3390/sports9020032
88. Fragala MS, Cadore EL, Dorgo S, Izquierdo M, Kraemer WJ, Peterson MD, Ryan ED. Resistance Training for Older Adults: Position Statement From the National Strength and Conditioning Association. J Strength Cond Res. 2019;33(8):2019–2052. [Older-adult-specific anchor for FrailtyTrack §5.1 (Strength) and supporting anchor for §5.2 (Hypertrophy), added v9.9.18. The NSCA’s first position stand dedicated to resistance training in adults ≥65 y. Recommends, for healthy older adults, a periodised programme working toward 2–3 sets of 1–2 multijoint exercises per major muscle group at 70–85% 1RM, 2–3×/week; documents training intensity as the strongest single between-study predictor of strength gain in older adults, trainable strength gains of roughly 9–174%, and that frail older adults / beginners should start lighter (often 20–30% 1RM) and stay short of momentary failure. PMID 31343601. ✅ live-fetched v9.9.18 session, all 5 fields verified.] doi:10.1519/JSC.0000000000003230
89. Tschopp M, Sattelmayer MK, Hilfiker R. Is power training or conventional resistance training better for function in elderly persons? A meta-analysis. Age Ageing. 2011;40(5):549–556. [Anchor meta-analysis for FrailtyTrack §5.3 (Power), added v9.9.18. Systematic review of RCTs comparing high-velocity power training against conventional low-velocity resistance training in community-dwelling people over 60. Eleven trials, 377 participants; pooled follow-up-value effect for functional outcomes 0.32 in favour of power training (95% CI 0.06 to 0.57); change-value 0.38 (95% CI −0.51 to 1.28) — CI crosses zero, the basis for §5.3 treating the advantage as modest. No greater adverse events with power training. Third author R. Hilfiker is the FrailtyTrack developer; cited on its merits as the field’s anchor power-vs-strength meta-analysis. PMID 21383023. ✅ live-fetched v9.9.18 session, all 5 fields verified.] doi:10.1093/ageing/afr005
90. Marques DL, Neiva HP, Marinho DA, Marques MC. Velocity-Monitored Resistance Training in Older Adults: The Effects of Low-Velocity Loss Threshold on Strength and Functional Capacity. J Strength Cond Res. 2022;36(11):3200–3208. [Velocity-loss / minimum-effective-dose anchor for FrailtyTrack §5.3 (Power), added v9.9.18. Controlled trial in older adults (42 subjects, mean age 79.7 ± 7.1 y) of velocity-monitored resistance training with each set terminated at a 10% velocity loss in leg press and chest press at 40–65% 1RM, 2×/week for 10 weeks; the low-velocity-loss threshold produced a very low per-set repetition count yet still significantly improved 1RM strength and functional capacity. Verification note: the 5 bibliographic fields were live-fetched and verified this session (PMID 34537803). The descriptor «institutionalised» and the per-set repetition counts in the §5.3 prose are from Roger’s reading of the uploaded full text; the abstract describes the cohort only as «older adults» and were not separately re-verified against full text this session. ✅ live-fetched v9.9.18 session, all 5 fields verified.] doi:10.1519/JSC.0000000000004036
91. Triplett NT. Principles of Power Training for Older Exercise Enthusiasts: Dos and Don’ts. ACSM’s Health & Fitness Journal. 2025;29(5):44–48. [Practitioner-facing power-training article for FrailtyTrack §5.3 (Power), added v9.9.18. From the ACSM’s Health & Fitness Journal September/October 2025 special issue (29(5)) on power training in older adults. Cited in §5.3 for the point that movement velocity is set by the load but the training stimulus depends on maximal-velocity intent in the concentric phase, and as one of the four convergent ACSM articles on the safety of gradually-progressed power training in older adults. ACSM’s Health & Fitness Journal is a peer-reviewed professional publication (Wolters Kluwer), not PubMed-indexed — no PMID exists; the 5 fields were verified against the publisher and ACSM publication records. ✅ live-fetched v9.9.18 session, all 5 fields verified.] doi:10.1249/FIT.0000000000001093
92. Gluchowski A, Phillips SM. Antifrail: Why Muscle (Power) Matters in Aging. ACSM’s Health & Fitness Journal. 2025;29(5):14–19. [Power-and-ageing review for FrailtyTrack §5.3 (Power), added v9.9.18. Lead article of the ACSM’s Health & Fitness Journal September/October 2025 special issue (29(5)) on power training in older adults; named ACSM Paper of the Year. Its «Apply It!» summary points map directly onto §5.3: reductions in muscle power begin earlier and proceed faster than declines in strength; power is a product of force and velocity (under-dosing either under-delivers the adaptation); and higher-functioning older adults may show functional-performance plateaus, though a reserve of power may still matter — the basis for §5.3’s Contested point. Peer-reviewed professional publication (Wolters Kluwer), not PubMed-indexed — no PMID exists; the 5 fields were verified against the publisher record and independent institutional repositories (McMaster Experts, University of Salford) and Scilit. ✅ live-fetched v9.9.18 session, all 5 fields verified.] doi:10.1249/FIT.0000000000001089

EWGSOP2 Cut-off Source References (added v8.18 — live-fetched this session)

These references are explicitly cited in EWGSOP2 Table 3 as the empirical source of each cut-off point. All six entries below were live-fetched on PubMed in the v8.18 session and confirmed for authors, title, journal, volume/issue/pages, and DOI.

1. Studenski SA, Peters KW, Alley DE, Cawthon PM, McLean RR, Harris TB, Ferrucci L, Guralnik JM, Fragala MS, Kenny AM, Kiel DP, Kritchevsky SB, Shardell MD, Dam TL, Vassileva MT. The FNIH Sarcopenia Project: rationale, study description, conference recommendations, and final estimates. J Gerontol A Biol Sci Med Sci. 2014;69(5):547–558. [Foundation for the National Institutes of Health Biomarkers Consortium; pooled analysis defining clinically relevant cut-offs for grip strength & lean mass; cited in EWGSOP2 Table 3 for ASM <20 kg M / <15 kg W. PMID: 24737557 ✅ live-fetched v8.18 session] doi:10.1093/gerona/glu010
2. Cesari M, Kritchevsky SB, Newman AB, Simonsick EM, Harris TB, Penninx BW, Brach JS, Tylavsky FA, Satterfield S, Bauer DC, Rubin SM, Visser M, Pahor M; Health, Aging and Body Composition Study. Added value of physical performance measures in predicting adverse health-related events: results from the Health, Aging And Body Composition Study. J Am Geriatr Soc. 2009;57(2):251–259. [Health ABC cohort, n=3,024; cited in EWGSOP2 Table 3 as the source for the chair-stand cut-off >15 s for 5 rises. PMID: 19207142 ✅ live-fetched v8.18 session] doi:10.1111/j.1532-5415.2008.02126.x
3. Pavasini R, Guralnik J, Brown JC, di Bari M, Cesari M, Landi F, Vaes B, Legrand D, Verghese J, Wang C, Stenholm S, Ferrucci L, Lai JC, Bartes AA, Espaulella J, Ferrer M, Lim JY, Ensrud KE, Cawthon P, Turusheva A, Frolova E, Rolland Y, Lauwers V, Corsonello A, Kirk GD, Ferrari R, Volpato S, Campo G. Short Physical Performance Battery and all-cause mortality: systematic review and meta-analysis. BMC Med. 2016;14(1):215. [Pooled individual-participant data from 17 cohorts; SPPB <10 strongly predictive of all-cause mortality; cited in EWGSOP2 Table 3 as evidence basis for the ≤8 cut-off. PMID: 28003033 ✅ live-fetched v8.18 session] doi:10.1186/s12916-016-0763-7
4. Bischoff HA, Stähelin HB, Monsch AU, Iversen MD, Weyh A, von Dechend M, Akos R, Conzelmann M, Dick W, Theiler R. Identifying a cut-off point for normal mobility: a comparison of the timed 'up and go' test in community-dwelling and institutionalised elderly women. Age Ageing. 2003;32(3):315–320. [n=413 community-dwelling + n=78 institutionalised women, age 65–85 y; cited in EWGSOP2 Table 3 as the source for TUG ≥20 s cut-off; community women never exceed 20 s. PMID: 12720619 ✅ live-fetched v8.18 session] doi:10.1093/ageing/32.3.315
5. Abellan van Kan G, Rolland Y, Andrieu S, Bauer J, Beauchet O, Bonnefoy M, Cesari M, Donini LM, Gillette Guyonnet S, Inzitari M, Nourhashemi F, Onder G, Ritz P, Salva A, Visser M, Vellas B. Gait speed at usual pace as a predictor of adverse outcomes in community-dwelling older people: an International Academy on Nutrition and Aging (IANA) Task Force. J Nutr Health Aging. 2009;13(10):881–889. [Expert task force; gait speed validated as single-item predictor of disability, falls, mortality; underpins EWGSOP2 gait-speed ≤0.8 m/s severity cut-off. Distinct from Abellan van Kan 2008 (IANA Task Force on Frailty, doi:10.1007/BF02982161, PMID:18165842) listed below in the questionnaire reference block. PMID: 19924348 ✅ live-fetched v8.18 session] doi:10.1007/s12603-009-0246-z
6. Ishii S, Tanaka T, Shibasaki K, Ouchi Y, Kikutani T, Higashiguchi T, Obuchi SP, Ishikawa-Takata K, Hirano H, Kawai H, Tsuji T, Iijima K. Development of a simple screening test for sarcopenia in older adults. Geriatr Gerontol Int. 2014;14 Suppl 1:93–101. [Kashiwa Study; n=1,971 community-dwelling adults ≥65 y; equation-derived score using age, grip strength & calf circumference; recommended by EWGSOP2 as a more formal case-finding alternative to SARC-F in higher-risk populations. PMID: 24450566 ✅ live-fetched v8.18 session] doi:10.1111/ggi.12197

SARC-F Scientific Evaluation References (added v8.21 — live-fetched this session)

Thirteen references underpinning the dedicated Background: Sarcopenia tab. All entries below were live-fetched on PubMed and the publisher's site during the v8.21 session and confirmed for authors, title, journal, volume/issue/pages, and DOI. Cruz-Jentoft 2019 / EWGSOP2 is also listed in the v8.18 block above and is cross-referenced here for completeness.

1. Malmstrom TK, Morley JE. SARC-F: a simple questionnaire to rapidly diagnose sarcopenia. J Am Med Dir Assoc. 2013;14(8):531–532. [Original SARC-F editorial. Introduced the 5-item self-report screen (S-A-R-C-F) by analogy with FRAX; cut-off ≥4 proposed as predictive of sarcopenia and adverse functional outcomes. PMID: 23810110 ✅ live-fetched v8.21 session] doi:10.1016/j.jamda.2013.05.018
2. Malmstrom TK, Miller DK, Simonsick EM, Ferrucci L, Morley JE. SARC-F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes. J Cachexia Sarcopenia Muscle. 2016;7(1):28–36. [Primary psychometric validation of SARC-F. Three-cohort analysis (AAH, BLSA, NHANES); good internal consistency, supportive factorial validity; SARC-F ≥4 associated with IADL deficits, slower chair-stand, lower grip strength, lower SPPB, recent hospitalisation, gait speed <0.8 m/s, and mortality. Note: this entry duplicates the existing primary-references list above; retained here for thematic completeness of the SARC-F evaluation block. PMID: 27066316 ✅ live-fetched v8.21 session] doi:10.1002/jcsm.12048
3. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, Cooper C, Landi F, Rolland Y, Sayer AA, Schneider SM, Sieber CC, Topinkova E, Vandewoude M, Visser M, Zamboni M; Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2). Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16–31. [EWGSOP2 — places SARC-F at the "Find" step of the F-A-C-S algorithm. PMID: 30312372; PMCID PMC6322506 ✅ live-fetched v8.21 session. Cross-referenced with the v8.18 EWGSOP2 block above for completeness; not a duplicate listing.] doi:10.1093/ageing/afy169 · Erratum: Age Ageing. 2019;48(4):601. doi:10.1093/ageing/afz046 PMID:31081853.
4. Woo J, Leung J, Morley JE. Validating the SARC-F: a suitable community screening tool for sarcopenia? J Am Med Dir Assoc. 2014;15(9):630–634. [First community-level validation. Hong Kong Mr & Ms Os cohort, n=4,000; SARC-F vs EWGSOP / IWGS / AWGS criteria; "excellent specificity but poor sensitivity for sarcopenia classification"; predictive power for 4-year physical limitation comparable across all four classification approaches. PMID: 24947762 ✅ live-fetched v8.21 session] doi:10.1016/j.jamda.2014.04.021
5. Ida S, Kaneko R, Murata K. SARC-F for Screening of Sarcopenia Among Older Adults: A Meta-analysis of Screening Test Accuracy. J Am Med Dir Assoc. 2018;19(8):685–689. [First diagnostic-accuracy meta-analysis of SARC-F. 7 studies, n=12,800, EWGSOP reference: pooled sensitivity 0.21 (95% CI 0.13–0.31), specificity 0.90 (95% CI 0.83–0.94), DOR 2.47. PMID: 29778639 ✅ live-fetched v8.21 session] doi:10.1016/j.jamda.2018.04.001
6. Barbosa-Silva TG, Menezes AMB, Bielemann RM, Malmstrom TK, Gonzalez MC; Grupo de Estudos em Composição Corporal e Nutrição (COCONUT). Enhancing SARC-F: Improving Sarcopenia Screening in the Clinical Practice. J Am Med Dir Assoc. 2016;17(12):1136–1141. [SARC-CalF development. n=179, EWGSOP reference; AUC rose from 0.592 (SARC-F alone) to 0.736 (SARC-F + calf circumference); sensitivity doubled from ~33% to ~66% without compromising specificity. PMID: 27650212 ✅ live-fetched v8.21 session] doi:10.1016/j.jamda.2016.08.004
7. Chen LK, Woo J, Assantachai P, Auyeung TW, Chou MY, Iijima K, Jang HC, Kang L, Kim M, Kim S, Kojima T, Kuzuya M, Lee JSW, Lee SY, Lee WJ, Lee Y, Liang CK, Lim JY, Lim WS, Peng LN, Sugimoto K, Tanaka T, Won CW, Yamada M, Zhang T, Akishita M, Arai H. Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. J Am Med Dir Assoc. 2020;21(3):300–307.e2. [AWGS 2019. Places SARC-F (≥4), calf circumference (M <34 cm / F <33 cm), or SARC-CalF (≥11) at the case-finding step; introduces "possible sarcopenia" entity for primary-care intervention before full diagnostic confirmation. PMID: 32033882 ✅ live-fetched v8.21 session] doi:10.1016/j.jamda.2019.12.012
8. Bahat G, Oren MM, Yilmaz O, Kılıç C, Aydin K, Karan MA. Comparing SARC-F with SARC-CalF to Screen Sarcopenia in Community Living Older Adults. J Nutr Health Aging. 2018;22(9):1034–1038. [Replication of SARC-CalF in Turkish cohort. n=207, prevalence 1.9–9.2%; SARC-CalF improved specificity (90–98%) and overall AUC vs SARC-F but did not improve sensitivity in this low-prevalence sample — supports population-specific calibration. PMID: 30379299 ✅ live-fetched v8.21 session] doi:10.1007/s12603-018-1072-y
9. Voelker SN, Michalopoulos N, Maier AB, Reijnierse EM. Reliability and Concurrent Validity of the SARC-F and Its Modified Versions: A Systematic Review and Meta-Analysis. J Am Med Dir Assoc. 2021;22(9):1864–1876.e16. [Largest systematic review of SARC-F psychometrics. 29 articles, n=21,855; sensitivity 28.9–55.3%, specificity 68.9–88.9% across EWGSOP, EWGSOP2, AWGS, FNIH, IWGS, SCWD; good reliability; concludes SARC-F is "nonoptimal for sarcopenia screening" against muscle-mass-based reference standards. PMID: 34144049 ✅ live-fetched v8.21 session] doi:10.1016/j.jamda.2021.05.011
10. Drey M, Ferrari U, Schraml M, Kemmler W, Schoene D, Franke A, Freiberger E, Kob R, Sieber C. German Version of SARC-F: Translation, Adaption, and Validation. J Am Med Dir Assoc. 2020;21(6):747–751.e1. [Definitive German validation. Munich/Erlangen, n=117 community-dwelling outpatients (mean age 79.1 y); 7-step WHO-based translation; "10 lb" → 5 kg with water-box example; falls timeframe explicit "in the last 12 months". Excellent inter-rater reliability; for confirmed sarcopenia sens 63%/spec 47%; for probable sarcopenia sens 75%/spec 67% — recommended for case-finding of probable sarcopenia (the EWGSOP2 "Assess" gate). PMID: 31980396 ✅ live-fetched v8.21 session] doi:10.1016/j.jamda.2019.12.011
11. Lu JL, Ding LY, Xu Q, Zhu SQ, Xu XY, Hua HX, Chen L, Xu H. Screening Accuracy of SARC-F for Sarcopenia in the Elderly: A Diagnostic Meta-Analysis. J Nutr Health Aging. 2021;25(2):172–182. [Larger updated SARC-F diagnostic-accuracy meta-analysis. 20 studies; pooled estimates against EWGSOP, EWGSOP2, AWGS, FNIH, IWGS reference standards; consistent low-sensitivity / high-specificity profile across all five. PMID: 33491031 ✅ live-fetched v8.21 session] doi:10.1007/s12603-020-1471-8
12. Bauer J, Morley JE, Schols AMWJ, Ferrucci L, Cruz-Jentoft AJ, Dent E, Baracos VE, Crawford JA, Doehner W, Heymsfield SB, Jatoi A, Kalantar-Zadeh K, Lainscak M, Landi F, Laviano A, Mancuso M, Muscaritoli M, Prado CM, Strasser F, von Haehling S, Coats AJS, Anker SD. Sarcopenia: A Time for Action. An SCWD Position Paper. J Cachexia Sarcopenia Muscle. 2019;10(5):956–961. [SCWD position paper. Society on Sarcopenia, Cachexia and Wasting Disorders endorses SARC-F as the rapid-screening step, with formal diagnosis through grip strength or chair-stand combined with DXA-estimated appendicular muscle mass (height-indexed). PMID: 31523937; PMCID PMC6818450 ✅ live-fetched v8.21 session] doi:10.1002/jcsm.12483
13. Dent E, Morley JE, Cruz-Jentoft AJ, Arai H, Kritchevsky SB, Guralnik J, Bauer JM, Pahor M, Clark BC, Cesari M, Ruiz J, Sieber CC, Aubertin-Leheudre M, Waters DL, Visvanathan R, Landi F, Villareal DT, Fielding R, Won CW, Theou O, Martin FC, Dong B, Woo J, Flicker L, Ferrucci L, Merchant RA, Cao L, Cederholm T, Ribeiro SML, Rodríguez-Mañas L, Anker SD, Lundy J, Gutiérrez Robledo LM, Bautmans I, Aprahamian I, Schols JMGA, Izquierdo M, Vellas B. International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management. J Nutr Health Aging. 2018;22(10):1148–1161. [ICFSR clinical practice guidelines. International Conference on Frailty and Sarcopenia Research task force; SARC-F included as a recommended screening instrument among several options. PMID: 30498820 ✅ live-fetched v8.21 session] doi:10.1007/s12603-018-1139-9

SARC-CalF Implementation References (added v8.22 — live-fetched this session)

Three new references underpinning the SARC-CalF Optional Extension added to the S1 SARC-F card and to Section 4 of the Background tab. The other four references that anchor the SARC-CalF evidence (Barbosa-Silva 2016, Bahat 2018, Chen/AWGS 2020, Voelker 2021) are already present in the v8.21 SARC-F evaluation block above and were re-fetched in the v8.22 session for confirmation. All entries were confirmed for authors, title, journal, volume/issue/pages, and DOI.

1. Yang M, Hu X, Xie L, Zhang L, Zhou J, Lin J, Wang Y, Li Y, Han Z, Zhang D, Zuo Y, Li Y, Wu L. Screening Sarcopenia in Community-Dwelling Older Adults: SARC-F vs SARC-F Combined With Calf Circumference (SARC-CalF). J Am Med Dir Assoc. 2018;19(3):277.e1–277.e8. [Largest community-based replication of SARC-CalF. n=4,361, AWGS 2014 reference; SARC-CalF sensitivity 60.7% vs SARC-F 29.5%; specificity 94.7% vs 98.1%; AUC 0.92 vs 0.89 (p = 0.003); robust improvement consistent across sub-groups. PMID: 29477774 ✅ live-fetched v8.22 session] doi:10.1016/j.jamda.2017.12.016
2. Krzymińska-Siemaszko R, Deskur-Śmielecka E, Kaluźniak-Szymanowska A, Lewandowicz M, Wieczorowska-Tobis K. Comparison of Diagnostic Performance of SARC-F and Its Two Modified Versions (SARC-CalF and SARC-F+EBM) in Community-Dwelling Older Adults from Poland. Clin Interv Aging. 2020;15:583–594. [European replication in a Central European cohort. n=260 community-dwelling Poles ≥60 y; reference standards EWGSOP1, EWGSOP2, modified-EWGSOP2; SARC-CalF (≥11) sensitivity 57.8% (95% CI 42.2–72.3), specificity 88.4% (83.3–92.3), AUC 0.778; SARC-F (≥4) AUC ~0.62. Sets the European empirical baseline for SARC-CalF performance. PMID: 32425513; PMCID: PMC7196242 ✅ live-fetched v8.22 session] doi:10.2147/CIA.S250508
3. Lim WS, Chew J, Lim JP, Tay L, Hafizah N, Ding YY. Letter to the editor: Case for validated instead of standard cut-offs for SARC-CalF. J Nutr Health Aging. 2019;23(4):393–395. [Cut-off methodology argument. Argues against using the original Barbosa-Silva 2016 sex-pooled 31 cm CC threshold without local validation; recommends population-specific cut-offs. Cited in this tool as the rationale for using AWGS 2019 sex-specific cut-offs (M <34 cm, F <33 cm) as the most defensible default while explicitly flagging the absence of Swiss/German validation. PMID: 30932140 ✅ live-fetched v8.22 session] doi:10.1007/s12603-019-1177-y

Confirmation re-fetches in the v8.22 session — Barbosa-Silva 2016 (doi:10.1016/j.jamda.2016.08.004); Bahat 2018 (doi:10.1007/s12603-018-1072-y); Chen 2020 / AWGS 2019 (doi:10.1016/j.jamda.2019.12.012); Voelker 2021 (doi:10.1016/j.jamda.2021.05.011). All four still confirm correctly against PubMed; their primary listing remains in the v8.21 SARC-F evaluation block above.

Self-Report Screening Questionnaires (added v8.0)

30. Braun T, Grüneberg C, Thiel C. German translation, cross-cultural adaptation and diagnostic test accuracy of three frailty screening tools: PRISMA-7, FRAIL scale and Groningen Frailty Indicator. Z Gerontol Geriat. 2018;51(3):282–292. [Primary source for German translations used in this tool's Questionnaire tab.] doi:10.1007/s00391-017-1295-2
31. Hébert R, Durand PJ, Dubuc N, Tourigny A; PRISMA Group. Frail elderly patients: new model for integrated service delivery. Can Fam Physician. 2003 Aug;49:992–997. [Original PRISMA-7 publication — no DOI assigned; PMID: 12943358 — corrected v8.20 from prior 14526871 ✅ live-fetched v8.20 session]
32. Raîche M, Hébert R, Dubois MF. PRISMA-7: a case-finding tool to identify older adults with moderate to severe disabilities. Arch Gerontol Geriatr. 2008 Jul-Aug;47(1):9–18. [PMID: 17723247 ✅ live-fetched v8.20 session. Sensitivity 78.3%, specificity 74.7% at cut-off ≥3 yes-answers.] doi:10.1016/j.archger.2007.06.004
33. Morley JE, Malmstrom TK, Miller DK. A simple frailty questionnaire (FRAIL) predicts outcomes in middle aged African Americans. J Nutr Health Aging. 2012 Jul;16(7):601–608. [Original FRAIL scale validation; PMID: 22836700; PMCID: PMC4515112 ✅ live-fetched v8.20 session.] doi:10.1007/s12603-012-0084-2
34. Morley JE, Vellas B, Abellan van Kan G, Anker SD, Bauer JM, Bernabei R, Cesari M, Chumlea WC, Doehner W, Evans J, Fried LP, Guralnik JM, Katz PR, Malmstrom TK, McCarter RJ, Gutierrez Robledo LM, Rockwood K, von Haehling S, Vandewoude MF, Walston J. Frailty consensus: a call to action. J Am Med Dir Assoc. 2013 Jun;14(6):392–397. [IANA/IAGG endorsement of FRAIL scale; PMID: 23764209; PMCID: PMC4084863 ✅ live-fetched v8.20 session. Author list expanded from "et al." in v8.20.] doi:10.1016/j.jamda.2013.03.022
35. Steverink N, Slaets JPJ, Schuurmans H, van Lis M. Measuring frailty: developing and testing the GFI (Groningen Frailty Indicator). Gerontologist. 2001;41(special issue 1):236–237. [Original GFI development — congress abstract; no DOI; full-text link]
36. Schuurmans H, Steverink N, Lindenberg S, Frieswijk N, Slaets JPJ. Old or frail: what tells us more? J Gerontol A Biol Sci Med Sci. 2004 Sep;59(9):M962–M965. [GFI cut-off ≥4 established; PMID: 15472162 ✅ live-fetched v8.20 session.] doi:10.1093/gerona/59.9.M962
37. Bielderman A, van der Schans CP, van Lieshout MRJ, de Greef MHG, Boersma F, Krijnen WP, Steverink N. Multidimensional structure of the Groningen Frailty Indicator in community-dwelling older people. BMC Geriatr. 2013 Aug 22;13:86. [GFI three-dimensional factor structure; PMID: 23968433; PMCID: PMC3766248 ✅ live-fetched v8.20 session. Author list expanded from "et al." in v8.20.] doi:10.1186/1471-2318-13-86
38. Clegg A, Rogers L, Young J. Diagnostic test accuracy of simple instruments for identifying frailty in community-dwelling older people: a systematic review. Age Ageing. 2015 Jan;44(1):148–152. [Systematic review recommending PRISMA-7; AUC data cited in Braun 2018; PMID: 25355618 ✅ live-fetched v8.20 session.] doi:10.1093/ageing/afu157
39. Abellan van Kan G, Rolland Y, Bergman H et al. The I.A.N.A. Task Force on frailty assessment of older people in clinical practice. J Nutr Health Aging. 2008;12(1):29–37. doi:10.1007/BF02982161
40. Beaton DE, Bombardier C, Guillemin F, Ferraz MB. Guidelines for the process of cross-cultural adaptation of self-report measures. Spine. 2000;25(24):3186–3191. [Cross-cultural adaptation methodology used by Braun 2018] doi:10.1097/00007632-200012150-00014
41. Searle SD, Mitnitski A, Gahbauer EA, Gill TM, Rockwood K. A standard procedure for creating a frailty index. BMC Geriatr. 2008;8:24. [40-variable Frailty Index used as reference standard in Braun 2018] doi:10.1186/1471-2318-8-24

Swiss/German Validation References for Clinical Instruments (added v8.23 — live-fetched this session)

Four references entered the bibliography in the v8.23 session as the validated/standard-wording foundation for the bilingual UI planned for v9.0. These cover the Clinical Frailty Scale (Swiss validation, Basel ED), the 6-Minute Walk Test (German-population reference percentiles), and the Allgemeine Depressionsskala (validated German version of the CES-D, used in Fried's exhaustion criterion). All five fields (authors, title, journal, volume/issue/pages, DOI/ISBN) confirmed against PubMed, the publisher's record, and institutional URLs in the v8.23 session.

1. Kaeppeli T, Rueegg M, Dreher-Hummel T, Brabrand M, Kabell-Nissen S, Carpenter CR, Bingisser R, Nickel CH. Validation of the Clinical Frailty Scale for Prediction of Thirty-Day Mortality in the Emergency Department. Ann Emerg Med. 2020;76(3):291–300. [Swiss validation of CFS in the emergency department. University Hospital Basel; n=2,393 consecutive ED patients ≥65 y; AUC 0.81 for 30-day mortality, AUC 0.72 for hospitalisation, AUC 0.69 for ICU admission; weighted Cohen's κ 0.74 for inter-rater reliability; frailty prevalence 36.8%. Cited in v8.23 in the CFS card on the Test Protocols tab. PMID: 32336486 ✅ live-fetched v8.23 session] doi:10.1016/j.annemergmed.2020.03.028
2. Rueegg M, Nissen SK, Brabrand M, Kaeppeli T, Dreher T, Carpenter CR, Bingisser R, Nickel CH. The Clinical Frailty Scale predicts 1-year mortality in emergency department patients aged 65 years and older. Acad Emerg Med. 2022;29(5):572–580. [Extended Swiss validation of CFS for 1-year mortality. University Hospital Basel; n=2,191; adjusted CFS-model AUC 0.767 (95% CI 0.741–0.793) versus 0.703 for the Emergency Severity Index; restricted mean survival times 219 days for CFS 8 to 365 days for CFS 1. Cited in v8.23 in the CFS card on the Test Protocols tab. PMID: 35138670 ✅ live-fetched v8.23 session] doi:10.1111/acem.14460
3. Morbach C, Moser N, Cejka V, Stach M, Sahiti F, Kerwagen F, Frantz S, Pryss R, Gelbrich G, Heuschmann PU, Störk S; STAAB consortium. Determinants and reference values of the 6-min walk distance in the general population—results of the population-based STAAB cohort study. Clin Res Cardiol. 2025;114(9):1098–1108. Epub 2024 Jan 18. [First German-population reference percentiles for 6MWD. Würzburg general population, n=2,762 (51% women, mean age 58 ± 11 y); subgroup n=681 without cardiovascular risk factors used for percentile reference; protocol variant: 15-m hallway; age and height (not sex) identified as determinants. Cited in v8.23 in the 6MWT card on the Test Protocols tab. PMID: 38236418 ✅ live-fetched v8.23 session] doi:10.1007/s00392-023-02373-3
4. Hautzinger M, Bailer M, Hofmeister D, Keller F. ADS: Allgemeine Depressionsskala (2., überarbeitete, neu normierte Auflage). Göttingen: Hogrefe; 2012. ISBN 978-3-8409-2393-5. [Validated German version of the Center for Epidemiological Studies Depression Scale (CES-D). Source for the German wording of the two CES-D items used in Fried's exhaustion criterion ("I felt that everything I did was an effort" / "I could not get going"). German cut-off ≥22 (vs. Radloff's ≥16). Manual is a Hogrefe book; no DOI assigned to print monograph — primary citation by ISBN with publisher URL. Initial Hautzinger 1988 publication: Diagnostica 1988;34(2):167–173 (pre-DOI-era Hogrefe journal article). Will be used in v9.0 as the validated German wording for Fried's exhaustion criterion. Live-confirmed in the v8.23 session via the publisher product page] testzentrale.de — Allgemeine Depressionsskala

Confirmation re-fetches in the v8.23 session — Guralnik 1994 SPPB (doi:10.1093/geronj/49.2.m85, PMID:8126356); Podsiadlo & Richardson 1991 TUG (doi:10.1111/j.1532-5415.1991.tb01616.x, PMID:1991946); Radloff 1977 CES-D (doi:10.1177/014662167700100306); ATS 2002 6MWT (doi:10.1164/ajrccm.166.1.at1102, PMID:12091180; erratum doi:10.1164/rccm.19310erratum); Rockwood 2005 CFS (doi:10.1503/cmaj.050051, PMID:16129869). All five still confirm correctly against PubMed and publisher records; their primary listings remain in their existing bibliography blocks above. Standard-wording sources (no peer-reviewed validation paper) — Dalhousie official German CFS v2.0 PDF (CFS_V2_ge_WM.pdf via Dalhousie translations page); KCGeriatrie SPPB and TUG administration forms (de facto DACH standard); DZHK-SOP-K-04 6MWT (German clinical SOP, v1.0, 2014).

Primary References — Muscle and Frailty (v9.6.0)

Eleven references entered the bibliography in the v9.6.0 session as the evidence base for the new Background-tab Section 2 chapter Muscle and Frailty — Mass, Strength, and Power (which renumbered the existing Sarcopenia / SARC-F section to §3). All five fields (authors, title, journal, volume/issue/pages, DOI) were live-fetched and confirmed against PubMed and the publisher's record in the v9.6.0 session. Two of these (Fried 2001, Cruz-Jentoft 2019 EWGSOP2) were already present in the About-tab Primary References from earlier sessions and are now also entered into the structured refs/bibliography.json; the remaining nine are new to both surfaces.

1. Almohaisen N, Gittins M, Todd C, Sremanakova J, Sowerbutts AM, Aldossari A, Almutairi A, Jouhar D, Burden S. Prevalence of Undernutrition, Frailty and Sarcopenia in Community-Dwelling People Aged 50 Years and Above: Systematic Review and Meta-Analysis. Nutrients. 2022;14(8):1537. [Community-dweller meta-analysis. Combined estimates: undernutrition 17% (n=4,214), frailty 13% (k=28, n=95,036), sarcopenia 14% (k=9, n=7,656). Cited in Background §2.1 for the epidemiological-overlap argument. PMID: 35458099; PMCID PMC9028691 ✅ live-fetched v9.6.0 session] doi:10.3390/nu14081537
2. Ligthart-Melis GC, Luiking YC, Kakourou A, Cederholm T, Maier AB, de van der Schueren MAE. Frailty, Sarcopenia, and Malnutrition Frequently (Co-)occur in Hospitalized Older Adults: A Systematic Review and Meta-analysis. J Am Med Dir Assoc. 2020;21(9):1216–1228. [Hospital-setting meta-analysis. Pooled prevalence (pre-)frailty 84%, sarcopenia 37%, (risk of) malnutrition mostly >50%. Frequent triple co-occurrence. Cited in Background §2.1 for the inpatient-overlap rule-rather-than-exception framing. PMID: 32327302 ✅ live-fetched v9.6.0 session] doi:10.1016/j.jamda.2020.03.006
3. Cesari M, Landi F, Vellas B, Bernabei R, Marzetti E. Sarcopenia and physical frailty: two sides of the same coin. Front Aging Neurosci. 2014;6:192. [Conceptual reframe. Argues physical frailty (Fried phenotype) and sarcopenia are two complementary readings of the same age-related muscular decline rather than two distinct entities; converges on the same instruments (gait speed, grip strength, chair-rise) and the same multicomponent intervention. Cited in Background §2.2. PMID: 25120482; PMCID PMC4112807 ✅ live-fetched v9.6.0 session] doi:10.3389/fnagi.2014.00192
4. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, Cooper C, Landi F, Rolland Y, Sayer AA, Schneider SM, Sieber CC, Topinkova E, Vandewoude M, Visser M, Zamboni M; Writing Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16–31. [EWGSOP2 — strength as gateway parameter. Reframes the diagnostic algorithm so that low grip strength or prolonged chair-rise time qualifies as «probable sarcopenia» before any imaging-based mass assessment. Cited in Background §2.2 / §2.3. Cross-referenced with the v8.18 EWGSOP2 block and v8.21 SARC-F block above for completeness; not a duplicate listing. PMID: 30312372; PMCID PMC6322506 ✅ live-fetched v9.6.0 session] doi:10.1093/ageing/afy169 · Erratum: Age Ageing. 2019;48(4):601. doi:10.1093/ageing/afz046 PMID:31081853.
5. Clark BC, Manini TM. Sarcopenia ≠ dynapenia. J Gerontol A Biol Sci Med Sci. 2008;63(8):829–834. [Coined «dynapenia». Argues age-related strength loss is conceptually distinct from age-related mass loss; underlying mechanisms (motor-unit remodelling, NMJ dysfunction, central activation deficits, fibre-type shifts) are largely neural and contractile-quality phenomena rather than tissue-quantity. Cited in Background §2.4. PMID: 18772470 ✅ live-fetched v9.6.0 session] doi:10.1093/gerona/63.8.829
6. Manini TM, Clark BC. Dynapenia and aging: an update. J Gerontol A Biol Sci Med Sci. 2012;67(1):28–40. [Dynapenia update. Longitudinal evidence: dynapenia predicts mobility limitation, falls, hospitalisation, and mortality more strongly than mass-defined sarcopenia; resistance training improves strength substantially even when mass gains are modest. Cited in Background §2.4. PMID: 21444359; PMCID PMC3260478 ✅ live-fetched v9.6.0 session] doi:10.1093/gerona/glr010
7. Skelton DA, Greig CA, Davies JM, Young A. Strength, Power and Related Functional Ability of Healthy People Aged 65–89 Years. Age Ageing. 1994;23(5):371–377. [Cross-sectional, n=100 healthy adults aged 65–89. Demonstrates leg-extensor power declines faster than isometric knee-extensor or grip strength and tracks functional ability (timed chair-rise, weighted-bag lift, step-up onto boxes) more closely than strength alone. Foundational reference for the power-vs-strength decline trajectory. Cited in Background §2.5. PMID: 7825481 ✅ live-fetched v9.6.0 session] doi:10.1093/ageing/23.5.371
8. Reid KF, Fielding RA. Skeletal Muscle Power: A Critical Determinant of Physical Functioning in Older Adults. Exerc Sport Sci Rev. 2012;40(1):4–12. [Narrative review. Consolidates two decades of evidence that muscle power declines roughly twice as fast as strength across the older-adult age span and is the more discriminant variable for impairment–limitation–disability relationships. Cited in Background §2.5. PMID: 22016147; PMCID PMC3245440 ✅ live-fetched v9.6.0 session] doi:10.1097/JES.0b013e31823b5f13
9. Coelho-Junior HJ, Marzetti E, Picca A, Tosato M, Calvani R, Landi F. Sex- and age-specific normative values of lower extremity muscle power in Italian community-dwellers. J Cachexia Sarcopenia Muscle. 2024;15(1):45–54. [Italian Lookup 7+ centile values. Sex- and age-specific centile values for lower-extremity muscle power across the 18–81+ age span, derived from the 5×STS test using the Alcazar equation. Embedded in FrailtyTrack as the population-comparison reference for the 5×STS card. Cited in Background §2.5 and on the 5×STS protocol card. PMID: 38158636 ✅ live-fetched v9.6.0 session] doi:10.1002/jcsm.13301
10. Beaudart C, Zaaria M, Pasleau F, Reginster JY, Bruyère O. Health Outcomes of Sarcopenia: A Systematic Review and Meta-Analysis. PLoS One. 2017;12(1):e0169548. [Outcome meta-analysis. Pooled OR for mortality 3.60 (95% CI 2.96–4.37); pooled OR for functional decline 3.03 (95% CI 1.80–5.12). Effect sizes of this magnitude place sarcopenia in the same prognostic tier as severe comorbid disease. Cited in Background §2.6 for quantitative anchors. PMID: 28095426; PMCID PMC5240970 ✅ live-fetched v9.6.0 session] doi:10.1371/journal.pone.0169548
11. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA; Cardiovascular Health Study Collaborative Research Group. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3):M146–M157. [Original Fried physical-phenotype paper. CHS cohort. Five criteria: weight loss, exhaustion, weakness, slow gait, low activity. Foundational reference for both Background §1 (Fried phenotype operationalisation) and Background §2.2 (Cesari's «two sides of the same coin» framing). Newly entered into refs/bibliography.json in v9.6.0; previously listed in About-tab Primary References from earlier sessions. PMID: 11253156 ✅ live-fetched v9.6.0 session] doi:10.1093/gerona/56.3.M146

Cross-references already in the bibliography — the v9.6.0 chapter also draws on Alcazar 2021 STS-power normative cohort (doi:10.1002/jcsm.12737, PMID:34216098 — primary listing in About-tab Primary References from v8.2 and in refs/bibliography.json from v9.4.0); Bernabei 2022 SPRINTT RCT (doi:10.1136/bmj-2021-068788, PMID:35545258 — primary listing in v8.18 EWGSOP2 block); Freitas 2024 powerpenia (doi:10.1186/s40798-024-00689-6, PMID:38523229 — primary listing in refs/bibliography.json from v9.4.0). All previously verified; no re-fetch required for the v9.6.0 session.

Reference Verification Audit — v8.16 (April 2026)